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Resumen
Los Receptores de Factor de Crecimiento Epide´rmico (EGFR, en ingle´s) son esen-
cialmente cuatro prote´ınas: EGFR/ErbB1, ErbB2, ErbB3 y ErbB4. E´stas esta´n
asociadas con determinados procesos biolo´gicos y cada vez son reconocidas como
dianas terape´uticas importantes contra el ca´ncer. En esta tesis, se proporcionan
modelos basados en homolog´ıa para los dominios extracelulares (ectodomio, ECD
en ingle´s) de ErbB3 y ErbB4 en sus conformaciones activas, incluyendo el lig-
ando heregulin, seguido de un posterior refinamiento de los modelos a trave´s de
dina´mica molecular a una resolucio´n atomı´stica (AA). Un modelo constru´ıdo para
la ErbB2 basado en informacio´n cristalogra´fica permitio´ el ana´lisis de las carac-
ter´ısticas comunes observadas entre los miembros de esta familia, concretamente,
el movimiento de periscopio del brazo de dimerizacio´n y el movimiento de bisagra
del subdominio IV. Adicionalmente a esta parte, se proporciona un modelo refi-
nado para la interaccio´n en las regiones ECD correspondientes al heterod´ımero
ErbB2/ErbB3. Este heterod´ımero es ampliamente reconocido por tener un alto
impacto en el desarrollo del ca´ncer.
El receptor ErbB2 es considerado como una onco-prote´ına transmembranal
que esta´ sobre-expresada en el ca´ncer de mama. Un tratamiento terape´u-tico ex-
itoso esta´ basado en el uso de un anticuerpo monoclonal llamado Trastuzumab el
cual se sabe que interactu´a con el dominio extracelular (ECD-ErbB2). Un mejor
entendimiento de la estructura de forma detallada, en la interaccio´n receptor–
anticuerpo es de primordial intere´s en el disen˜o de terapias antica´ncer ma´s efecti-
vas. Con el fin de discutir la flexibilidad del complejo ECD-ErbB2/Trastuzumab,
se han hecho tanto una simulacio´n de dina´mica molecular de multi-segundos como
una ana´lsis de componentes principales (PCA, en ingle´s) de este sistema. Con el
propo´sito de validar estas simulaciones, se ha realizado un ana´lisis detallado de
las interacciones entre el dominio variable del anticuerpo y el subdominio IV de
ECD-ErbB2. Esta estructura ha sido elucidada esta´ticamente mediante cristalo-
graf´ıa de Rayos-X. Ciertamente, los resultados de la simulacio´n esta´n en excelente
concordancia con la informacio´n experimental disponible durante toda la trayec-
toria. Los resultados de PCA muestran fluctuaciones colectivas asocia-das a un
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movimiento de bisagra, en el cual, el subdominio II y el dominio constante (CH)
se acercan entre s´ı. Este movimiento es probablemente estabilizado por la fo-
macio´n de puentes de hidro´geno y puentes salinos entre residuos del brazo de
dimerizacio´n en el subdominio II y residuos localizados en el dominio constante
CH del anticuerpo Trastuzumab. Finalmente, en este punto, se discutio´ la flexi-
bilidad del modelo descrito por dina´mica molecular en relacio´n con la estructura
cristalogra´fica. Se ha reportado por primera vez un movimiento del anticuerpo
hacia el dominio de dimerizacio´n del receptor ErbB2. Este hallazgo podr´ıa tener
consecuencias importantes en la accio´n biolo´gica del anticuerpo monoclonal.
Adema´s de lo anteriormente mencionado en modelos puramente ato´micos, se
ha validado un mapeo desde la resolucio´n AA hacia una resolucio´n de grano–
grueso (Coarse–Grained , CG, en ingle´s). De esta manera, AA MD sobre el
complejo ECD-ErbB2/Trastuzumab-Fab ha sido usada para comparar con sim-
ulaciones CG MD. Espec´ıficamente, se ha comparado el campo de fuerzas CG
Martini con el AA OPLS. Se ha analizado la flexibilidad conformacional y las
interacciones entre el anticuerpo y el receptor. En esta tesis han sido examinados
los siguientes para´metros en los algoritmos de MD para llevar a cabo las simu-
laciones con Martini: el me´todo de ca´lculo de interacciones no-enlazantes para
la descripcio´n de las interacciones electrosta´ticas, el valor del radio cut-off de
la lista de vecinos (rlist) y el me´todo de Redes Ela´sticas (Elastic Network , EN,
en ingle´s). Los resultados muestran que en simulaciones de CG MD los modelos
basados en domElNeDyn (redes ela´sticas por dominios), PME y un rlist de 1.4
nm, son comparables a los modelos AA. Los resultados proporcionan una luz para
validar el campo de fuerzas Martini tanto en las interacciones prote´ına–prote´ına
como en la prediccio´n de estructura.
Siguiendo este formalismo se han aplicado simulaciones CG MD han sido apli-
cadas para estudiar la influencia del Trastuzumab en la estructura y dina´mica
del d´ımero ErbB2 entero, incluyendo la bicapa lip´ıdica. El uso de modelos CG
para estudiar tales complejos es al menos de momento, obligatorio, debido al
gran taman˜o del sistema entero. El modelo Martini lo hace satisfactoriamente
bien, arrojando resultados a la par con aquellos obtenidos por modelos AA, como
tambie´n con la informacio´n experimental existente sobre receptores homo´logos.
Por ejemplo, los dominios ECD e intracelular se aproximan a la superficie de
la bicapa lip´ıdica en sendos casos, el mono´mero y el d´ımero. El Trastuzumab-
Fab dificulta la interaccio´n de los receptores con la bicapa lip´ıdica. Otro efecto
interesante del anticuerpo es la alteracio´n de la disposicio´n anti-paralela de los
segmentos yuxtamembrana en el caso del d´ımero. Estos hallazgos ayudan a en-
tender el efecto del anticuerpo sobre la bioactividad del receptor.
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Summary
The family of epidermal growth factor receptors (EGFR) is composed by four
members: EGFR/ErbB1, ErbB2, ErbB3 and ErbB4. They are associated with a
number of biological processes and are becoming increasingly recognized as im-
portant therapeutic targets against cancer. In this thesis, some models, based on
homology, there are provided for the extracellular domains (ectodomain, ECD)
of ErbB3 and ErbB4 in their active conformations, including a heregulin ligand,
followed by further refinement of the models by molecular dynamics (MD) simu-
lations at atomistic (AA) resolution. A model built for ErbB2 based on crystallo-
graphic information allowed an analysis of the common features observed among
members of the family, namely, the periscope movement of the dimerization arm
and the hinge displacement of subdomain IV. In addition, a refined model for the
interaction of the ECD corresponding to a ErbB2/ErbB3 heterodimer is given.
This heterodimer is widely recognized to have a high impact in cancer develop-
ment.
The ErbB2 receptor is a transmembrane oncoprotein that is over expressed in
breast cancer. A successful therapeutic treatment is a monoclonal antibody called
Trastuzumab which interacts with the ErbB2 extracellular domain (ECD-ErbB2).
A better understanding of the detailed structure of the receptor-antibody inter-
action is indeed of prime interest for the design of more effective anticancer thera-
pies. To analyze the flexibility of the complex ECD-ErbB2/Trastuzumab, a multi-
nanosecond MD simulation together with an analysis of fluctuations through a
principal component analysis (PCA) of this system, was carried out. For vali-
dating the simulations, a detailed analysis of the variable antibody domain in-
teractions with the extracellular subdomain IV of ErbB2 was performed. This
structure has been statically elucidated by X-ray crystallography. Indeed, the
simulation results are in excellent agreement with the available experimental in-
formation. The PCA shows collective fluctuations resulting in a hinge motion
in which subdomain II and constant domain (CH) approach each other. This
movement is likely stabilized by the formation of H-bonds and salt bridge inter-
actions between residues of the dimerization arm in the subdomain II and the
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antibody Trastuzumab residues located in the CH domain. Finally, the flexibility
of the molecular dynamics model in relation with the static X-ray structure was
discussed. A movement of the antibody towards the dimerization domain of the
ErbB2 receptor is reported for the first time. This finding could have relevant
consequences on the biological action of the monoclonal antibody.
In addition to the above mentioned pure atomistic models, a mapping from
AA to coarse-grained (CG) resolution has been validated. In this manner AA
MD on ECD-ErbB2/Trastuzumab-Fab has been used to compare with CG MD
simulations. Specifically, the CG Martini force field has been compared with
the AA OPLS representation. The conformational flexibility and interactions
between the antibody and the receptor have been analyzed. In this thesis the
following parameters have been tested in the MD algorithms to carry out the
Martini simulations: the non-bonded interactions methods to calculate the elec-
trostatic interactions, the value of the neighbor lists cut-off radius (rlist) and the
Elastic Network method. The results show that when used in MD simulations
domElNeDyn models, PME and an rlist of 1.4 nm, are comparable to the AA
protein models. The results shed light to validate the Martini force field in the
protein–protein interactions and towards protein prediction structure.
Therefore, CG MD simulations have been applied to study the influence of
the Trastuzumab monoclonal antibody on the structure and dynamics of the
full-length ErbB2 receptor dimer, including the lipid bilayer. The usage of CG
models to study such complexes is almost mandatory, at present, due to the
large size of the whole system. The Martini model performs satisfactorily well,
giving results well-matched with those obtained by AA models as well as with
the experimental information existing on homologous receptors. For example, the
ecto and intracellular domains approach the bilayer surface in both the monomer
and dimer cases. The Trastuzumab-Fab hinders the interaction of the receptors
with the lipid bilayer. Another interesting effect of the antibody is the disruption
of the antiparallel arrangement of the juxtamembrane segments in the dimer case.
These findings might help to understand the effect of the antibody on the receptor
bioactivity.
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Chapter 1
Molecular Dynamics
Simulations
Molecular Dynamics (MD) can be defined as the study of the
molecular movement caused by atomic interactions. However, the
term molecular dynamics has become a synonym for molecular dy-
namics computer simulations. This Molecular Dynamics Subject has
been studied since the 19th century. The field of computational molec-
ular dynamics, due to its dependence on extensive, iterated computa-
tion, had to wait for the invention of the electronic computer in the
mid 20th century to be feasible. Despite this relatively short history,
the field has expanded at lightning pace and found applications in a
wide range of research areas. Both Levitt [1] and Karplus [2] may be
considered the founders of the MD developments on the light of their
personal research. Since then, a lot of work has been done to improve
the methodology. In an effort to compile these works, some papers
provide a combination of a short historical overview and an outlook
to the future [3, 4]. This chapter points to some studies that have
played an important role in the field treated in this thesis: molecular
dynamics simulations of Epidermal Growth Factor Receptors.
1.1 A Brief History
There are a lot of experimental techniques that can provide information about
the dynamics of biomolecules, but they are limited in their spatial and temporal
resolution. Most of these techniques report ensemble average properties rather
than the motion of individual molecules. Some examples can be seen in Figure
1.1.
1. Molecular Dynamics Simulations
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Spatiotemporal resolution of various biophysical techniques. The temporal (abscissa) and spatial (ordinate)
resolutions of each technique are indicated by colored boxes. Techniques capable of yielding data on single
molecules (as opposed to only on ensembles) are in boldface. NMR methods can probe a wide range of
timescales, but they provide limited information on motion at certain intermediate timescales, as indicated
by the lighter shading and dashed lines. The timescales of some fundamental molecular processes, as well as
composite physiological processes, are indicated below the abscissa. The spatial resolution needed to resolve
certain objects is shown at the right. Adapted from Reference 19. Abbreviations: AFM, atomic force
microscopy; EM, electron microscopy; FRET, Fo¨rster resonance energy transfer; NMR, nuclear magnetic
resonance.
simulations. Events such as protein folding, protein–drug binding, and major conformational
changes essential to protein function typically take place on timescales of microseconds to mil-
liseconds (Figure 2).MD simulations, by contrast, were until recently generally limited in practice
to nanosecond timescales. Simulations of even a few microseconds required months on the most
powerful supercomputers available, and longer simulations had never been performed. Recent
advances in hardware, software, and algorithms have increased the timescales accessible to simula-
tion by several orders of magnitude, enabling the ﬁrst millisecond-scale simulations and allowing
MD to capture many critical biochemical processes for the ﬁrst time.
The other major factor limiting the applicability of MD has been the accuracy of the force ﬁeld
models that underlie the simulations. A number of improved force ﬁelds have been introduced
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Figure 1.1: Spatiotemporal resolution of various biophysical techniques. The temporal
(abscissa) and spatial (ordinate) resoluti ns of each technique are indicated by colored
boxes. Techniques capable of yielding data on single molecules (as opposed to only
on ensembles) are in boldface. NMR methods can probe a wide range of timescales,
but they provide limited information on motion at certain intermediate timescales, as
indicated y the lighter shading and dashed lines. The timescales of so e fundamental
mole ular process s, as well as composite physiological processes, are indicated below
the abscissa. The spatial resolution needed to resolve certain objects is shown at the
right. Abbreviations: AFM, atomic force microscopy; EM, electron microscopy; FRET,
Forster resonanc energy transf r; NMR, nucl ar magnetic resonance. Figure from [5],
reproduced with permission.
An alternative to resolving these experimental limitations, in principle, is to
model atomistic motions comput tionally, based on fir t principles physics. The
compu ational expense, combined with the challenge of developing appropriate
physical models, has limited both their length and their accuracy. A timeline
4
1.1. A Brief History
table (Table 1.1) contextualizes and summarizes the historical progress step by
step in molecular dynamics, mainly in the biomolecules targeted in this thesis:
proteins, lipids and logically combined systems. Historically, the timescales acces-
sible to MD simulation have been shorter than those on which most biomolecular
events of interest take place (see Table 1.1). This is the limit of the applicability
of these simulations. Events such as protein folding, protein-drug binding, and
major conformational changes essential to protein function typically take place
on timescales of microseconds to milliseconds (Figure 1.1). MD simulations have
generally been limited in practice to nanosecond timescales. Simulations of even
a few microseconds required months on the most powerful supercomputers avail-
able, and longer simulations had never been performed. However, coarse-grained
methods appear like a real option for performing such simulations as will be
mentioned in the section 1.3.
It is important to highlight that the Bovine Pancreatic Trypsin Inhibitor
(BPTI), a 58 amino acid protein has been used very often as the subject of choice
in the early days of MD computer simulations. First because of its small size and
second because it was one of the first proteins for which a high resolution crystal
structure was available. Different papers might be honored as the first simulation
of a water solvated protein, all of them using BPTI. This protein has been used
as the reference protein in the historical progress of molecular dynamics shown
in Table 1.1.
One of the main topics of molecular dynamics simulations has been the fold-
ing of proteins. Along the “short” and “fast” history of the molecular dynamics
simulations of proteins, it is hard to define the first successful atomistic simu-
lations of a protein in explicit solvent at physiological temperature by looking
at the timeline of Table 1.1. This is due to many examples reported of protein
unfolding, partial folding or folding of small peptides. To pinpoint to some ex-
amples, the work mentioned in Table 1.1 at 1975 was only marginally successful
in folding, but was the first attempt to fold a protein using molecular dynamics.
On the other hand, it is interesting to address molecular dynamics advances in
function of how the computational cost has been continously reduced, as is shown
in Table 1.1. The report shown at 2010 in Table 1.1 indicated that long time-scales
MD simulations could be achieved using a computer specifically designed for MD
simulations [31], called Anton. Although this super-computer can generate long
simulations it is not available for use to the general community and this is a
disadvantage.
5
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Table 1.1: Timeline of the most important results in the history of molecular dynamics
simulations of both proteins and lipids.
1955 MD of an one-dimensional string of beads[6]
1957 MD of a two-dimensional system with which they called “spheres”[7]
1959 First extensive description of the MD method and algorithms[8]
1964 MD simulation of a system of 864 Ar(l) atoms[9]
1971 First MD simulation of water[10]
1975 First “coarse grained” MD simulation of BPTI protein: residues
represented by only one/two interaction sites[11]
1976 Onset to the simulations of lipid bilayers using a two dimensional
system of 240 dumbbell shaped “molecules”[12]
1977 First atomistic simulation of a BPTI protein contained four water
molecules (called “united atom” model)[13]
1980 First atomistic simulation of a monolayer (not explicit water)[14]
1981 Water models: Simple Point Charge (SPC) and Transferable
Inter-molecular Potential functionS (TIPS)[15, 16]
1982 First atomistic simulation of a bilayer (not explicit water)[17]
1984 BPTI in a truncated octahedron surrounded by 1467 water molecules
for 20 ps[18]
1987 BPTI in 4785 water molecules for 42 ps in 1987[19]
1986 First study of a micelle in explicit water (1094 water molecules)[20]
1988
– BPTI solvated in 2607 water molecules for 210 ps[21]
– First bilayer with explicit water (526 water molecules for 180 ps)[22]
1994 First study of an atomistic phospholipid (DPPC) bilayer[23, 24]
1995 Lipids and proteins: simulating bacteriorhodopsin in a lipid bilayer[25]
1998
– First attempt to fold a protein using molecular dynamics[26]
– First 1 µs simulation of the peptide Villin Headpiece in water[27]
2001 First simulation of the self-assembly of a lipid bilayer (64 randomly
oriented DPPC-molecules)[28]
2002 First folding study of a 23 residue protein (β-hairpin, turn and
α-helix) in implicit solvent[29]
2010 First MD study reaching the millisecond for a single trajectory (23
residue WW-domain designed)[30]
1.2 Building a MD model
Components of a MD Simulation
The progress in MD simulations has faced different problems such as computa-
tional cost, size of proteins, number of particles or folding and unfolding phenom-
ena with the development of new algorithms. As a consequence there has been
6
1.2. Building a MD model
a growth of new, more sophisticated and complex software. However, the main
components of a MD model remain unchanged.
Basically, to build a MD model it is necessary (combining software and force
fields) to input the molecular coordinates and to choose the force field that de-
scribes the interactions between all atoms in the molecules. The software provides
the algorithms to integrate the laws of motion and evolve the system through time
to maintain system properties such as temperature and pressure. In this section
a partial overview on this topic is described. For a complete discussion there are
many reviews, however, those written by Gunsteren are particularly illustrative.
[32, 33].
1.2.1 Force Fields and Interaction Functions
The term “force field” refers to the combination of a mathematical formula and
associated parameters that are used to describe the energy of the protein as a
function of its atomic coordinates. This set of parameters for interaction poten-
tials takes a specific form which differs from one force field to another. The most
important and most widely used atomistic force fields are AMBER (Assisted
Model Building with Energy Refinement), CHARMM (Chemistry at HARvard
Macromolecular Mechanics), GROMOS (GROningen MOlecular Simulation)
and OPLS (Optimized Potentials for Liquid Simulations). A direct compari-
son between these force fields is given by Guvench et al.[34]. The simulation
packages contain the algorithms that hand the laws of physics. These pack-
ages mostly appeared around the same time as the force fields and are often
co-developed. The software also includes implementations of the most common
algorithms in MD simulations together with programs to setup and analyze simu-
lations. Well-known examples are GROMACS, GROMOS and NAMD (Not just
Another Molecular Dynamics program)[34].
These force fields were built in the 1980s and different versions have been
published since then. In spite of the many differences between them, they share
some basic characteristics which can be subdivided into three parts:
(i) Non-bonded
Van der Waals interactions that can be described by the known Lennard-
Jones (LJ) or Buckingham potentials, and Electrostatic interactions described
by the Coulomb potential. The non-bonded interactions are computed on the
basis of a neighbor list (a list of non-bonded atoms within a certain radius), in
which exclusions are already removed.
(ii) Bonded
Covalent bond-stretching, angle-bending, improper dihedrals, and proper di-
hedrals. These are computed on the basis of fixed lists.
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(iii) Others and Restraints
Position restraints, angle restraints, distance restraints, orientation restraints
and dihedral restraints are all based on fixed lists.
The first two terms are inherent to the force field form and both can be repre-
sented by the well–known expressions:
Ebond =
∑
bonds
Kb(b− b0)2 +
∑
angles
Kθ(θ− θ0)2 +
∑
dihedrals
Kχ[1 + cos(nχ−σ)] (1.1)
and
Enon bond =
∑
nonbond
pairs ij
(
εij
[(
Rmin,ij
rij
)12
− 2
(
Rmin,ij
rij
)6]
+
qiqj
rij
)
(1.2)
where Ebond and Enonbond are the bonded and non-bonded interactions con-
tributions to the total energy. The total energy is then:
Etotal = Ebond + Enonbond + Eothers (1.3)
Very often, the LJ term in the equation (1.2) is written as the functions of
the pair of parameters Aij and Bij where Aij = εijR
12
min,ij and Bij = 2εijR
6
min,ij .
As an alternative form, the LJ potential may also be written as:
VLJ(rij) = 4εij
[(
σij
rij
)12
−
(
σij
rij
)6]
(1.4)
Where σij = 2
1/6Rmin,ij corresponds to the finite distance at which the poten-
tial VLJ is zero. The interactions (parameters) matrix is built with the different
values of the parameters εij and σij according to the combinations rules set up by
the MD software or for the force field. These combination rules can be Lorentz–
Berthelot rules.
Although the equations (1.1) and (1.2) contain the basic forms to describe the
interactions types between particles, there are some differences or similarities in
the different force fields. In the equations and the force fields there is no explicit
term for hydrogen bonding: but the biologically important hydrogen bonds are
handled by the combinations of the LJ and Coulomb terms.
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1.2.2 The Algorithms
The following section describes the laws of physics and the algorithms handling
them, ranging from Newton’s laws of motion and the leap-frog integrator to
schemes to handle electrostatics and chemical calculations.
(i) Integration Schemes
Newton’s equation of motion can be integrated using a simple algorithm in
small time steps ∆t. Using a precedure with Taylor expansions we obtain equa-
tions which form the so-called leap-frog scheme. It is one, the most accurate,
stable, and yet simple and efficient algorithms available for molecular dynam-
ics simulations. There are several things worth mentioning about this algorithm:
high number of force evaluations per time step, appropiate order of the algorithm
and minimal memory storage and computational requirements.
(ii) Application of Constraints
Constraint methods are used for molecular bond lenghts and bond angles.
They are used to save computing time. The length of the time step ∆t in MD
simulation is limited by highest frecuency (νmax) motions occurring in the system.
By freezing the generally uninteresting high-frequency internal vibrations, such
as bond-length or possibly bond-angle vibrations, ν−1max is increased, which allows
for a longer time step ∆t.
(iii) Searching Neighbors
The bulk (approximately 90%) of the computer time required by a MD sim-
ulation is used for calculating the non-bonded interactions (equation 1.2), that
is, for finding the nearest neighbor atoms and subsequently evaluating the Van
der Waals and Coulomb interaction terms for the atom pairs obtained. Two
schemes for performing this task as efficiently as possible have been proposed:
scanning all possible atom pairs in an operation proportional to N2, and grid
search techniques whose operation is proportional to N .
1.2.3 Statistical Considerations
The Thermodynamic properties of a system containing N particles may be de-
termined by solving the 3N Newtonian equations of motion for infinite sampling
time. In practice, this is both impossible and unnecessary. It is impossible be-
cause only the deterministic equations for systems composed of a handful of par-
ticles could be solved even with modern computing resources. It is unnecessary
because a wealth of information may be obtained about a particular system by
9
1. Molecular Dynamics Simulations
concentrating on its probabilistic configurations (field of study of statistical me-
chanics). It consists of taking into account systems at equilibrium by probability
functions, and with some elementary assumptions, connecting the microstates of
a system to macroscopic thermodynamic quantities (such as temperature, chem-
ical potential and free energy). Molecular dynamics simulation, which solves the
Newtonian equations of motion for each atom in a system, allow connections
to be made between statistical mechanics and the thermodynamics of molecular
recognition [35].
On the other hand, since the beginning of protein molecular dynamics sim-
ulation, the issues of sampling have been a major concern. This is subject to
the ergodicity principle (usually called ergodic hypothesis), “The properties of a
system are the same when averaged over time as averaged over many systems”.
A number of reports have tested the degree of ergodicity in a simulation, but
there are still some discussions about how to demostrate that a simulation is not
converged or that it may be converged. In some sense, a priori any molecular
dynamics simulation has not fully sampled the phase space, because some events,
such as spontaneous unfolding of a soluble protein under native conditions, could
not be seen [36, 37].
The set of all states of the system is called an “ensemble”, the mathemati-
cal space in which it is described is called “phase-space”. Depending on which
constraints are applied to the system different ensembles can be obtained. For ex-
ample: a system of classical particles that is isolated from the outside world such
that the macroscopic properties N (number of particles), V (the volume), and E
(the total energy of the system) remain constant. Such a system is referred to
as the microcanonical ensemble or the NVE ensemble (for constant Number,
Volume, and Energy). This system can be in one of V accessible microstates, if
one assumes that transitions to and from each microstate are permissible (again,
the ergodic hypothesis). However, for our purposes, a more pertinent system is
one that still has a constant N and V, but that is in thermal equilibrium with its
environment and thus has a non-constant E but a constant temperature T. This
is the canonical ensemble, or NVT (constant Number, Volume, and Tempera-
ture) ensemble. The canonical ensemble assumes a constant number of particles,
volume and temperature; however, it is often desirable to consider a system in
which the volume is allowed to fluctuate to maintain a constant pressure. This
is referred to as the isobaric-isothermal ensemble, or NPT (constant Num-
ber, Pressure, and Temperature) ensemble [35, 38]. As a more general case, the
system of interest may be allowed to exchange particles with its environment in
the Grand Canonical Ensemble, where the chemical potential is considered a
constant instead of the number of particles in the system. In general, the canoni-
cal ensemble provides a sufficient description for our purposes, making the grand
canonical ensemble beyond the scope of this thesis.
As a final consideration in this section, the ergodicity principle for systems
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in equilibrium, running one long simulation, will give the same result as running
multiple short simulations. In this framework, one can do multiple simulations at
the same time on different computers. However, this assumes that the separated
systems are in equilibrium, which for some processes might not be feasible in
short simulations. For these cases most of the software packages mentioned before
have implemented parallelization schemes that allow a single simulation to run
on multiple processors, by distributing the calculations or by changing the seed
number for each simulation. In this way, longer simulations of larger systems can
be simulated at the same time by using very large computers [39].
1.3 Coarse Graining
Coarse graining makes reference to the omission of irrelevant degrees of freedom of
a system, in order to simplify the model. Strictly speaking every potential used for
MD simulations is in some sense a coarse-grained potential. For example, in all-
atom force fields the dynamics of electrons and nuclei are not explicitly considered
(most force fields) and for example united-atom force fields (like GROMOS) do
not explicitly consider carbon-bound hydrogen. However, in this section and
in this thesis Coarse Graining (CG) will refer to those force fields that do not
explicitly consider every heavy atom as a separate interaction site. In other
words, the term coarse graining will mean the existence of a lower resolution in
comparison to atomistic models. This does not mean that CG force fields are
always derived from an atomistic force field.
As shown earlier in Table 1.1, in 1975 Levitt made a first approximation
to molecular dynamics coarse-grained simulation using the BPTI protein repre-
sented as residues with one or two interaction sites. In 1976 Cotterill represented
a lipid using simple dumbbell shaped objects. These examples show that CG
force fields can have a wide range of different resolutions (the number of heavy
atoms mapped to one CG site) and very different methods can be used to con-
struct the potential energy function. A compendium of many different methods,
force fields and applications is given in [40].
It is possible to distinguish three categories in the methods used to obtain
a CG force field: (a) entirely based upon an atomistic force field, (b) entirely
independent of any atomistic force field and (c) combinations of these two. The
first category involves methods like inverse Boltzmann[41] and force matching[42,
43], where both bonded and non-bonded terms are directly derived from atomistic
simulations. The second category includes force fields that have been purely
parametrized to match macroscopic properties of the system to experimental
quantities, like bilayer properties or protein packing data derived from the Protein
Data Bank (PDB). Examples of this type of force field are described in [44,
45]. Methods in the third category often derive non-bonded interactions from
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experimental quantities, like partitioning free energies or liquid properties, while
they (partially) rely on atomistic simulations for bonded interactions. Examples
of this last category are the force fields derived by DeVane and coworkers[46] and
the Martini force field[47]. Thus, this thesis will focus on the Martini force field
due to its simplicity to apply [48] and its versatility of use in different systems
[28, 47, 49, 50].
Martini Force Field
The Martini CG force field applies a mapping of (on average) four heavy atoms
to one CG interaction site. Four CG bead types have been defined: charged (Q),
polar (P), non-polar (N) and apolar (C), which in turn are subdivided in four or
five levels, giving a total of 18 bead types. For the interactions between these
bead types, 10 different interactions levels are defined (O–IX) [47]. The inter-
actions between these beads are Lennard-Jones potentials at ten different levels,
corresponding to different values of the interaction parameter . The interaction
between two beads has been parametrized by matching the free energies of vapor-
ization, hydration and partitioning between water and apolar solvents for model
compounds. These model compounds are chemical entities covering a wide range
of molecules. Each of them are represented by one bead type and serve as build-
ing blocks for larger molecules. This modular setup and relatively small number
of pre-parametrized bead types make it easy to build new molecules compatible
with the Martini force field. The initial publication contained parameters for
water, organic solvents, surfactants, lipids and cholesterol [47, 49]. In later pub-
lications parameters were added for more types of molecules, including proteins
[48].
The loss of resolution in the Martini model compared to atomistic force fields
brings along different limitations and challenges. Except for the obvious loss in
structural detail, there are a few problems that especially are worth mentioning.
First, the grouping together of four heavy atoms reduces the entropy in a
molecule. In order to obtain correct free energies, this is corrected for by adapting
the enthalpic interactions [51]. As a result, the balance between entropy and
enthalpy will be disturbed and separating these two contributions has to be done
with the greatest care.
Second, a mapping of four heavy atoms to one CG interaction site, means
four water molecules are grouped together in one bead. This works fine, unless
one wants to study the behavior of single water molecules, for example water
inside water channels in proteins or interfacial water at protein interfaces. Note
that grouping four water molecules to one bead leads to a decrease in the number
of interaction sites by a factor of 12 and is also responsible for the mass used for
beads in Martini: 72 amu.
Third, coarse grain beads do not explicitly represent a possible polar nature
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of the underlying molecular building block. The polar nature is mimicked by a
slightly stronger interaction between polar beads and charged beads. In the case
of a four water cluster the polarizability is also lost. For water this has been
solved by introducing polarizable Martini water [52] and for polar amino acids a
solution is introduced by Djurre et al [53].
Fourth, the secondary and tertiary structure of the proteins are not stable
due to the lack of detail in the (backbone) interactions and the resulting lack
of polarity mentioned above. For the secondary structure this has been solved
by constraining α–helices and β–strands by angles, dihedrals and local elastic
networks [48]. The tertiary structure can be kept stable by using a global elastic
network, the so-called ElNeDyn approach, which connects backbone beads in
different parts of the protein by long elastic bonds [54].
Compared to united atom models, the coarse grain mapping decreases the
number of interaction sites by four, and for water by 12. The resulting total speed-
up of a simulation, as compared to a united-atom force field is between a factor
of 100 to 1000. There are three contributions to the speed-up. First, a reduced
number of interaction sites means less calculations to be performed per time step.
Notice that this goes roughly with the square of the reduction in the number of
particles, since not only the number of particles for which the interactions have
to be calculated is reduced, but also the number of interactions to other particles.
For Martini, this would be on average 42 = 16, although for water it is for more
(122 = 144). Second, coarse graining leads to a smoother energy landscape due
to the omission of fast modes in the molecules. The smoother energy landscape
allows for larger time steps without making large integration errors. For Martini,
typically a time step between 20 and 40 fs can be applied [55], 4 to 40 times longer
than those used in atomistic simulations. Last, the smoother energy surface is
also responsible for a faster progress in dynamic processes, for example diffusion.
In others words, in the same simulation time a system will sample a larger part
of phase space.
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Chapter 2
Epidermal Growth Factor
Receptors
Epidermal Growth Factor Receptors (EGFR) consists of four dif-
ferent members: EGFR/ErbB1, ErbB2, ErbB3 and ErbB4. They are
associated with a number of biological processes and are becoming
increasingly recognized as important therapeutic targets against can-
cer. Additionally, they are also proteins with a big size and therefore
a study by long-timescale molecular dynamics simulation is hard to
achieve. For that reason only their domains (extracellular, transmem-
brane and intracelullar) are considered by separated parts to perform
any molecular modeling. On the ohter hand, the dynamic nature of
these proteins is very related to their biological function. Molecular
dynamic simulation appears as a well-established method for modeling
such motions because it provides a characterization which is difficult
to access experimentally. Taking into account both the size limita-
tion and the molecular dynamics advantages, the protein–protein and
protein–membrane interactions regarding the EGFR receptors sup-
pose an interesting challenge that has been explored on this thesis.
2.1 Structure and Function
Epidermal Growth Factor Receptors (EGFR) control multiple cellular processes,
including cellular proliferation, survival differentiation and migration [2]. The
EGFR family consists of four different members: EGFR or ErbB1, ErbB2, ErbB3
and ErbB4. These receptors are formed by three differentiated domains: an extra-
cellular ligand-binding domain or ectodomain (ECD) containing four subdomains
(I-IV), a single transmembrane α-helix (TM) spanning the cellular membrane
and intracellular juxtamembrane (JM), a tyrosine-kinase (TKD) and autophos-
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EGFR FAMILY OF RECEPTOR
TYROSINE KINASES
The EGFR family of RTKs comprises four
members (collectively referred to as the
ErbB or HER family): EGFR itself, ErbB2
(HER2/Neu), ErbB3 (HER3), and ErbB4
(HER4). Like all RTKs, each ErbB receptor
comprises a large extracellular region, a sin-
gle spanning transmembrane (TM) domain,
TM:
transmembrane
JM: juxtamembrane
EGF: epidermal
growth factor
an intracellular juxtamembrane (JM) region,
a tyrosine kinase domain, and a C-terminal
regulatory region (Figure 1a). The ligands
that regulate ErbB receptors can be separated
into two main groups (Figure 2): the EGF
agonists that activate EGFR, and the neureg-
ulins (NRG) that bind ErbB3 and ErbB4
(69). There are at least seven different EGF
agonists: EGF, transforming growth factor
Figure 1
The domains of EGFR. (a) The extracellular region comprises four domains: I–IV, sometimes referred to
as L1, CR1, L2, and CR2 or L1, S1, L2, and S2. Domains I (red ) and III ( gray with red outline) share
about 37% sequence identity, while domains II ( green) and IV ( gray with green outline) are cystine rich.
The N-lobe of the kinase domain is in lavender and the C-lobe is in blue. This color scheme is used in all
ﬁgures unless otherwise noted. Amino acid numbers are noted for each domain boundary. The
conventional numbering system is used in which amino acid one of EGFR is the assumed ﬁrst amino acid
of the mature protein. In some recent papers, including those deﬁning EGFR cancer mutations,
alternative numbering is used where the signal peptide of EGFR is included. To convert to this alternative
scheme, add 24 to the numbers used here. (b) Representative ribbon diagrams of the domains of EGFR.
Domains I and III adopt a β-helix fold; here domain I from PDB ID 1YY9 is shown. Domains II and IV
adopt extended structures comprising a series of disulﬁde-bonded modules. Domain IV from PDB ID
1YY9 is shown with the disulﬁdes in stick representation and the disulﬁde-bonded modules numbered.
There are two types of disulﬁde-bonded module. One has a single disulﬁde bond and the intervening
loops adopt a bow-like arrangement (modules 2, 3, 5, and 6). The second type has two disulﬁde bonds
with consecutive cysteines linked in the pattern Cys1-Cys3 and Cys2-Cys4 (modules 1, 4, and 7). The
inactive kinase is shown (PDB ID 2GS7) with the ATP analogue (AMP-PNP) in stick representation.
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gle spanning transmembrane (TM) domain,
TM:
transmembrane
JM: juxtamembrane
EGF: epid rmal
growth factor
an intracellular juxtamembrane (JM) region,
a tyrosine kinase domain, a d a C-terminal
regulatory region (Figure 1a). The ligands
that regulate ErbB eceptors can be separated
into two main groups (Figure 2): the EGF
agonists that activate EGFR, and the neureg-
ulins (NRG) that bind ErbB3 and ErbB4
(69). There a t least seven different EGF
agonists: EGF, transforming growth factor
Figure 1
The domains of EGFR. (a) The extracellular region c mprises four domains: I–IV, someti s refer d to
as L1, CR1, L2, and CR2 or L1, S1, L2, and S2. Domains I (red ) and III ( gray with red outline) share
about 37% sequence identity, while domains II ( green) and IV ( gray with green outline) ar cystine r ch.
The N-lobe f the kinase domain is lavender and the C-lobe is in blue. This color scheme is used in all
ﬁgures nless otherwise noted. Amino acid numbers are noted for each domain boundary. The
conventional numbering system is used in which amino acid one f EGFR is the assumed ﬁrst amino acid
of the mature protein. In some rec nt papers, including those deﬁning EGFR cancer mutations,
alternative numbering is used where the signal peptide of EGFR is included. To convert to this alternative
scheme, add 24 to the numbers used h re. (b) Representative r bbon diagrams of the domains of EGFR.
Domains I and III adopt a β-helix fold; here domain I from PDB I 1YY9 is shown. Domains II and IV
adopt extended structures comprising a serie of disulﬁde-bonded modules. Domain IV from PDB I
1YY9 is shown with the disulﬁdes in stick representation and the disulﬁde-bonded modules numbered.
There are two ypes of disulﬁde-bonded module. One has a single disulﬁde bond a the int rvening
loops adopt a bow-like arrangement (modules 2, 3, 5, and 6). The second type has two disulﬁde bonds
with consecutive cysteines linked in the pattern Cys1-Cys3 and Cys2-Cys4 (modules 1, 4, and 7). The
inactive k nase is hown (PDB I 2GS7) with the ATP analogue (AMP-PNP) in stick representation.
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Figure 2.1: The domains of EGFR. (A) The extracellular region comprises four do-
mains: I–IV, sometimes referred to as L1, CR1, L2, and CR2 or L1, S1, L2, and S2.
Domains I (red ) and III ( gray with red outline) share about 37% sequence identity,
while domains II ( green) and IV ( gray with green outline) are cystine rich. The N-lobe
of the kinase domain is in lavender and the C-lobe is in blue. A ino acid numbers
are no ed for each do ain bou dary. (B) Repres ntative ribbon diagr ms of the do-
mains of EGFR. Domains I and III ado t a β-helix fold; her d mai I fr m PDB ID
1YY9 is shown. Domains II and IV adopt extended structures comprising a series of
disulfide-bonded modules. Domain IV from PDB ID 1YY9 is shown with the disulfides
in stick representation and the disulfide-bonded modules numbered. There are two types
of disulfide-bonded module. One has a single disulfide bond and the intervening loops
adopt a bow-like arrangement (modules 2, 3, 5, and 6). The second type has two disulfide
bonds with consecutive cysteines linked in the pattern ys1-Cys3 and Cys2-Cys4 (mod-
ules 1, 4, a d 7). The inactive kinase s s ow (PDB ID 2GS7) with the ATP a l gue
(AMP-PNP) in stick representation. Figure from [1], reproduced with permission.
phorylation domains. A schematic representation of these domains is shown in
Figure 2.1. On the other hand, it is well established that epidermal growth factors
(EGF) bind to the ECD domain, promoting EGFR dimerization and increasing
the tyrosine-kinase activity of its intracellular domain (See Figure 2.1) [1, 3].
The orientation of the four ECD subdomains has been revealed by recent
crystallographic studies (see Figure 2.2 for illustration). On the basis of these
studies, both tethered (ErbB3 [4], ErbB1/EGF [5], ErbB1/Cetuximab [6], ErbB4
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Tethered
I
II
III
IV
Extended
Ligand-bound
Extended
Ligand-free
I
II
III
IV
Figure 2.2: Possible Conformational Structures of Ectodomain. Roman numbers indi-
cate the different subdomains. In the tethered structure the subdomain II are bound
to subdomain IV (Structure from PDC code: 1M6B and common for ErbB1, ErbB3 and
ErbB4). The extended ligand-bound structure exhibits the subdomains I binds to
subdomain III mediated by ligand in blue (Structure from PDB code: 3NJP and com-
mon for ErbB1, ErbB3 and ErbB4). The extended ligand-free structure shows the
subdomains I binds to III with no ligand (Structure from PDB code: 1N8Z and only for
ErbB2)
[7]) and extended (EGF-bound [8] and TGF-α bound [9] truncated ErbB1 dimers,
Trastuzumab [10] and pertuzumab [11] ErbB2 complexes and full EGF-bound
ErbB1 dimer [12]) conformations have been proposed for ECD-EGFR receptors
(Figure 2.2). The tethered or autoinhibited conformation ties subdomains II
and IV, forming intramolecular interactions. Accordingly, the dimerization arm
in subdomain II is buried by subdomain IV, impairing the formation of EGFR
dimers. On the contrary, interactions between subdomains II and IV are broken
in the active untethered or extended conformation, provoking a release of the
dimerization arm, which can now dimerize with other EGFR monomers.
The ECD of ErbB1, ErbB3, ErbB4 contains a specific region where the EGF
ligand is bound (Figure 2.2). This binding is thought to promote intracellular
signaling cascades that regulate cellular growth and proliferation. Ligand binding
promotes signaling activation by homo or hetero-dimerization in the membrane
surface, changing the receptor conformation from a tethered structure to an ex-
tended dimerization-exposed arm conformation [13]. Other authors, however,
claim that the ligand can alter the equilibrium between previously formed ac-
tive/inactive dimers [13, 14]. Unlike other members of the family, the ErbB2
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receptor can adopt a unique conformation (extended conformation) resembling
the ligand-activated state, which is able to dimerize even in the absence of ligand
[15]. These receptors are engaged in the regulation of many processes such as
cell proliferation, differentiation and apoptosis. The abnormal regulation of these
receptors generates a number of human diseases, such as cancer [2, 16].
The biological activity of these receptors is known to depend on the formation
of homo or heterodimers in such a way that the intracellular kinase domains in
close contact can interact, initiating a signaling cascade that ends with cellular
proliferation [17]. The complex formed by ErbB2 and ErbB3 has been recognized
as being of pivotal importance in cancer development and evolution [18].
2.2 Structure as Revealed by MD Simulations
In 1994, Garnier et al [19] performed the firt MD simulation reported about
EGFR family. It was the transmembrane domain of ErbB2 (27 residues). In
this study a 160-ps simulation was performed in vacuum using GROMOS force
field and the influence of the mutation Val(659)→Glu(659) was examined. Later,
the same team published at 1996 another 160-ps simulation with two transmem-
brane peptides of ErbB2 in vacuum [20]. These studies reported that a single
amino acid replacement generates a propagation of local conformational changes
along the transmembrane segment which is important in the signal transduc-
tion mechanisms of transmembrane receptors. Garnier at el [21] reported at
1997 the first trasnmembrane dimer of ErbB2. They performed a MD simula-
tion by 575 ps without water. Two years later, Duneau at el [22] reported the
first work of an ErbB receptor within an explicit membrane environment with
a trasnmembrane ErbB2. It was a MD simulation by 500 ps using a fully sol-
vated dilauroylphosphatidyl-ethanolamine bilayer (DLPE). They reported that
one membrane simulation shows that the initial α-helix undergoes a local pi-helix
conversion in the peptide part embedded in the membrane core similar to that
found in simulation vacuum.
According to the historical progress on computational resources (see Chapter
1) both protein size and time scale have increased along the years. That is
the reason why the first studies on EGFR family were on the smaller domain:
transmembrane region, particularly on ErbB2. Consequently, just in 1999, the
first approximation on the tyrosine kinase domain by molecular dynamics was
done. They performed a 1-ns simulation of ErbB1 with water [23]. However, a
more extensive study on TK domain was performed by Suenaga [24] in 2003. A
simulation by 1 ns with 98 residues belonging to SH2 domain (see Figure 2.1),
fully solvated.
Finally, it was in 2005 when the first report about ectodomain was done.
Luo et al [25] performed MD simulations on homology structures for ErbB3 and
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ErbB4. Those structures were built using as template the X-ray structure of 2:2
EGF:EGFR complex (PDB ID: 1IVO). A total of 1 ns of time simulation was
performed in this study.
On the other hand, the first microsecond MD simulations, was reported in
2012. Du et al. [26] performed microsecond MD simulations of ErbB4 tethered
with its endogenous ligand neuregulin–1 β (NRG–1 β). While the conforma-
tional transition of the ECR-ErbB4/NRG–1β complex from a tethered inactive
conformation to an extended active-like form is observed clearly in the simula-
tion, the conformational change of ECD-ErbB4 is not. Therefore, it could be
proposed that ligand binding is indeed the active driving force for the conforma-
tional transition and further dimerization to occur. These authors constructed
an energy landscape for the conformational transition of ECD-ErbB4/NRG–1β
complex and reported that the energy barrier for the tether opening has a value
of 2.7 kcal/mol, which is in agreement to the experimental value (1-2 kcal/mol)
reported for ErbB1.
In adition of those mentioned above, relevant studies on tyrosine kinase do-
main have been performed by Telesco team [27–30]. They have revelead by MD
simulations transitions between inactive and active conformations in almost every
EGFR family receptors. Time simulations of 10 ns were used in their studies.
Finally, the study of the structure of EGFR receptors has been performed to
know the dynamic behavior. Thus, due to the X-ray or NMR structure absence,
the molecular dynamics has been used to predict structure, intra and/or inter
molecular interactions and conformational flexibility. Due to the experimental
difficult to get a complete structure of the EGFR receptor, only separated do-
mains have been studied by structural techniques (X-ray or NMR) and at the
same time by atomistic molecular dynamics. However, in 2013, another related
system studied by atomistic molecular dynamics simulation is the near half mil-
lion atom complex simulated over tens of microseconds by Shaw’s group on the
Anton supercomputer, a “hardware” specifically designed to accommodate molec-
ular dynamics algorithms (see section 1.1). This system consisted of a complete
EGFR dimer including the lipid bilayer [31]. This work reported that, in ligand-
bound dimers, the ectodomains take conformations favoring dimerization of the
transmembrane helices, dimerization of the juxtamembrane segments, and forma-
tion of asymmetric kinase dimers. In ligand-free dimers, the ectodomain does not
favor the N-termini interaction in the transmembrane domain, then, promote the
juxtamembrane segment dissociation and formation of symmetric kinase dimers.
Our molecular dynamics simulations of membrane-embedded EGFR suggest
that, in ligand-bound dimers, the extracellular domains assume conformations fa-
voring dimerization of the transmembrane helices near their N termini, dimeriza-
tion of the juxtamembrane segments, and formation of asymmetric (active) kinase
dimers. In ligand-free dimers, by holding apart the N termini of the transmem-
brane helices, the extracellular domains instead favor C-terminal dimerization
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tumor and in metastatic sites [17], indicating that anti-
HER-2 therapy may be effective in all disease sites.
2. Mechanisms of action of Herceptin
Herceptine (trastuzumab; Genentech; South San
Francisco, CA), a recombinant humanized mono-
clonal antibody (MAb) directed against the extra-
cellular domain (ECD) of the HER-2 protein (Fig. 1),
was engineered by inserting the complementary
determining regions of a murine antibody (clone
4D5) into the framework of a consensus human IgG1
[18]. Currently, Herceptin is the only HER-2-targeted
therapy approved by the United States Food and Drug
Administration for the treatment of metastatic breast
cancer (MBC). Although the mechanisms by which
Herceptin induces regression of HER-2-overexpres-
sing tumors are incompletely deﬁned, several
molecular and cellular effects have been observed in
experimental in vitro and in vivo models (Table 1).
2.1. Diminished receptor signaling
HER-2 activates multiple cellular signaling path-
ways, including the PI3 kinase (PI3K) and MAP
kinase (MAPK) cascades. Herceptin reduces signal-
ing from these pathways, and thus promotes cell cycle
arrest and apoptosis. Diminished receptor signaling
may result from Herceptin-mediated internalization
and degradation of the HER-2 receptor [19,20].
However, it is unclear whether Herceptin actually
downregulates HER-2, as some groups have demon-
strated that receptor levels are unchanged in response
to Herceptin treatment [21–23]. An alternative
mechanism by which Herceptin may block PI3K
signaling was recently described. Nagata et al. [24]
demonstrated that the interaction between HER-2
Fig. 1. Proposed mechanisms of action of Herceptin (trastuzumab). The illustrated mechanisms are described in detail in the text.
R. Nahta, F.J. Esteva / Cancer Letters 232 (2006) 123–138124
Figure 2.3: Proposed mechanisms of action of Herceptin (Trastuzumab). The illus-
trated mechanisms are described in detail in the text. Figure from [33], reproduced with
permission.
of the transmembrane helices, juxtamembrane segment dissociation and mem-
brane burial, and formation of symmetric (inactive) kinase dimers. Electrostatic
interactions of EGFRs intracellular module with the membrane are critical in
maintaining this coupling.
2.3 ErbB2 and Trastuzumab Antibody
The overexpression of ErbB2 leads to EGFR receptor activation in tissue culture,
while overexpression of other EGFR receptors is not active unless a ligand is
added [32].
Trastuzumab (Tzb), currently constitutes a part of the immunotherapy treat-
ment of advanced breast cancers, i.e., those with extensive metastasis, and in
general, solid tumors overexpressing ErbB2. Different clinical trials confirm the
efficiency of the antibody as an anticancer treatment. The monoclonal anti-
body Trastuzumab can bind to ECD-ErbB2 domain [10] (see Figure 2.3). The
fragment antigen binding (Fab) of Trastuzumab that binds to subdomain IV of
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the ECD-ErbB2 categorizes this site as a possible target for anticancer thera-
pies. Additionally, some authors claim, based on these structural studies, that
Trastuzumab is not effective in blocking dimerization of ErbB2 with ligand ac-
tivated EGFR or ErbB3 [34, 35]. However it has been reported that ligand
independent ErbB2/ErbB3 complex is disrupted by Trastuzumab [35].
The monoclonal antibody Trastuzumab was designed to target an extracel-
lular epitope of the ErbB2 receptor [36–38], being the first specific anti-ErbB2
treatment approved by the Food and Drug Administration (FDA). However, the
molecular mechanism of action of Trastuzumab is not at all understood. Differ-
ent effects have been reported regarding its anticancer activity [33, 39, 40]. For
example, Trastuzumab has been identified as an inhibitor of the downstream sig-
naling cascade for cellular proliferation by its action through a number of different
mechanisms (see Figure 2.3).
Those mechanisms are still incompletely defined, however, several molecu-
lar and cellular effects have been observed in experimental in vitro and in vivo
models, which can be the following:
(i) Internalization and degradation of ErbB2. Disrupts receptor dimerization;
disrupts downstream signaling pathways
(ii) G1 arrest and reduced proliferation. The G1 phase, or Growth 1/Gap
1 phase, is the first of four phases of the cell cycle that takes place in
eukaryotic cell division. Thus, Induces p27kip1-cdk21 complex formation;
induces p27kip1 levels.2
(iii) Apoptosis. Inhibits Akt3 activity
(iv) Suppresses angiogenesis. Reduces tumor vasculature in vivo; reduces ex-
pression of pro-angiogenic VEGF4, TGF-α, Ang-1, PAI-1; induces anti-
angiogenic TSP-1
(v) Immune-mediated responses. ADCC5; stimulates natural killer cells
(vi) Inhibits ECD-ErbB2 proteolysis
(vii) Inhibits DNA repair
The ErbB2 epitope targeted by Trastuzumab is located in subdomain IV of
the ECD. The tight interaction of the monoclonal antibody Fab with subdomain
1cdk, cyclin-dependent kinase
2p27kip1 is a cell-cycle regulatory protein that interacts with cyclin-CDK2 and -CDK4, in-
hibiting cell cycle progression at G1
3Akt, alpha serine/threonine-protein kinase
4VEGF, vascular endothelial growth factor
5ADCC, antibody-dependent cellular cytotoxicity
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IV of the ErbB2 was elucidated by crystallography [10]. Additionally, molecular
dynamics simulations performed at the atomistic scale on the complex have shown
an additional interaction between the antibody constant domain and the dimer-
ization arm located in subdomain II of the receptor [41, 42]. The authors argued
that the additional interaction does not appear in the crystallographic structures
due to strong crystal packing conditions which are not present in solution (see
Chapter 4).
Considering some computational works concerning ECDs, Fuentes et. al. [42]
have carried out several molecular dynamics studies on ErbB2 along with two
different antibodies, Trastuzumab (Tzb) and pertuzumab. They estimated the
binding free energy for several receptor/antibody complexes. They reported that
Trastuzumab has a higher affinity for apo ErbB2 than pertuzumab. Furthermore,
the epitope for Trastuzumab is domain IV whereas pertuzumab is bound to the
dimerization arm located in domain II. Subsequently, they found an increase in
affinity when both antibodies are bound to the receptor.
On the other hand, the Pertuzumab antibody, which binds to subdomain
II (dimerization arm), has shown to be effective to disrupt the ErbB2/ErbB3
ligand activated complex but ineffective for the independent ligand specie. In
the light of these findings, it has been hypothesized that the ligand independent
interaction between ErbB2/ErbB3 is different from the ligand-induced dimeriza-
tion. Thus, the subdomain II – sudomain II interfaces may not mediate in the
ligand-independent complex [35]. In contrast, very recent single-molecule force
spectroscopy studies suggest a mechanism of blocking of the heterodimerization
of ErbB2/Trastuzumab and ErbB3 receptors even in presence of the heregulin
(HRG) ligand [43].
Additionally, Bagossi et al. [44] reported the first 2:2 ErbB2/Trastuzumab
complex from homology based on the X-ray or nuclear magnetic resonance struc-
tures of extracellular, transmembrane, and intracellular domains. They predicted
some favourable dimerization interactions for the extracellular, transmembrane,
and protein kinase domains in the model of a nearly full-length dimer of ErbB2,
which may act in a coordinated fashion in ErbB2 homodimerization. The Bagossi
model was used in this thesis as the initial model to study the complete ErbB2
system.
Aim of this Thesis
According to the background previously mentioned, the following aims have been
proposed to performed an extensive approximation between EGFR family recep-
tor and the molecular dynamic simulations:
(i) Due to absences of the X-ray or NMR structure absences of ECD-ErbB3 and
ECD-ErbB4 in their active forms, an homology and a subsequent molecular
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dynamics refinement was targetted.
(ii) There is only X-ray structures for ECD-ErbB1 homodimers, therefore, to
study one of most relevant dimers, ECD-ErbB2/ECD-ErbB3, by homology
and molecular dynamcis refinement was proposed.
(iii) Study the conformational flexibility of the ECD-ErbB2/Trastuzumab com-
plex by molecular dynamics at an atomic resolution.
(iv) Validate the Martini coarse-grained force field on the protein-protein in-
teractions with the atomistic molecular dynamics results on the ECD-
ErbB2/Trastuzumab complex.
(v) Perform coarse-grained molecular dynamics on the full-length ErbB2 recep-
tor and learn about the protein-protein and protein-membrane interacions
regarding the monomer, homodimer, antibody-monomer and antibody -
homodimer systems.
As was mentioned along this Chapter, the size limitation of the EGFR recep-
tors and the molecular dynamics advantages offer a very fascinating challenge to
propose and explain the intra-protein and protein–protein interactions governing
the EGFR receptors in their active conformation.
A conformation stabilized by molecular dynamics for each receptor described
in the section 2.2 is proposed in Chapter 3. Additionally, their dynamic behavior
in water is studied in an attempt to explain some results that are experimentally
difficult to obtain.
Conformational flexibility of the ErbB2 ectodomain and Trastuzumab anti-
body complex is studied in Chapter 4. In this Chapter an exhaustive structural
analysis as revealed by atomistic molecular dynamcis is performed.
This interesting complex is used as the subject to validate the proper parame-
ters that should be used in molecular dynamics at coarse-grained resolution scale.
This is performed as a comparative work between atomistic and coarse-graining
in Chapter 5.
The comparison between these two scale resolution was used to perform
an exploration of the dynamics and interaction of a full ErbB2 receptor and
Trastuzumab-Fab antibody in a lipid bilayer model using Martini coarse-grained
force field. These results are reported in Chapter 6. A detailed description of the
type of interactions governing the homodimerization and antibody complexation
phenomena and the role that the membrane plays on that is presented.
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Chapter 3
Homology and MD Models of
the Extracellular Domains
This chapter is based on the published article “Simulation of homology models for
the extracellular domains (ECD) of ErbB3, ErbB4 and the ErbB2–ErbB3 complex
in their active conformations” by JF Franco-Gonzalez, J Ramos, VL Cruz and J
Mart´ınez-Salazar, J. Mol. Model., 19(2):931-941, 2013
Abstract
In this work, we provide models based on homology for the follow-
ing ectodomain (ECD) receptors in their active conformation: ErbB3,
ErbB4 and ErbB2/ErbB3 complex. All of them including their own
ligand (except for ErbB2), Heregulin-α. We also performed a re-
finement of the models by molecular dynamics simulations at atom-
istic scale. We compare the results with a model built for ErbB2
based on crystallographic information and analyze the common fea-
tures observed among members of the family, namely, the “periscope”
movement of the dimerization arm and the “hinge” displacement of
subdomain IV.
3. Homology and MD Models of the Extracellular Domains
3.1 Introduction
As mentioned in the Chapter 2, crystal structures for the extended configurations
of ErbB1 [1, 2] and ErbB2 [3, 4] are available. Additionally, homology structures
for ErbB3 and ErbB4 have been built using as template the crystal structure of
2:2 EGF:EGFR complex (PDB code: 1IVO) [5]. Note that this template lacks
the disordered subdomain IV, and homology structures can be obtained without
this critical domain. It is only recently that the crystal structure of the 2:2
EGF:EGFR dimer containing subdomain IV has been reported [6]. Therefore,
we propose to use this structure as a template to model a more complete structure
of the ErbB3 and ErbB4 receptors.
The objective of the present study was to build homology models of the ECDs
corresponding to ErbB3 and ErbB4 receptors in their extended conformations
along with a model of the back-to-back ErbB2/ErbB3:HRG-α heterodimer.
Water-equilibrated models of the ErbB2, HRGα:ErbB3 and HRGα:ErbB4
complexes were built using as templates the X-ray crystal structure of the ErbB2
/ Tzb (PDB code: 1NZ8) and 2:2 EGF:EFGR dimer (PDB code: 3NJP) com-
plexes, respectively, as starting structures, due to the high homology of this
receptor family. MD simulations (100 ns) were performed and details of the inter-
actions and intrinsic motions were investigated for each model through Principal
Component Analysis (PCA). Additionally, a homology structure of the ECDs of
the back-to-back ErbB2/ErbB3:HRGα complex were built and refined through
multi-nanosecond MD simulation. To our best of our knowledge, this is the first
computational model of this important complex.
3.2 Computational Methods
3.2.1 ECD-Complexes Models
The amino acid sequences of HRG-α, ErbB3 and ErbB4 were obtained from the
SwissProt database (P04626,P21860,Q15303). Homology models of the HRG-
α:ErbB3 and HRG-α:ErbB4 complexes were built using as a template the X-ray
crystal structure of chain A of the 2:2 EFG:EGFR dimer (PDB code: 3NJP)
[6]. Unlike the published homology models for HRG-α:ErbB3 and HRG-α:ErbB4
based on the 1IVO structure [5], our template allows the region of sub-domain
IV to be included in the homology model. The importance of the orientation of
this tight domain has been recognized because of the dependence of intracellular
protein kinase domain orientation on sub-domain IV disposition [1, 2].
All models were generated using the PRIME application of the Schro¨dinger
Suite 2011 (Schro¨dinger, New York, NY). First, pairwise sequence alignments be-
tween ErbB3 and ErbB4 and the EFGR template sequences were performed. The
BLAST alignment gives 61% and 63% of positives (percentage of residues that
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are positive matches to the BLOSUM62 similarity matrix [7]) and 46% and 47%
of identities (percentage of residues that are identical between sequences) using
1% and 1% of gaps between the template and ErbB3 and ErbB4, respectively.
However, this simple alignment does not assign adequately the secondary struc-
ture between the template and the query, as predicted by SSpro program [8]. For
this reason, we adopted an alignment algorithm (single template algorithm, STA)
that takes into account both secondary structure matching and profile–sequence
matching. The Figures 3.8–3.7 in the section 3.6 show the Alignment used for
the homology modeling of the Ecto-ErbB2, Ecto-ErbB3, Ecto-ErbB3 and HRG-α
proteins, respectively. This procedure minimizes the inaccuracy in a single sec-
ondary structure prediction at the expense of increasing the percentage of gaps.
This algorithm was designed specially for protein sequences with medium-to-
high sequence identity (>25%). The 3D-structures were built by replicating the
backbone atom coordinates for the aligned regions and side chains of conserved
residues, followed by optimization of the side chains and non-template residues.
Finally, the gaps were filled by insertions and final closing of deletions in the
alignment. In all cases, the gap length was less than 15. Finally, the homology
model coordinates were minimized with Schro¨dinger [9] using OPLS-2005 with
the default threshold of 0.05 kJ/mol as the convergence criteria. The same pro-
cedure was used for the homology model of the HRG-α peptide ligand taking as
template the EGF peptide of the 3NJP structure. The final HRG-α:ErbB3 and
HRG-α:ErbB4 models were built using both sets of coordinates, i.e., receptor and
ligand moieties, respectively.
3.2.2 ECD-Erbb2 Model
The initial model of the ErbB2 ectodomain was extracted directly from the 3D-
crystal structure deposited in the Protein Data Bank server (PDB code: 1N8Z)
[3]. The missing residues N124–A132 (sub-domain I), E325–G327 (sub-domain II),
G383–G386 (sub-domain III) and G603–P612 (sub-domain IV) were modeled based
on homologous sequences using the PRODAT database implemented in Sybyl
8.0 [10]. The loop fragment that affords the best geometric fit as monitored by
the homology score and RMS fit, was incorporated automatically into the model
[10, 11]. The side chains were built using the rotamer library of Sybyl by taking a
scan angle of 30o and a VDW factor of 0.9. The selected side-chain conformation
is the one that presents the fewest bumps on the rest of the molecule. Finally,
the structure was relaxed over 2500 steps using the steepest descent minimization
algorithm as implemented in GROMACS 4.5.3 [12]
We assume that the pKa of the individual amino acid residues at physiological
pH does not change when they are assembled into the protein receptor. Thus,
histidine (H) residues were kept neutral while lysine (L) and arginine (R) were
protonated and aspartic (D) and glutamic (E) acids were deprotonated. The
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resulting total charge for the complex was -10e. The system was then solvated
by adding 60717 water molecules and 10 Na+ ions to yield an electrically neutral
system. The system was finally equilibrated in a 2 ns NPT-MD simulation with
position restraint for all protein atoms.
3.2.3 Molecular Dynamics Simulations
The OPLS force field [13–15] for protein and SPC model [16] for water were
used throughout this work. Short-range repulsion-dispersion interactions were
truncated smoothly at 10 A˚. The Particle Mesh Ewald (PME) method [17, 18] was
used to calculate long-range electrostatic interactions, by means of a maximum
grid spacing of 2.5 A˚ and using fourth-order (cubic) interpolation for the fast
Fourier transforms. The temperature was kept constant at 300 K by coupling
the protein, the ions and the solvent independently to an external bath using the
Berendsen algorithm [19] with a coupling constant of 0.2 ps.
We used isotropic scaling for the pressure (1 bar) and a coupling constant
of 1.0 ps and a compressibility of 4.5e105 bar−1 when applying the Berendsen
algorithm [19]. The dynamics were integrated using the velocity Verlet integrator,
with a time step of 2 fs and bonds constrained using the LINCS algorithm [20].
Production dynamics were performed at constant pressure and temperature
(NPT ensemble) releasing all constraints on the heavy atoms during 100 ns, and
storing the trajectory every 10 ps. All minimizations, restrained and unrestrained
MD runs were performed with GROMACS 4.5.3 [12]. Molecular graphics were
drawn using the VMD 1.8.7 package [21].
3.2.4 PCA, Hydrogen Bonds and Contact Maps
PCA is a method that takes the trajectory of long MD simulations and calculates
the dominant modes in the motion of the molecule. Thus, the conformational
space is reduced, resulting in few relevant collective degrees of freedom over which
long-range fluctuation can be studied [22, 23]. PCA diagonalizes the covariance
matrix of the atom fluctuations from their average trajectory. In this framework,
the larger eigenvalues capture the larger fluctuations fraction. The ordering of
these eigenvalues gives rise to a small set of modes that capture most of the
protein’s fluctuation. We performed PCA in order to identify the most relevant
motions occurring in the EGFR family. In this work, we make use of the first
five eigenvectors, which were projected along the MD trajectory.
Hydrogen bonds (HB) are considered to exist when both distance between the
donor (D) and the acceptor (A) is less than 0.30 nm and the DHA (hydrogen-
donor-acceptor) angle is less than 30o.
The contact maps show the smallest distance between any pair of atoms be-
longing to two different residues. The output is a symmetrical matrix of smallest
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(a) HRG-α:ErbB3
*
*
(b) HRG-α:ErbB4
*
*
Figure 3.1: Refined Homology Model. (a) HRGα(orange):ErbB3(blue)
and (b) HRGα(orange):ErbB4(blue) superimposed on the X-ray structure
EGF(green):EGFR(red) (PDB code: 3NJP). The areas on the right are enlarge-
ments showing ligand–receptor interactions.
distances between all residues. Plotting these matrices for different time-frames
is a useful tool with which to analyze changes in the structure, HB networks and
hydrophobic contacts.
The root-mean square fluctuation (RMSF) for each residue was calculated
using the g rmsf tool from GROMACS. The change in secondary structure el-
ements during the simulation was monitored using the program DSSP (Define
Secondary Structure of Proteins) [24].
3.3 Comparative Homology Modeling
3D homology models were built for the ECD domain of HRG-α/ErbB3 and HRG-
α/ErbB4 complexes, using as template the X-ray structure corresponding to chain
A of the 2:2 EGF:EGFR dimer (PDB code: 3NJP) [6]. The EGFR template has
a high sequence similarity of 41% and 42% for the ErbB3 and ErbB4 proteins,
respectively. Cysteine residues forming disulfide bonds in both receptor and
ligand were well conserved during the alignment process. Figure 3.1 shows the
Cα backbone superposition of the refined HRGα:ErbB3 and HRGα:ErbB4 on the
X-ray structure of the EGF:EGFR. The root mean squared deviations (RMSD)
are 0.8 and 0.7 A˚ for both ErbB3 and ErbB4 Cα backbones, respectively. As
expected, a high degree of structural similarity was observed due to the high
sequence homology. Furthermore, all secondary motifs are well captured as seen
in Figure 3.1.
The HRG-α ligand has been modeled using the EGF structure in the 3NJP
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Figure 3.2: ErbB2/ErbB3:HRGα ex-
tracellular heterodimer complex (blue
for ErbB2 and ErbB3 receptors and
green for HRGα ligand) using the
(EGFR:EGF)2 homodimer (red and yel-
low) as template. The asterisk marks the
residues from 70 to 114 (flexible loop)
where the major differences between the
target and the homology model are found
ErbB2 ErbB3
HRGα
EGFREGFR
EGF
*
complex as template for both ErbB3 and ErbB4 cases. The sequence identity of
the EGF template and HRGα ligand is found to be around 25%. There are a
couple of NMR-solved structures for HRGα (PDB code: 1HAF [25] and 1HRF
[26]) . However, the EGF ligand in the 3NJP complex is preferred here over the
NMR structure in solution, because in principle the ligand–protein interactions
are better modeled in the 3NJP structure where the surroundings are taken into
account. RMSD values of 3.1 and 3.0 A˚ were calculated between the EGF Cα
backbone atoms in 3NJP and HRGα in ErbB3 and in ErbB4 homology models,
respectively. These high values are attributable to different residues in the region
of 1-6 (unbounded loop) and 23-28 (flexible loop between β-sheet structures) of
EGF and HRG-α ligands (asterisks in the zoomed area of Figure 3.1).
The models were evaluated using Ramachandran plots calculated by the
Procheck program. The percentage occupancies for favored, allowed, generously
allowed and disallowed regions are collected in Table 3.1. A percentage of 96.1
and 97.3 % of the residues are in favored and allowed regions for the HRGα:ErbB3
and HRGα:ErbB4 models, respectively. After these analyses, the quality of the
HRGα:ErbB3 and HRGα:ErbB4 complexes seem to be good enough for further
study.
The homology model of the ErbB2:ErbB3:HRGα extracellular complex fitted
on the X-ray structure of EGFR:EGF homodimer is shown in Figure 3.2. The
RMSD of the Cα backbone atoms are 3.1, 0.8 and 3.0 A˚ for ErbB2, ErbB3 and
HRGα ligand, respectively. The flexible loop made up of the 70-114 residues in
ErbB2 is causing the high RMSD value (marked with an asterisk in Figure 3.2).
This value is reduced to 0.7 A˚ once the loop is discarded. Again, the high values
of RMSD for the ligand are attributable to the flexible loops discussed above.
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Table 3.1: Ramachandran data of HRGα:ErbB3, HRGα:ErbB4 and
ErbB2/ErbB3:HRGα homology models calculated with the Procheck software.
The 3NJP and 1N8Z X-ray structures are shown as reference. Glycine and proline
residues are not taken into account.
Favored Allowed Generously Allow Disallowed
EGF:EGFRa 78.2 19.9 1.1 0.8
ErbB2b 82.6 15.3 2.0 0.0
HRGα:ErbB3 72.2 23.9 2.7 1.3
HRGα:ErbB4 72.5 24.8 1.2 1.5
ErbB2/ErbB3:HRGα 72.3 23.5 2.7 1.5
a Chain A of the X-ray structure in 3NJP pdb structure
b Chain C of the X-ray structure in 1N8Z pdb structure
Following the Ramachandran plot, the 95.8 % of the residues are in favored
and allowed regions for the models. Thus, the ErbB2:ErbB3:HRGα extracellular
complex is good enough for further MD studies.
3.4 Molecular Dynamics Analysis
We have performed MD simulations of each extracellular system in Table 3.1
(except for the EGF:EGFR complex) for at least 100 ns. The aim of these
simulations was to study the stability and the dynamics of the homology models.
3.4.1 ErbB2, HRGα:ErbB3 and HRGα:ErbB4
First, the time evolution of different sub-domains RMSD (Figure 3.3a) was used
to track conformational motions along the trajectory. No global conformational
switch from the extended to the tethered structure was detected in any case.
Thus, the extended conformations remain stable for ErbB2, HRGα:ErbB3 and
HRGα:ErbB4 systems as corresponding to active states. Subdomains I and III
remain stable along the whole trajectory to values smaller than 2 A˚ from the
crystal structure (ErbB2) or homology models (HRGα:ErbB3 and HRGα:ErbB4).
Sub-domains II and IV for ErbB2 are stable with respect to the reference crystal
structure, showing only a small deviation of around 3 A˚.
On the contrary, subdomains II and IV for the HRG-α:ErbB3 and HRG-
α:ErbB4 receptors exhibit deviations in the range of 4-7 and 6-10 A˚, respectively.
The RMSD profiles for HRGi-α:ErbB3 and HRG-iα:ErbB4 complexes are similar,
but the subdomain II deviations, which are larger for HRG-α:ErbB4 (7 A˚ versus
4-5 A˚, blue lines in Figure 3.3a), point to a more movable dimerization arm.
In summary, the largest deviations were observed for homology-based structures
along the MD trajectories.
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Figure 3.3: (a) RMSD of the different domains as a function of time. Subdomains
I, II, III and IV are shown as green, blue, magenta and red lines, respectively. (b)
RMSF as a function of the residue number in backbone atoms. The monomers ErbB2,
HRGα:ErbB3 and HRGα:ErbB4 are shown as red lines. The blue lines corresponds to
ErbB2 and HRGα:ErbB3 in the heterodimer complex. The last 50 ns of the trajectory
were taken in all cases.
Additionally, some remarkable residue moves were observed through RMSF
analysis. As shown in Figure 3.3b, the intense peak observed in sub-domain I
(peak 1) for ErbB2 corresponds to the motion of a flexible loop (N124–A132). On
the contrary, this loop becomes more constrained in ErbB3 and ErbB4 proteins
as a consequence of the presence of the HRGα ligand. It should be noted that
this loop has not been solved experimentally for the ErbB2 extracellular domain
by X-ray techniques, suggesting that the loop is very flexible in that protein [3].
The dimerization arm residues exhibit high RMSF values for all proteins (peak
II in Figure 3.3b), showing a periscope-like motion [27]. This motion can assist
the formation of dimers between different members of the EGFR family. Finally,
domain IV is very mobile with the highest RMSF values (peak 2) in all cases for
the proteins alone, corresponding to a hinge motion within this domain. This
flexibility could explain the difficulty encountered by other studies in elucidating
domain IV by crystallographic techniques on the extended conformations of pro-
tein monomers [2, 3]. Although sub-domain II is very flexible in all members of
the EGFR family, inspection of both trajectory and RMSD values suggests that
ErbB4 is the most flexible.
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Eigenvalue 1 Eigenvalue 2 Eigenvalue 3
Figure 3.4: Dominant motions represented by the first three eigenvectors in EGFR
systems. Several projections are shown in different colors between the two extreme
points(blue and red colors). Arrows indicate the direction of motion along the MD
simulation for each eigenvector. This figure shows the eigenvectors on the ErbB2 molecule
as a example.
Let focus now our analysis on the slowest modes that could provide informa-
tion on the collective motions of EGFR domains. PCA was performed on the
Cα atoms for the three molecules. Despite the fact that PCA was calculated
for a single trajectory, some useful qualitative information can be extracted from
this analysis. The first three eigenvectors account for Cα 80 % of the motion
in ErbB2, HRG-α:ErbB3 and HRG-α:ErbB4 molecules, respectively. The prin-
cipal motions for the first three eigenvectors of the ErbB2 molecule are shown in
Figure 3.4. The motions are similar for both ErbB3 and ErbB4 receptor. They
are shown in the Figure 3.11 in the section 3.6. The corresponding videos are
also available in the Supplementary Information1 section of the manuscript by
Franco-Gonzalez, et. al [28]. A concerted hinge movement of sub-domain IV is
observed clearly for the first PCA eigenvector. The other two eigenvectors show
clockwise and counterclockwise torsions of sub-domains II and IV, respectively.
Thus, PCA analysis confirms that sub-domains II and IV are very flexible, in
agreement with the previous discussion.
Summarizing, MD analysis of the free EGFRs led to the conclusion that
great flexibility of domains II and IV exists in the extended structures. It could
be hypothesized that this intrinsic flexibility would increase the possibility of
forming dimers among different members of the EGFR family.
1http://dx.doi.org/10.1007/s00894-012-1613-y
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Figure 3.5: RMSD of the domains
as a function of time for ErbB2 and
HRGα:ErbB3 systems in the heterodimer
complex. Domains I, II, III and IV are
shown as green, blue, magenta and red
lines, respectively.
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3.4.2 ErbB2/ErbB3:HRG-α Complex
Global conformation dynamics
The homology model for the ErbB2:ErbB3:HRGα heterodimer is shown in Figure
3.2. We used this model as the initial structure for a 100 ns MD simulation. The
overall change in conformation of the heterodimer from the homology structure
can be tracked by plotting the RMSD of each sub-domain (Figure 3.5). All
sub-domains in the monomers remain stable within less than 0.4 nm from the
homology model and they all relax over the first 10 ns. The exception is sub-
domain II in ErbB3, which has higher RMSD values (ca. 0.6 nm) and large
fluctuations, even at the end of the simulation. Moreover, the flexibility of each
subdomain of the heterodimer was quantified by calculating the RMSF for Cα
atoms in each residue (Figure 3.3b). The fluctuations in subdomains II and
IV (peaks 2 and 3) are reduced in the heterodimer (blue lines in Figure 3.3b) as
compared to the free monomers (red lines in Figure 3.3b). Therefore, as expected,
interactions between the dimerization arms (subdomain II) and domain IV of
both ErbB2 and ErbB3 monomers reduce the flexibility of such domains in the
heterodimer.
Intermolecular dimerization interfaces
Experimentally, the crystal structure of the (EGFR:EGF)2 homodimer is medi-
ated by intermolecular interactions involving both the dimerization arm in do-
main II [1, 2, 6] and the C terminus located at subdomain IV [6]. In the present
case, the dimerization arm in subdomain II of any monomer (i.e., ErbB2) tends
to interact with a region between subdomains I and II of the neighboring re-
ceptor. Interactions between residues placed at subdomain IV are also observed
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Figure 3.6: (a) Subdomain IV – subdo-
main IV interface. Interactions in region
defined as I (b) and II (c) are zoomed.
White surfaces are Hydrophobic contacts
and green surfaces are polar contacts. The
main residues responsible for each interac-
tion are labeled inside the figure. ErbB2
and ErbB3 receptors are shown as blue
and red cartoon models
(see Figure 3.2). The most important non-bonded close contacts between the
ErbB2 and ErbB3 are collected in Table 3.2. These contacts take into account
salt bridges, HB, aromatic interactions and hydrophobic contacts. As it can be
seen in Table 3.2, the subdomain II – subdomain II interface is made up of both
hydrophobic and HB interactions in which the 15 residue dimerization arms go
through the pocket region of subdomains I and II of the neighboring receptor.
However, a persistent interaction with subdomain III of ErbB2 was observed only
for the ErbB3 dimerization arm. The subdomain IV – subdomain IV interfaces
are shown in Figure 3.6. As can be seen, two regions are kept from the last 50 ns
of the trajectory. The first region (Figure 3.6) corresponds to residues A599–L609
and S587–E596 in ErbB2 and ErbB3, respectively. This region has a marked hy-
drophobic character with residues P602 and V605 in the ErbB2 receptor and P590,
V593 and L594 in the ErbB3 receptor.
On the other hand, the second region (Figure 3.6) corresponds to residues
C631–C635 and C617–G623 in ErbB2 and ErbB3, respectively. In this case, the
interaction is maintained by the formation of two hydrogen bonds (see Table
3.2).
PCA was carried out on the MD trajectory to identify the most significant
cooperative motions of the ErbB2:ErbB3:HRGα complex. The first three eigen-
vectors account for 75% of the overall motions. These three eigenvectors consist
mainly of concerted motions of both subdomains IV (not shown). Remarkably,
the motion of subdomain II is more constrained in comparison with the ErbB2
and ErbB3 free receptors.
3.5 Conclusions From This Work
The present work provides a useful collection of homology models for the ECD
ErbB receptors updated with the information provided by the latest crystallo-
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Table 3.2: Interface non-bonded close contacts (salt bridges, H-bonds,aromatic and
hydrophobic interactions) in the ErbB2/ErbB3:HRG-α complex. The domain to
which each amino acid belongs is given in parentheses. Only residue-residue contacts
with averaged contact area above 20 A˚2 are displayed. The H-bonds reported fulfill
the criteria that the donoracceptor distance and angle cutoffs of 3.5 A˚ and 30o are
maintained during at least 50% of the last 50 ns of the trajectory. The distance in
salt bridges is less than 4.0 A˚.
ErbB2 ErbB3 Interaction Type
Dim. Arma
V273 R258 Hydrophobic
Y275 C301 H-bond
D278 T108(I) Hydrophobic
F280 R267, Y282 Hydrophobic, aromatic
E281 A304 Hydrophobic
Dim. Armb
T291, C312(III) Y265 Hydrophobic, H-bonds
H258 K267 Hydrophobic
Q58(I) L268 H-bonds
F292, Y304 F270 Hydrophobic, aromatic
L314(III) Q271 Hydrophobic
T313(III) L272 Not assigned
II – IIc
G224 N224 H-bond
P233 Q213 H-bond
K333 E321 Salt bridge
R352 E273 Salt bridge
IV – IVd
P602, V605 P590, V593, L594 Hydrophobic
H633 C621 H-bond
A645 L622 H-bond
a Interaction between residues at the dimerization arm of the ErbB2 with the ErbB3
receptor. The dimerization arm in ErbB2 receptor is defined as residues 271–286.
b Interaction between residues at the dimerization arm of the ErbB3 with the ErbB2
receptor. The dimerization arm in ErbB3 receptor is defined as residues 261–276.
c Persistent hydrogen bonds between residues belonging to subdomain II.
d Persistent contacts between residues located at subdomain IV.
graphic structures of suitable templates deposited in the Protein Data Bank. In
particular, the model for ErbB3 and ErbB4 receptors includes the structure of
sub-domain IV which was absent in previous studies. The quality of the models is
proved to be very satisfactory in view of the resulting RMSD differences with the
template structures and Ramachandran maps showing suitable backbone torsion
angle distributions.
These models were subsequently refined by MD simulation. It is worth men-
tioning that, according to the RMSD time evolution, the ErbB2 receptor, built
from crystallographic data, exhibits the most stable structure along the whole
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simulation. A set of common features was found for all the receptors, namely
a “periscope” movement of the dimerization arm in domain II, which confirms
the findings of previous studies. What is more important is the remarkable flex-
ibility found for sub-domain IV. A “hinge” movement of this domain towards
sub-domains II and III was observed in all cases. In this context, PCA reveals
that the first eigenvectors are associated to this collective movement.
We have also proposed a model for the interaction of ErbB2 and ErbB3.
This complex forms one of the most biologically relevant heterodimers associated
with aggressive carcinomas. To the best of our knowledge, the model proposed
in our work is the first atomistic scale model for ECD interaction in this het-
erodimer. The structure presents the expected interaction between the two re-
ceptors through the dimerization arms in sub-domain II, which immobilizes these
domains with respect to the unbound structures. In addition to this, a weaker
interaction through sub-domain IV is also observed. However, the “hinge” move-
ment observed in the separated receptors is also noticeable in the complex in an
asymmetric way, being less mobile in ErbB2 than in ErbB3.
The biological consequences of this information are not so evident, and further
studies need to be carried out. However, the generation of the ECD ErbBs models
presented in this work will serve as an starting point for a systematic study of
these important receptors in order to provide clues for the development of more
effective therapeutic strategies.
3.6 Additional Information
Alignment for the homology models
Figure 3.7: Alignment used for the homology modeling of the Heregulin-α.
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Figure 3.8: Alignment used for the homology modeling of the Ecto-ErbB2 receptor.
Figure 3.9: Alignment used for the homology modeling of the Ecto-ErbB3 receptor.
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Figure 3.10: Alignment used for the homology modeling of the Ecto-ErbB4 receptor.
Additional PCA eigenvectors
Figure 3.11: First three PCA eigenvectors corresponding to the simulations of the
HRGα:ErbB3 and HRGα:ErbB4 ECD receptors
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Chapter 4
ECD-ErbB2/Trastuzumab-Fab
Complex
This chapter is based on the published article “Conformational Flexibility of the
ErbB2 Ectodomain and Trastuzumab Antibody Complex as Revealed by Molecular
Dynamics and Principal Component Analysis” by JF Franco-Gonzalez, J Ramos,
VL Cruz and J Mart´ınez-Salazar, J. Mol. Model., 19(3): 1227-1236, 2013
Abstract
As a successful therapeutic treatment against breast cancer the
monoclonal antibody Trastuzumab is used. Its interaction with the
ECD-ErbB2 is well-known. A better understanding of the detailed
structure of the receptor-antibody interaction is indeed of prime in-
terest for the design of more effective anticancer therapies. In order
to discuss the flexibility of the complex ECD-ErbB2/Trastuzumab, a
multi-nanosecond molecular dynamics simulations together with an
analysis of fluctuations, through a PCA of this system are shown in
this chapter.
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4.1 Introduction
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Figure 4.1: Schematic representation
of the different domains in the ECD-
ErbB2/Trastuzumab-Fab complex.
ECD-ErbB2 receptor is shown in green
(I and III subdomains) and blue (II
and IV subdomains), whereas Tzb, the
variable (V) and the conserved domain
(C) are represented in yellow (light
chain) and red (heavy chain)
Several computational studies based on
computer simulations have tackled the
structure and interactions between trans-
membrane ErbB2 domains in lipidic bi-
layer models [1–6] and in tyrosine kinase
domain activation [7–9]. However, compu-
tational studies of the interaction of ErbB2
ectodomain (ECD-ErbB2) with antibod-
ies, such as Trastuzumab (Tzb), are less
considered. Wang et al. have studied
the binding regions of ECD-ErbB2 with
inhibitory (Tzb) and non-inhibitory (HF)
monoclonal antibodies using a combina-
tion of site-directed mutagenesis, dock-
ing and short molecular dynamics simula-
tions. They concluded that the inhibitory
Tzb antibody binds to subdomain IV (C-
terminal region) of the ECD and that
the non-inhibitory HF antibody recognizes
subdomain II (N-terminal region) [10]. In
other study, the 3D structure of an auto-
inhibitor (herstatin)/ECD-ErbB2 complex
has been proposed using molecular docking methods. The binding site of her-
statin of the ECD-ErbB2 domain was proposed to be at the S1 subdomain (here
subdomain II). That observation was verified by inmunoprecipitation, confocal
microscopy and fluorescence resonance energy transfer experiments [11]. Very
recently, Fuentes et al. have published a 20 ns MD study and a fluctuation anal-
ysis of the interaction between ErbB2 and a combination of Tzb and pertuzumab
antibodies [12]. Their simulations shed light on two important aspects of the
interaction: on one hand, the fluctuations in subdomain II are enhanced by the
Tzb binding, and on the other hand, the existence of a cooperative mechanism
between these two antibodies and the ErbB2 ECD that could avoid the homo
and heterodimerization of ErbB2 with other members of the EGFR family.
In our work we performed a long 170 ns MD simulations of the ECD-ErbB2
/Tzb complex to elucidate details of the interaction between its components using
as starting point the x-ray crystal structure [13]. Additionally, an analysis of the
large scale fluctuations has been performed using the PCA analysis. It should be
mentioned here the experimental finding that the variable Tzb domains bind to
subdomain IV (juxtamembrane domain) of ECD-ErbB2. These interactions have
been largely conserved along the MD simulation. However, large fluctuations are
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observed which allow the formation of novel contacts between the dimerization
arm of subdomain II ErbB2 and the Tzb residues in the constant domain. To
our best knowledge this interaction has not been yet reported.
4.2 Computational Methods
Structure Modeling
The initial model of the ECD-ErbB2 and Tzb-fab (ECD-ErbB2/Tzb) was directly
taken from the 3D crystal structure deposited in the Protein Data Bank server
(PDB code: 1N8Z) [13]. A schematic representation can be seen in Figure 4.1.
The missing residues 102-110, 303-305, 361-364 and 581-590 have been modeled
based on homologue sequences using the PRODAT database implemented in
Sybyl 8.0 [14]. The loop fragment that gave the best geometric fit, based on
the homology score and RMS fit, was automatically incorporated into the model
[14, 15]. The side chains were built residue by residue, one at a time, using the
rotamer library of Sybyl using a scan angle of 30o and VDW factor of 0.9. The
selected side chain conformation for each modeled residue is the one that presents
the fewest VDW contacts with the rest of the molecule. Finally, the structure
was relaxed for 2500 steps using the steepest descent minimization algorithm
as implemented in GROMACS 4.5.3 [16]. The Procheck analysis of the added
fragments reports a Ramachandran plot with the following statistics: 64.3 % in
most favored regions, 21.4 % in additional allowed regions, 14.3 % in generously
allowed regions and 0 % in disallowed regions. From that point of view the
structure of the added fragments seems to be quite reasonable.
We assumed that the pKa of the individual amino acid residues at physi-
ological pH does not change when assembled into the protein receptor. Thus,
histidine (H) residues remained neutral; lysine (L) and arginine (R) were proto-
nated and aspartic (D) and glutamic (E) acids were deprotonated. The resulting
total charge for the complex was -10 e units. The system was solvated by 60717
water molecules and 10 Na+ ions have been added to yield an electrically neutral
system. Periodic boundary conditions were applied along the three dimensions.
The initial rectangular box lengths were 13.9 nm, 12.5 nm and 11.5 nm respec-
tively. The system was equilibrated in a 2 ns NPT-MD simulation with position
restraint for all protein atoms.
Molecular Dynamics
The OPLS force field [17–19] for protein and the SPC model [20] for water were
used along the whole work. Short range repulsion-dispersion interactions were
smoothly truncated at 10 A˚. The Particle Mesh Ewald (PME) method [21, 22]
was used to calculate long range electrostatic interactions, with a maximum grid
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spacing of 2.5 A˚ and using fourth-order (cubic) interpolation for the fast Fourier
transforms. The temperature was kept constant at 300 K by coupling the protein,
the ions and the solvent independently to an external bath using the Berendsen
algorithm [23] with a coupling constant of 0.2 ps.
We used isotropic scaling for the pressure (1 bar). A coupling constant of 1.0
ps and a compressibility of 4.5e10−5 bar−1 were used in the Berendsen algorithm
[23]. The dynamics were run using the velocity Verlet integrator, with a time
step of 2 fs and bonds constrained conditions using the LINCS algorithm [24].
Production dynamics was performed at constant pressure and temperature
(NPT ensemble) releasing all constraints on the heavy atoms during 170 ns and
accumulating the trajectory frames every 10 ps. All minimizations, restrained
and unrestrained MD runs were performed with GROMACS 4.5.3 [16]. Molecular
graphics have been drawn using the VMD 1.8.7 package [25].
PCA analysis, Hydrogen Bonds and Contact Maps
With PCA analysis the configurational space is reduced, containing few relevant
collective degrees of freedom in which long range fluctuation can be studied [26,
27]. A PCA diagonalizes the covariance matrix of the atom fluctuations from
their average trajectory. In this framework, the larger eigenvalues correspond to
eigenvectors which explain most of the variance of the atomic fluctuations. The
ordering of these eigenvalues gives rise to a small set of modes that capture most of
the proteins fluctuations. We have performed a PCA analysis in order to identify
the lowest frequency motions occurring in the ECD-ErbB2/Tzb complex. Along
this work, we make use of the first three eigenvectors, which were projected along
the MD trajectory. The g covar and g anaeig tools in the GROMACS package
were used to perform the PCA analysis.
Hydrogen bond (HB) is considered to exist when both distance between the
donor (D) and the acceptor (A) is less than 0.30 nm and the hydrogen-donor-
acceptor (HDA) angle is lower than 30o. The contact maps show the smallest
distance between any pair of atoms belonging to two different residues. The
output is a symmetrical matrix of smallest distances between all residues. Plot-
ting these matrices for different time-frames is useful to analyze changes in the
structure, and particularly hydrogen bond networks and hydrophobic contacts.
The root-mean square fluctuation (RMSF) for each residue has been calculated
using the g rmsf tool from GROMACS. The change of secondary structure ele-
ments during the simulation was monitored using the program define secondary
structure of proteins (DSSP) [28].
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ECD-ErbB2
Tzb-Fab
VL
VH CH
CL
IV
III
I
II
0 ns 2 ns 5 ns
10 ns 20 ns
III–VH
II–CH
IV–VH
IV–VL
170 ns
Figure 4.2: Selected structures of the ECD-ErbB2/Tzb complex along the MD trajec-
tory. The ECD-ErbB2 protein and Tzb-fab are shown as yellow and blue/red ribbons,
respectively. The configuration at t=0ns corresponds to the x-ray elucidated structure
4.3 Stability Analisys of Full Trajectory
Figure 4.2 shows the time evolution of the interaction in the ECD-ErbB2/Tzb-fab
complex from the MD simulations. At t=0 ns, the initial conformation matches
to the x-crystal solved structure. It is relevant to mention that the secondary
structures are well conserved along the whole MD trajectory (see DSSP analy-
sis section in the section 4.8). Furthermore, the interaction values between the
ECD-ErbB2 subdomain IV and VH/VL domains of Tzb, which have been ex-
perimentally reported, are well preserved during the whole MD trajectory (as
will be discussed below). However, after 20 ns, the ECD-ErbB2 subdomain II
(dimerization arm) makes contact with the CH subdomain of the Tzb. Later on,
after 100 ns (not shown in Figure 4.2), less important contacts between III and
VH subdomains are found. Most likely, these interactions are a consequence of
the driven-contacts between II and the CH domain.
The time evolution of the Cα-RMSD (root mean square deviation) for the
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Figure 4.3: ErbB2 residue fluctuations
along the MD. Root mean square fluctua-
tion (RMSF) of backbone atoms of ECD-
ErbB2 residues from the initial structure
(blue line), the apo-protein case (red line)
and from the B factors (black line) using
the formula RMSF=(3B/8pi2)1/2. Aster-
isk stands for missing loops in the x-ray
structure 1N8Z. The shaded area indicates
residues in subdomain II
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ECD-ErbB2 receptor has been used to track the equilibration and any possible
reorganization of present domains in the whole complex (see Stability analysis
section in the section 4.8). The Cα-RMSD relaxes over the first 70 ns to a value
of around 0.41±0.03 nm (averaged over the interval 70-170 ns). These structural
changes are mainly due to subdomains IV and II of the ECD-ErbB2, showing the
largest values (Cα-RMSD(70ns−170ns) 00.27±0.02 and 0.31±0.04 for subdomains
IV and II, respectively). On the other hand, Cα-RMSD values for the subdomains
I and III keep stable around 0.12±0.02 nm along the whole trajectory. As shown
in Scheme 4.1 and Figure 4.2, the subdomains II and IV are more exposed to the
interaction with the VL and CH domains of the antibody structure, respectively.
The ECD-ErbB2 residue RMSF values for the x-ray structure (calculated
from B factors of the 1N8Z file as (3B/8pi2)1/2 ) and for the MD simulations
are presented in Figure 4.3. As can be seen in the MD simulations, the largest
fluctuations are concentrated in the missing loops of the x-ray structure (marked
with an asterisk). These large fluctuations are compatible with the fact that these
residues cannot be solved in the crystalline structure [13]. Furthermore, several
peaks corresponding to the dimerization arm residues (subdomain II) show large
fluctuations (shaded area in Figure 4.3), which are well-suited with the movement
discussed above. This is in agreement with similar fluctuations of subdomain II
recently observed in shorter MD simulations (20 ns) of the ECD-ErbB2/Tzb
complex using a different force field [12]. However, these residue fluctuations in
the subdomain II are not observed in the experimental data. This may indicate
that the subdomain II region in the x-ray structure is rather constrained due
to the crystalline packing [29, 30]. We will come back to this difference in a
subsequent section. We have included in Figure 4.3 the RMSF values of the
ECD-ErbB2 simulation in water to compare with the values corresponding to the
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Figure 4.4: PCA analysis. Eigenvalues
(squares, scale on left side) and accumu-
lated percentage (circles, scale on right
side) of the first 50 PCA modes
ErbB2/Tzb complex. As can be observed, the fluctuations in the dimerization
arm are very similar in both cases. The main difference between both RMSF
profiles corresponds to subdomain IV, which shows a higher flexibility in the
apo-protein case.
4.4 PCA Analysis
The PCA allows the projection of the complex protein dynamics on a set of
collective modes which can be ordered from the largest to smallest contributions of
the protein fluctuation variance, as measured by the eigenvalues of the covariance
matrix [26, 27]. The largest eigenvalue corresponds to the slowest motion, and
so forth.
The contributions to the motion for the 50 first collective modes are shown
in Figure 4.4. The major contribution to the collective motion is given by the
first nine modes with 90 % of the total protein fluctuations. Modes 1 and 2
contribute with 30 and 26 % of the overall motion with fluctuations of 73 and 63
nm2, respectively. Mode 3 gives 12 % with a fluctuation value of 30 nm2. These
three first modes account for ∼70 % of the total protein fluctuations and only the
nine first eigenvalues have a value greater than 1 nm2 (Kaiser criterion discarding
eigenvalues below 1) [31] accounting for a 90 % of the total fluctuations.
The three first modes along with the RMSF residue values for each of them
are shown in Figure 4.5. In the first mode, part of the subdomain II in ErbB2
translates in a concerted way to domain CH in the Tzb protein. Upon this
movement, large fluctuations of the flexible loops (102-110 and 581-590, marked
with asterisk) in the subdomain I and IV are also observed (Figure 4.5b, black
line). Mode 2 is dominated by the movements of the loop 102-110 in subdomain
I with some minor contributions from a concerted rotational approach of the II
and CH domains of the ErbB2 and Trastuzumab proteins (Figure 4.5b, red line).
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Figure 4.5: Eigenvectors from the PCA analysis. (a) The motion of the three first
principal components is overlaid sequentially. Red and blue colors represent large and
low-amplitude mode, respectively. The dimerization arm and the Transtuzumab domains
exhibit the largest localized motions assisting to the interaction between both regions (see
text for details). (b) RMSF of residues for each mode, 1 (black line), 2 (red line) and 3
(yellow line) in the ERBB2 and Tzb proteins. Asterisk stands for missing loops in the
x-ray structure 1N8Z. The shaded area indicates residues in subdomain II of the ErbB2.
Finally, in mode 3, only a torsional combined motion of the II and CH domains
contributes significantly to the overall fluctuation.
These eigenvalues involve large motions of the subdomain II and CH motions
which can be confirmed by visualizing the distances between the center of mass
of the different domains in ErbB2 and Trastuzumab moieties. The approach of
II and CH domains is evidenced by a decrease of more than 2 nm of the center
of mass distance (CMD). On the other side, the CMD between subdomain IV in
ErbB2 and Tzb domains are kept nearly constant throughout the full dynamics
and close to those found in the x-ray structure.
In summary, these principal component eigenvectors show a hinge motion in
which subdomain II and CH domains approach each other, allowing the formation
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Index Donor Acceptor Occupancy (%)
1 ARG577(IV) ASP102(VH) 99.8
12 LYS593(IV) GLY103(VH) 3.1
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Index Donor Acceptor Occupancy (%)
2 MET585(IV) TYR49(VL) 28.2
5 GLN602(IV) ASN30(VL) 50.4
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1
Figure 4.6: Hydrogen bond network between antibody and domain IV. (a) Hydrogen
bonds between IV and VH domains, (b) Hydrogen bonds between IV and VL domains
and (c) Snapshot at 170 ns of the hydrogen bond networks between IV (yellow), VH
(blue) and VL (red) domains
of some interactions between the dimerizarion arm in the subdomain II of ErbB2
protein and the Tzb residues located in the CH domain. These interactions will
be discussed in the next section where a detailed analysis of the inter-domain
hydrogen bonds and electrostatic interactions between ErbB2 and Tzb proteins
is given. Movies containing the motion of the first three eigenvectors can be seen
in the Supplementary Information1 section of the manuscript by Franco-Gonzalez,
et. al [32].
4.5 Subdomain IV – Tzb Interactions.
Hydrogen bonds have been characterized according to their residence times during
the MD trajectory using the distance and angle criteria defined in the Compu-
1http://dx.doi.org/10.1007/s00894-012-1661-3
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tational methods section. Firstly, we study the described interactions between
subdomain IV and Tzb and compare them with the experimentally available
data. Figure 4.6a shows the time evolution of the hydrogen bonds which de-
scribes the interaction of the subdomain IV of the ECD-ErbB2 protein and
the domain VH of the Tzb-fab antibody. According to the calculations, three
pairs are maintained from the starting structure during the whole simulation,
Arg577(IV)–Asp102(VH), Arg50(VH)–Glu558(IV) and Arg59(VH)-Asp560(IV)
with occupancies close to 100 %. These interaction pairs can be better consid-
ered as salt bridges between charged acidic and basic residues. Similarly, the
hydrogen bonds between the subdomain IV of the ECD-ErbB2 protein and the
domain VL of the Tzb-fab antibody are shown in Figure 4.6b. As can be seen, hy-
drogen bonds are more labile (small residence time) and they are mainly formed
by two pairs, Asn30(VL)–Gln602(IV), and Thr94(VL)-Asp560(IV). Furthermore
two new H-bonds are alternatively formed by the pair Tyr49(VL)–Leu586(IV)
and Met589(IV)–Tyr49(VL) after 80 ns. All these interactions (Figure 4.6c)
are in close agreement with the experimental data reported by Cho et al. [13],
who showed electrostatic interactions between the 557–560 and 593–603 loops of
the ErbB2 ectodomain and the Tzb antibody. Hydrophobic interactions have
also been described between the loop 570–573 located in the subdomain IV of
the ErbB2 receptor and the Tzb-fab antibody in the same experimental work
[13]. The hydrophobic interactions were analyzed with the help of the contact
map analysis utility which is available at the SPACE server for protein struc-
ture analysis (http://ligin.weizmann.ac.il/cma/) [33]. The hydrophobic contacts
were selected from the list provided by CMA (Contact Map Analysis) with two
conditions, namely, the contact surface should be above 0.4 nm2 and the two
involved residues should be hydrophobic. Along the MD simulation, the main
hydrophobic interactions between these domains are effectively located between
the loop 570–573 of the ErbB2 receptor and the hydrophobic CDR3 loop of the
VH domain (loop 101–110) in the Tzb-fab. In addition, hydrophobic interactions
between the 570–573 loop and the CDR3 loop of the VL domain (loop 93–99) are
also observed. Thus, it can be concluded that these hydrogen bond interactions
and hydrophobic contacts are very stable, maintaining their distances along the
full simulated trajectory.
4.6 Subdomain II – Tzb Interactions.
Based on the global structural changes observed in the previous section for the
subdomain II, we have investigated possible hydrogen bond interactions and elec-
trostatic contacts with the antibody domains. Figure 4.7 shows the hydrogen
bond network between subdomain II and CH region. It can be observed that no
hydrogen bonds are presented at the beginning of the simulation. Later on, some
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Index Donor Acceptor Occupancy (%)
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Figure 4.7: Hydrogen bond network between antibody and domain II. (a) Hydrogen
bonds between II and CH domains, (b) Snapshot at 170 ns and zoom of the hydrogen
bond networks between II (yellow) and CH (blue) domains
residues start forming hydrogen bonds, being the pairs Asn211(CH)–Thr256(II)
and Lys213(CH)–Asp255(II) the most stable along the trajectory. The occu-
pancy (fraction of time in which the H-bond is formed) of these H-bonds are
27 % and 74 %, respectively, for the last 70 ns. Predominantly, a salt bridge
between Asp73(VH) and Lys346(III) is formed at distances fluctuating between
3.0 and 4.0 A˚. The formation of these H-bonds and electrostatic contacts might
contribute to stabilize the structure resulting from the hinge motion described
above in the PCA analysis, where we stated that the subdomain II has a large
RMSD drift and RMSF values closer to the CH domain of the antibody.
As shown in the previous paragraph, the dimerization arm is at least as flexible
as loops 102–110 and 581–590, which are missed in the x-ray structure indicating
its high flexibility (Figure 4.3). However, the dimerization arm structure has been
experimentally solved. A close inspection of the crystallographc packing can help
to interpret this issue. Figure 4.8 illustrates two views of the monomer surround-
ings in the unit cell of the x-ray structure. It can be seen that the dimerization
arm is located close to the back-position of a different ErbB2/Tzb monomer and
interacting with the Trastuzumab domain of another different monomer. Thus,
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Figure 4.8: Crystal packing of the ErbB2/Tzb complex. On the left Schematic represen-
tation of the crystal packing of three ErbB2 complexes in 1N8Z. At center and right Front
and Side views of the 1N8Z crystal packing. Cartoons shows an ErbB2/Trastuzumab
complex along with the nearest spatial neighbor domains represented with lines. The
dimerization arm is shown as red VdW spheres
both the dimerization arm and the hinge motions are hindered by the closed
presence of other monomers in the crystal structure. In our simulations, the
lack of other monomers shows evidence of the intrinsic flexibility of the com-
plex ErbB2/Tzb, being likely stabilized by H-bond and electrostatic interactions
between both components.
On the other hand, the binding free energy has been calculated according to
the molecular mechanics-Poisson-Boltzmann surface area (MM-PBSA) method.
The “in-silico” binding energy ∆Gbind is quite large (−285.0 kcal mol−1) in com-
parison with the reported experimental values between −12.4 and −14.0 kcal
mol−1 [34, 35]. In this sense, Fuentes et. al. [12] reported an “in-silico” value of
∆Gbind −1144.6 kcal mol−1 using molecular mechanics-generalized-Born surface
area (MM-GBSA) approximation without entropic terms. Thus, it seems clear
that entropic terms are needed in order to improve the binding energy between
the apo-ErbB2 protein and the Tzb ligand. Details of the MM-PBSA calculation
are given in the section 4.8 in the section 4.8.
4.7 Conclusions From This Work
A molecular dynamics and PCA study of the flexibility of the complex be-
tween the extracellular domain (ectodomain) of the ErbB2 receptor and the
Trastuzumab antibody has been presented. The initial structure was prepared
from the crystal structure reported by Cho et al. (PDB code: 1N8Z) [13]. From
this study the following conclusions can be drawn. Firstly, both secondary struc-
tures for the full complex and putative interactions between subdomain IV of
ErbB2 and variable domains (VH and VL) of Trastuzumab are well conserved
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along the molecular dynamics trajectory. Secondly, a hinge move approaching
the subdomain II to the Trastuzumab component is revealed by combining the
MD trajectory and principal component analysis. This global motion allows the
interaction between the dimerization arm of the ECD-ErbB2 subdomain II and
subdomain CH of the antibody. The effect of this interaction on the heterodimer-
ization of ErbB2 and other EGFR receptors is under study in our group. In
addition, we have observed some differences between the MD simulation and the
x-ray structure attributed to the crystal packing. Thus, the monomer packing in
the crystalline cell hinders the hinge move discussed above due to the presence of
two other nearby ErbB2/Tzb complexes, thus preventing the interaction between
the dimerization arm and the CH domain of its own Tzb protein. In any case, we
expect that these results are useful to identify the underlying interaction mecha-
nism between receptor and antibody, which could help to design new therapeutic
antibodies. The observed interaction of the antibody with the dimerization arm
could provide us with new clues to design possible modifications of the antibody
that may then enhance its therapeutic power. An effective blockade of the dimer-
ization arm would impede the ErbB dimerization and consequently would lead to
the interruption of the signaling cascade. The simultaneous effect on both ErbB2
subdomains II and IV exerted by a modified Tzb would be of great interest in
the treatment of ErbB2 over-expressed tumors.
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4.8 Additional Information
Secondary Structure Analysis
Figure 4.9: Secondary structures along the trajectory of the different domains found
in the ErbB2-ECD/TrastuzumabFab complex as calculated by DSSP analysis
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Stability Analysis
4
Figure S2: a) Root mean square deviations (RMSD) as a function of simulation time of the
Erbb2‐ECD receptor backbone atoms in the complex. b) RMSD along the MD simulation for the
backbone atoms for each of the individual domains defined in the Erbb2‐ECD protein (Domain I
in black, II in red, III in green and IV in blue). The complex Erbb2‐ECD/Tzb‐fab crystal structure
(PDB code: 1n8z) was used in all cases as reference structure.
Figure 4.10: a) Root mean square deviations (RMSD) as a function of simulation
time of the Erbb2ECD receptor backbone atoms in the complex.b) RMSD along the
MD simulation for the backbone atoms for each of the individual domains defined in
the Erbb2ECD protein (Doma n I in black, II in red, III in green and IV in blue). The
complex Erbb2ECD/Tzbfab crystal structure (PDB code: 1n8z) was used in all cases as
reference structure
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MM-PBSA to calculate binding energy
The protein-ligand binding free energy for the ErbB2-Trastuzumab complex was
calculated using the following equation:
∆Gbind =< Gcomplex > −(< Gprotein > + < Gligand >) (4.1)
where Gcomplex, Gprotein and Gligand are the free energies of the complex
(ErbB2-Trastuzumab), the apo-protein (ErbB2) and the ligand (Trastuzumab),
respectively. The symbols < and > denote average over snapshots taken from the
MD trajectories. We ran 170-ns simulations of the apo-ErbB2 and Trastuzumab
isolated systems in solution using the same protocol described in the MD simula-
tion section. In all cases, 100 snapshots were extracted from the last 10 ns of the
production runs. For each snapshot the free energy can be evaluated as follows:
Gx = EMM +Gsol − TSMM (4.2)
Thus, the free energy for each component x (i.e, complex, protein and ligand)
is evaluated by summing the configurational entropy (SMM ), the solvatation free
energy (Gsol), and gas-phase molecular mechanical energy (EMM ). The EMM
term is calculated as,
EMM = Einternal + Evdw + Eelec (4.3)
Here, Einternal is the sum of bond, bend and dihedral energies, Evdw is the van
der Waals energy and Eelec is the electrostatic energy evaluated in the gas-phase
for each component using the OPLS force field with no cut-off.
Solvation free energies may be separated into polar (electrostatic) and non-
polar components,
Gsol = Gpolar +Gnonpolar (4.4)
The polar contribution (Gpolar) was calculated by solving the finite-difference
Poisson-Boltzmann equation using Delphi v5.1 [36, 37]. In the Delphi calculations
a grid space of 0.5 A˚and a grid size of 291. The OPLS radii and charges were
employed for all atoms. The exterior and interior (solute) dielectric constants
were set to 80 and 2, respectively. The nonpolar contribution was determined on
the basis of accessible surface area (SASA) using the following expression:
Gnonpolar ≈ γSASA+ b (4.5)
with γ = 0.0054 kcal/mol and b = 0.92 kcal/mol [38, 39].
The entropy consists of three terms:
S = Str + Srot + Svib (4.6)
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for the translational, rotational and vibrational entropy, respectively. The
expressions for translational and rotational entropies are given for the following
expressions according to the reference [40]:
Str = Rln
V e
3
2
Λ3L
(4.7)
Srot = Rln
8pi2e
3
2
σΛxLΛ
y
LΛ
z
L
(4.8)
Where V is the volume of the complex, protein or ligand, e is the natural loga-
rithm base, ΛL =
h1/2
2pimkBT
is the translational thermal de Broglie wavelength, σ is
the symmetry number , ΛiL =
h1/2
2piIiLkBT
is the rotational thermal de Broglie wave-
length and IiL represents the moments of inertia about the principal components
denoted by x, y and z. The vibrational entropy of each system (protein, ligand
and complex) was estimated using the quasi-harmonic analysis. This method has
been used previously to evaluate the entropy of peptides and proteins [41, 42].
Details of the calculation can be seen in those references. In summary, the entropy
contribution to the free energy of binding was using the Schlitter formula [43] by
calculating the covariance matrix of fluctuations for frames of each individual
system extracted from the MD trajectories.
The binding free energy has been calculated according to the MM-PBSA
(Molecular Mechanics-Poisson-Boltzmann Surface Area) method. The calcu-
lated binding energies of Trastuzumab ligand to ErbB2 are shown in Table
4.1. The “in-silico” binding energy ∆Gbind is quite large (-285.0 kcal/mol)
in comparison with the reported experimental values between -12.4 and -14.0
kcal/mol [34, 35]. In this sense, Fuentes et al. [12] reported an “in-silico”
value of ∆Gbind = −1144.6 kcal/mol using MM-GBSA (Molecular Mechanics-
Generalized-Born Surface Area) approximation without entropic terms. Thus,
it seems clear that entropic terms are needed in order to improve the binding
energy between the apo-ErbB2 protein and the Trastuzumab ligand.
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Chapter 5
Mapping from Atomistic to
Coarse–Grained Resolution
This chapter is based on the submitted manuscript “Comparing Atomistic and
Martini Coarse-Grained Models on Protein-Protein Interactions applied to the
ErbB2/Trastuzumab Complex” by JF Franco-Gonzalez, J Ramos and VL Cruz
Abstract
The coarse grained Martini force field has been compared with the
atomistic OPLS representation. We tested the Martini model con-
sidering variants of the following molecular dynamics settings: the
non-bonded interactions methods to calculate the electrostatic inter-
actions, the value of the neighbor lists cut-off radius (rlist) and the
Elastic Network method. The ectodomain-ErbB2/Trastuzumab-Fab
complex, which is of relevant importance in anticancer therapy, was
selected to analyze the protein-protein interactions. The results show
that when used in molecular dynamics simulations domElNeDyn mod-
els, PME and an rlist 1.4 nm, are comparable to the atomistic protein
models. The results support the value of the Martini force field in the
study of protein-protein interactions and towards protein structure
prediction.
5. Mapping from Atomistic to Coarse–Grained Resolution
5.1 Introduction
The coarse graining simulation techniques emerge as a useful paradigm to per-
form simulations at the microsecond time scale on protein complexes of large size.
Particularly, the Martini force field has been established as a suitable model for
the coarse-grained (CG) description of biological systems [1, 2]. Four atoms per
CG particle are mapped in Martini, which offers parameters for several types of
molecules including, essentially, lipids, carbohydrates and proteins. However, the
appropriate usage of Martini on protein-protein interactions is still a matter of
research [3–5]. For example, Stark et al. suggested a scaling down of the Van
de Waals parameters that describe the interactions between protein pseudoatoms
to reproduce experimental data on the thermodynamics of protein-protein in-
teractions in aqueous solution [5]. Another aspect investigated by some authors
focused on the use of an elastic network (EN) protocol named ElNeDyn [3], which
is a necessary addition to the Martini force field when studying protein-protein
association processes. An elastic network by domains (domElNeDyn) is a varia-
tion of the original EN protocol that permits more flexibility of the interdomain
regions of the protein while maintaining, at the same time, the overall shape of
the protein [6]. Several authors reported the effect of different parameters of
the domElNeDyn protocol when simulating different protein complexes [6, 7]. A
suitable knowledge of the protein domain composition and stability is required to
get reasonable results [8]. Hence, although the Martini force field has improved
parameter sets [9], it still needs further work to get better in the protein-protein
interactions and specially in structure predictions [4, 10, 11].
Therefore, there is considerably interest to understand better the behavior of
the Martini force field regarding protein complex systems. In this work we explore
the effect of three simulation parameters to be combined with the Martini force
field, namely, the non-bonded methods to calculate electrostatic interactions, the
value of the neighbor lists cut-off radius and the Elastic Network method. To
examine the first one we perform simulations with the Shift model to treat elec-
trostatic interactions, which is the original choice of the Martini parameterization
[2], and Particle Mesh Ewald (PME) [12, 13]. Additionally, we explore the effect
of increasing the neighbor lists cut-off radius from the original value of 1.2 nm
[1, 2, 5, 7, 9, 14] to 1.4 nm. The third variable we have taken into account were
both elastic networks protocols: ElNeDyn and domElNeDyn.
In this work, we have chosen the ECD-ErbB2/Trastuzumab-Fab complex to
analyze the performance of CG models when compared to all-atomistic simula-
tions (AA) of the same system. This protein complex offers high flexibility, very
well defined domains, stable protein-protein contacts along the molecular dynam-
ics and large movements that involve interfaces with additional protein-protein
interactions [15, 16]. We have carried out a structural comparison between AA
and CG simulations at two different time windows. On one hand, the AA and
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CG trajectories are matched considering the time window of 500 ns, which is
the period used for the atomistic simulations. On the other hand, a larger time
window of several microseconds of CG dynamics was also used for a comparative
analysis as well as to assess the stability of the CG models at those large time
scales.
We used the clustering analysis proposed by Daura and et al. [17] to get
representative structures from the different trajectories in order to facilitate the
comparative study [18].
Specifically, the epidermal growth factor receptors (EGFRs) are a family of
membrane proteins engaged in a number of biological processes such as cellular
proliferation. The over expression of some of these receptors at the cell surface
has been associated with cancer [19]. Particularly, ErbB2 over expression on
breast cancer cells has been identified as a negative factor affecting cancer pro-
gression and final survival time [20, 21]. The monoclonal antibody Trastuzumab
(Trastuzumab) has been designed to target an extracellular epitope of the ErbB2
receptor [22–24], being the first specific anti-ErbB2 treatment approved by the
Food and Drug Administration (FDA). However, the molecular mechanism of ac-
tion of Trastuzumab is not well understood [25–27]. Some mechanisms consider
that Trastuzumab inhibits activation of ErbB2 disrupting the cleavage of the
ectodomain region caused by the interaction between ErbB2 and proteases [28].
In fact, Cho and et al. [29] elucidated a crystallographic structure of the ECD-
ErbB2/Trastuzumab-Fab complex, where Trastuzumab binds to subdomain IV
of ECD-ErbB2.
The ErbB2 ectodomain consists of four very well defined subdomains classi-
fied according to leucine-rich domains (I and III) and cystein-rich domains (II
and IV) [28–35]. This receptor is distinguished by an extended conformation
in absence of the ligand unlike the rest of family receptors [30]. This kind of
conformation makes it possible to form dimers with other receptors through an
exposed dimerization arm that is located in subdomain II. Regarding the dimer-
ization as a therapeutic target, a monoclonal antibody known as pertuzumab
was developed to bind to the epitope in the subdomain II [36]. The ErbB2-
Trastuzumab complex has been studied by molecular dynamics simulation (MD)
at both resolution scales, namely, AA and CG. These simulations have revealed
an additional interaction between the antibody constant domain and the dimer-
ization arm [6, 15, 16, 37]. In this chapter a direct comparison between both
models is performed.
The chapter is organized as follows: The Computational Methods section de-
scribes the different tools and settings used to perform the simulations and anal-
ysis of the atomistic and coarse-grained models. The Results section presents in
the first two subsections an analysis of the conformational flexibility exhibited
by the atomistic and coarse-grained simulations. In the two following subsec-
tions the clustering tool is used to select the representative structures to perform
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the comparative analysis. An additional Discussion section is provided to give
a detailed description of the ErbB2-Trastuzumab complex interface. Finally,
the Conclusions section summarizes the most relevant results obtained from the
present work.
5.2 Computational Methods
General Settings
MD simulations of ECD-ErbB2/Trastuzumab-Fab complex were carried out start-
ing from the crystal structure available in the Protein Data Bank server as PDB
code: 1N8Z [29]. The missing residues in the loops 102-110, 303-305, 361-364 and
581-590 have been modeled based on homologous sequences as was reported in
reference [16] for the same system. Trastuzumab-Fab component consists of two
protein chains: light chain (LC) and heavy chain (HC), each of one with their
variable and constant domains labeled as VL and CL for LC and VH and CH for
HC. For the ECD-ErbB2 protein, four different domains are described, namely,
domains I, II, III and IV or similarly leucine-rich domains 1 and 2 (L1 and L2) and
cystein-rich domains 1 and 2 (CR1 and CR2). We assumed that the pKa of the
individual amino acid residues at physiological pH does not change in the protein
receptor. Thus, histidine (H) residues remained neutral; lysine (L) and arginine
(R) were protonated and aspartic (D) and glutamic (E) acids were deprotonated.
The resulting total charge for the complex was −10 e units. In all setups (includ-
ing the coarse grained simulations) 10 Na+ counter ions were added to yield an
electrically neutral system. Periodic boundary conditions were applied along the
three dimensions. The setups were relaxed along 2500 steps using the steepest
descent minimization algorithm. The GROMACS package version 4.6.3 [38] was
used for all simulations. The pressure and temperature were kept constant at
1 bar and 300 K, respectively, using the Berendsen coupling algorithm [39] by
coupling the proteins (ECD-ErbB2 and Trastuzumab-Fab), solvent and ions in-
dependently with isotropic scaling for the pressure (1 bar) and a compressibility
factor of 4.5x10−5bar−1.
Atomistic Simulation
The OPLS [40] force field for the protein and SPC [41] water model for the solvent
were used in this simulation. The system was solvated by 60717 water molecules.
The temperature and pressure were kept constant with the time constants τT =
0.2ps and τP = 1ps. The Particle Mesh Ewald method (PME) [12, 13] was used
for the long-range electrostatic interactions with a maximum grid spacing of 0.25
nm and using fourth-order (cubic) interpolation for the fast Fourier transforms.
A short-range electrostatic cut-off radius of 1.0 nm, a Van der Waals cut-off
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radius of 1.0 nm and a short-range neighbor list cutoff of 1.0 nm were used.
Bond lengths were constrained using the LINCS algorithm [42] for all bonds
in the protein. The system was equilibrated for 2 ns at constant pressure and
temperature (NPT ensemble) with position restraint for all protein atoms with
a force of 1000 kJmol−1nm−2. Production dynamics were performed at NPT
releasing all constraints on the heavy atoms during 500 ns and accumulating the
trajectory frames every 10 ps without any restraints.
Coarse-Grained Simulations
The simulations were performed with MARTINI CG 2.1 [2]. The coarse-grained
representation (topologies and parameters) of the ECD-ErbB2/Trastuzumab-Fab
complex was generated from a minimized atomistic structure. Standard MAR-
TINI CG water beads were used to model the solvent [43] (a total of 38986 beads).
The setups were energy-minimized and the solvent and ions were relaxed with
position restraints (1000 kJmol−1nm−2) applied to the backbone beads. The
relaxation with position restraints was performed in two steps, firstly, a NPT
protocol with a time step of 2 fs for 1 ns and, secondly, a NPT protocol with
a time step of 20 fs for 10 ns. The temperature and pressure were kept con-
stant with time constants τT = 1ps and τP = 2ps. The short-range electrostatic
and Van der Waals cut-off radius were 1.2 nm and shifted from 0.9 nm for the
Lennard-Jones potential and from 0.0 for the electrostatic potential. The neigh-
bor lists cut-off radius used was 1.2 nm and 1.4 nm (updated every 10 steps). To
calculate the electrostatic interactions (EIs), Shift and PME non-bonded inter-
actions methods were taken into account. As implemented in GROMACS, the
Van der Waals methods considered were Shift and Cut-Off respectively. For Mar-
tini CG simulation it has been shown that the simulation time typically should
be multiplied by a factor of 4 to roughly account for the increase in diffusion
observed for CG water beads [1, 43]. Thus, in this work the simulation time is
multiplied by 4 resulting in an “effective” time. All production simulations were
run using NPT with 20 fs time step for 10 µs (40 µs effective time).Two replicas
of each one were run with different seed number. Every CG protein model was
built using the martinize.py script downloaded from http://cgmartini.nl
Elastic Network
The ElNeDyn [3] method was used to assign the elastic network to each protein
(an elastic network for ErbB2 protein and an elastic network for each chain of
Trastuzumab-Fab) in two ways: for the entire proteins without distinction be-
tween domains (ElNeDyn) and by domains in each protein (domElNeDyn). In
ElNeDyn simulations, an elastic network (EN) is built on the backbone beads
of the MARTINI protein model to maintain the initial tertiary structure as is
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Table 5.1: Simulations performed in the present chapter
FFa EI Method EN rlist(nm) # Rep.
b Time (µs) Label
OPLS n.a n.a 1.0 1 0.5 AA
Martini
PME
Elnedyn
1.2 2 10 P1.2
1.4 2 10 P1.4
domElnedyn
1.2 2 10 Pd1.2
1.4 2 10 Pd1.4
Shift
Elnedyn
1.2 2 10 S1.2
1.4 2 10 S1.4
domElnedyn
1.2 2 10 Sd1.2
1.4 2 10 Sd1.4
a FF. Force Field .
b Rep. Replica.
described by Periole et al [3]. It is well-known that MARTINI protein models in
water need an EN to further constrain the protein close to a particular conforma-
tion, e.g. native state [3, 7, 14]. On the other hand, based on the knowledge of
the EGFR receptor, the ECD-ErbB2 [29, 44] domains are well defined, therefore
it is possible to assign domElNeDyn. We have compared the domains defined in
this way with the assignment by the DomFOLD method [8] via its online server
[45]. We have found that there are not significant differences between these two
domain definitions. Additionally, the work by Siuda and et al. concluded that
“ domElNeDyn simulations do not depend significantly on the exact domain as-
signment” [7].
The parameters controlling the elastic networks were a cutoff radius Rc =
0.8nm and a spring constant Kspring = 500kJmol
−1nm−2. These are the values
to reach the best overlap with the atomistic simulations, as were optimized by
Periole et al [3]. Additionally, these parameters values have been chosen according
to the previous reports published elsewhere [6, 7]. A complete list of simulations
and the number of replicas of each one are shown in Table 5.1.
GPU simulations
PME dynamics simulations were run on local workstations equipped with 4
Nvidia GPUs each, called Metrocubo and bought to Acellera Ltd. Metrocubo.
This is a highly compact hardware-software solution for running GPU accelerated
molecular dynamics simulations that can reach supercomputing performance.
Conformational Stability Analysis
Root mean square deviation (RMSD) has been used to examine the conforma-
tional stability of the complex and the root mean square fluctuations (RMSF)
was calculated on individual residues of the complete trajectory. Both RMSD and
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RMSF were determined on the Cα atoms for the AA simulation or the backbone
beads (BB beads) for the CG simulations. The minimized atomistic structure
was used as the reference to compare RMSD as well as RMSF.
Principal Component and Residue-Mean-Square Inner Product
(RMSIP ) analysis
Principal component analysis (PCA) calculates the dominant modes in the mo-
tion of the molecule along the MD simulation trajectory. Thus, the configu-
rational space is reduced, containing few relevant collective degrees of freedom
in which long range fluctuation can be studied [18, 46]. PCA diagonalizes the
covariance matrix of the atom fluctuations from their average trajectory. The
resulting eigenvectors correspond to the dominant low frequency motions. We
have performed a PCA analysis in order to identify these lowest frequency mo-
tions occurring in the ECD-ErbB2/Trastuzumab-Fab complex. The g covar and
g anaeig tools in the GROMACS package were used to perform the PCA analysis.
The PCA diagonalization yields the principal directions of the large-amplitude
concerted motions that characterize the essential subspace of the internal dy-
namics of the protein. The RMSIP between the essential subspaces of both AA
and CG simulated systems has been used to assess their dynamical similarity.
The RMSIP was calculated on the first ten eigenvectors along the complete MD
trajectory using the Bio3D package [47].
Clustering Analysis
Due to the complexity and big size of the data produced in this work, we have
done a clustering analysis on the trajectories to be able to compare between AA
and CG conformations obtained with the different methodologies. Each frame
in the AA trajectory was mapped to a CG representation. Clustering based on
pairwise RMSD was performed using a previously reported clustering algorithm,
namely, “gromos” implemented in GROMACS (g cluster) [17]. In this method an
RMSD cut-off should be selected to find two neighbor structures. RMSD cut-offs
were selected using a pairwise frame to frame RMSD as explained by Karplus et
al. [48], McCammon et al. [49] and Schulten et al. [50]. The distribution has
been calculated using the positions of the Cα atoms for the AA simulation and
BB beads for the CG simulations. The final cutoff values selected are shown in
Table 5.2. The atomistic structures were mapped to the CG representation with
the martinize.py tool available in the Martini site (http://md.chem.rug.nl/). In
this way a more direct comparison between AA and CG clusters can be done.
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5.3 Results
Sections 5.3.1 and 5.3.2 analyze the molecular flexibility in two different time
windows. The first one corresponds to the 500 ns interval calculated with the
atomistic model (from now on atomistic simulation time window). The second
one is extended to several µ-seconds accessible to the CG models (microsecond
time window). Sections 5.3.3 and 5.3.4 show the results obtained after clustering
the trajectories in order to compare the conformations produced by both AA and
CG simulations.
5.3.1 Conformational Flexibility at Atomistic Simulation Time
Window
The RMSD and RMSF analysis were done over the “effective” time (see Compu-
tational Methods) on CG simulations for the first 500 ns, in order to compare with
the AA simulation (See Figures 5.1 and 5.2). In all cases the minimized atom-
istic structure mapped on CG representation was used as the reference structure.
The AA trajectory reaches a relative stability at around 1 nm, as can be seen in
Figure 5.1. This relatively large RMSD value is due to the departure of the pro-
tein complex geometry from the initial structure containing the crystallographic
arrangement. The RMSF profile for the AA simulations shows the largest fluctu-
ations on both group residues 100-110 and 480-490, as it is depicted in Figure 5.2
(subdomains I and IV, respectively). This high flexibility can be explained be-
cause these loops are absent in the crystallographic structure and they were built
by homology, as reported in [51]. Both the ECD-ErbB2 and Trastuzumab-Fab
secondary structures are well conserved along the AA trajectory as can be seen in
the Define Secondary Structure of Proteins (DSSP) analysis of the protein (See
Figure 5.12 of the Additional Information). These results support the applica-
tion of the Martini CG model along with the elastic network, where secondary
structure has to be preserved along the simulation.
The conformational flexibility in the CG simulation is larger than in the AA
one (see Table 5.4). However, when PME with ElNeDyn protocol is used the
RMSD profile is lower than or equal to 1.0 nm, whereas with ElNeDyn by domains
there are RMSD values higher than 1.0 nm, as shown in Figure 5.1. On the other
hand, if one compares CG and AA simulations by RMSF, it is possible to see
that, in general, there is a good agreement between them. Regarding only the
CG simulations, it is clear that the Shift based methods produce larger RMSF
fluctuations than PME. This is particularly evident at shorter rlist values.
ElNeDyn protocols have similar fluctuations to the AA simulations while the
domElNeDyn presents more differences respect to the AA profiles. In particular,
simulations labeled with Pd1.4 and S1.4 show the most similar RMSF profiles
to the AA production, as is shown in the Figure 5.2. In summary, the RMSD
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Figure 5.1: RMSD Comparison between CG and AA simulation at the atomistic sim-
ulation time window. Every CG simulation was plotted comparing with the different
rlist and with the corresponding replica: (A) Shift-ElNeDyn, (B) Shift-domElNeDyn,
(C) PME-ElNeDyn and (D) PME-domElNeDyn.
and RMSF values show a systematic behavior depending on the choice of Elastic
Network protocols, cutoff radius rlist and non-bonded electrostatic methods. In
general, it can be observed more rigidity with ElNeDyn than with domElNeDyn.
Simulations performed with rlist equal to 1.4nm are closer to AA values (see
Figures 5.1 and 5.2). In order to compare the dominant modes extracted from
the different MD simulations, a PCA analysis followed by a RMSIP evaluation was
carried out following the methodology described in the Computational Methods
section. The RMSIP values, in all cases, are greater than 0.5. Therefore, a good
overlapping should be expected since the CG simulations show both flexibility
and conformational stability similar to the AA, as was suggested in reference
[7]. The RMSIP seems to behave similarly independently of the different CG
protocols, because no significant differences between the different CG models are
observed (see Table 5.6). It might be safe to suppose that the CG simulations
sample a similar conformational phase space than the AA simulation. It can be
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simulation time window. Every CG simulation was plotted comparing with the different
rlist and with the corresponding replica: (A) Shift-ElNeDyn, (B) Shift-domElNeDyn,
(C) PME-ElNeDyn and (D) PME-domElNeDyn.
assumed, from the above results, that 500 ns is an acceptable production time to
find a stable conformation in this protein-protein complex.
5.3.2 Flexibility and Dynamics at Microsecond Time-Scale
An extension of the CG simulations to µ-second timescales is interesting to further
explore the conformational space and compare with the AA results at shorter time
scales. We have assumed that 500 ns in the AA simulations are sufficient to reach
an equilibrated protein-protein complex (Figures 5.1 and 5.2). The RMSD gives
a measure of the stability along the simulation runs at the microsencond scale.
In Figure 5.3 the RMSD results for CG simulations are shown. In all cases, the
minimized atomistic structure mapped on the CG model was used as a reference
structure. In addition to this, RMSFs were calculated on each residue for both
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Figure 5.3: RMSD for the BB particles as a function of effective time in the Martini CG
simulations. The minimized atomistic structure converted to CG was used as reference.
(A) Shift-ElNeDyn methods, (B) Shift-domElNeDyn [the inset (B) shows an extension
on the vertical axis], (C) PME-ElNeDyn methods, and (D) PME-domElNeDyn
AA and CG simulations as can be seen in Figure 5.13. The complete trajectory
was used to calculate the RMSF.
In general, the CG RMSD profiles show larger fluctuation than the AA RMSD
ones, as can be seen in Figure 5.3 and Table 5.5 . This is a standard behavior on
Martini protein models in water and that is the reason why it is necessary to add
EN to the models [3]. ElNeDyn shows RMSD values higher than domElNeDyn
when the rlist and EI method are the same, as can be seen in Figures 5.3A- 5.3B
and Figures 5.3C-5.3D. At equal EN protocol and rlist, the RMSD values are
higher for Shift than for PME (Compare Figures 5.3A-5.3C and Figures 5.3B-
5.3D). Finally, the RMSD values are always higher for a rlist = 1.2nm than for a
rlist = 1.4nm under the same EN protocol and EI method (See Figures 5.3A-D).
In Figure 5.13 the RMSF values are presented for the different CG models
compared to the atomistic simulation. Shift-ElNeDyn and PME-domElNeDyn
show a good agreement with the atomistic fluctuations (see Figure 5.13B and
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Table 5.2: The RMSD cutoff selection for the different methodologies
Method RMSDcutoff (nm) # Clusters
AA 0.35 12
P1.2 0.26 16
P1.4 0.39 8
Pd1.2 0.45 8
Pd1.4 0.73 6
S1.2 0.38 15
S1.4 0.51 7
Sd1.2 0.63 26
Sd1.4 0.44 15
5.13C). The worse match to AA fluctuations corresponds to the Shift-domElNeDyn
method which, additionally, shows a replica with very large fluctuations. The
domElNeDyn simulations present more variability between the two replicas in
contrast with the uniformity of the ElNeDyn replicas due to the additional flex-
ibility shown by the interdomain freedom in the former method. In general, the
subdomain IV C-terminal fragment is less flexible in the CG representations that
in the AA simulations. This fragment along with the homology built loop in
subdomain I are highly flexible in the AA system and not well captured by the
CG models.
Finally, the RMSIP analysis performed between the µ-second CG trajectories
and the AA simulation shows very similar results to that reported for the 500
ns interval except for the Shift-domElNeDyn method, as can be observed by
comparing Tables 5.6 and 5.6.
5.3.3 Cluster Analysis to Find out Structural Similarity
The clustering analysis is performed to facilitate the selection of average con-
formations from the simulations and further comparison between AA and CG
trajectories.
In order to select a cutoff value for generate the clusters, a pairwise frame to
frame RMSD distribution along the AA and the CG trajectories are calculated
and shown in Figure 5.4. The RMSD cutoff used to generate the clusters for
every method considered in the present work was selected according to the criteria
described in the Computanional Methods section and reported by Schulten et al
[50]. Table 5.2 presents the values chosen for every model.
Let us keep in mind that the AA structures were mapped on the CG repre-
sentation to facilitate a direct comparison with the CG models. A total of 12
clusters were found applying a RMSD criterion of 0.35 nm to discriminate con-
formations in the AA simulation taking into account the full 500 ns trajectory
82
5.3. Results
 0
 0.2
 0.4
 0.6
 0.8
 0  0.1  0.2  0.3  0.4  0.5  0.6  0.7  0.8  0.9  1  1.1  1.2  1.3  1.4  1.5
P
r o
b
a
b
i l
i t
y
Pairwise RMSD (nm)
P
r o
b
a
b
i l
i t
y
P
r o
b
a
b
i l
i t
y
P
r o
b
a
b
i l
i t
y
P
r o
b
a
b
i l
i t
y
Pd1.4
P1.4
Pd1.2
P1.2
 0
 0.2
 0.4
 0.6
 0.8
Sd1.4
S1.4
Sd1.2
S1.2
AA
Figure 5.4: Pairwise Frame to Frame
RMSD distribution calculated on the Cα
atoms for the AA simulation and BB
beads for the CG simulations. Top: Shift
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(See Table 5.2). The first and second clusters represent 70.5 and 13.1 % of the
trajectory, as is shown in Figure 5.14. These clusters amount a total of 83.6 %
of the production dynamics and therefore, we have not taken into account the
remaining clusters in the subsequent analysis. Representative structures corre-
sponding to average geometries for both clusters are shown in Figure 5.5. The
representative structures were depicted emphasizing on the protein interaction
between the ErbB2 and the antibody Fab.
We have performed the same analysis for each CG trajectory. Similarly to
AA simulations, we have taken into account only the two more representative
structures of the cluster analysis. Clusters 1 and 2 from the AA simulation were
used as reference. The percentage distribution for the RMSD values calculated
on the frames corresponding to each CG trajectory is represented in Figure 5.6.
The Pd1.4 model gives a good match with the structure represented by cluster 2
of the AA simulation and slightly worse with cluster 1, as shown in Figure 5.6.
In general, Pd1.4 shows the higher percentage values, giving conformations with
small RMSD (RMSD less than 0.7 nm) for both clusters. However, despite the
fact that Pd1.4 shows good percentage values they have a high variability around
the mean value (see the error bars in Figure 5.6). This points out that the two
different production runs, on average, compare satisfactorily well with the AA
system.
5.3.4 Cluster Analysis to Study the Protein Complex Interface
AA simulations
A more detailed description of the protein-protein interaction on each method can
be obtained by the calculation of distance matrices between the BB particles of
the ECD-ErbB2 and the Trastuzumab-Fab protein moieties. The corresponding
distance matrices for the two clusters derived from the AA simulation are shown
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Figure 5.5: Structural comparison between both atomistic clusters 1 (left) and 2 (right).
They are represented by cartoons in which blue is for ECD-ErbB2 while Trastuzumab-
Fab is red and yellow for the HC and LC respectively. The inset boxes show a zoom
on the interfaces involved in the protein complex interaction. The RMSD between these
structures is 0.45 nm
in Figure 5.7. The matrix shows the pattern corresponding to the different inter-
action interfaces involved in the ECD-ErbB2/Trastuzumab-Fab interaction.
In addition to this, residue pair lists involved in these distance matrix pattern
between the proteins in the ECD-ErbB2/Trastuzumab-Fab complex have been
calculated and compiled in Tables 5.8-5.12 in the Additional Information section.
The pair list corresponds to the pair of residues which BB particles are within
a cutoff distance of 0.8 nm. According to this analysis a total of 5 interfaces
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were found, namely, subdomains VL and IV (VL-d4), subdomains VH and IV
(VH -d4), subdomains VH and III (VH -d3), subdomains VH and II (VH -d2) and
subdomains CH and II (CH -d2).
The reported crystallographic contacts are kept in the structures depicted in
the clusters 1 and 2 as can be seen in Figure 5.7 (see below in the Discussion
section). The interfaces CH -d2 and VH -d2 present the largest differences between
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Figure 5.7: Distance matrices between ECD-ErbB2 and Trastuzumab-Fab for the atom-
istic clusters. Cluster 1 (Left) and cluster 2 (Right). The averaged interfaces are shown
in dashed lines for VL-d4, VH -d4, VH -d2, VH -d3 and CH -d2 respectively.
both clusters (See Figure 5.7). The main difference is that there are more residues
from the subdomain II in cluster 2 than in cluster 1. About the interfaces VH -d4
and VL-d4 there are more overlapping in cluster 1 than in cluster 2, as can be
seen in Figure 5.7. Another difference in the clusters mentioned above is the con-
formational disposition of ECD-ErbB2: cluster 2 shows contacts in its C-terminal
coil, whereas cluster 1 shows a single contact in subdomain III. Therefore, taking
into a count that the structures have been fitted on the Trastuzumab-Fab moiety,
it can be seen that ECD-ErbB2 in cluster 1 is above the pseudo-plane described
by the Fab while it is below that plane in cluster 2 (See Figure 5.5).
CG simulations
The first and second clusters of each CG simulation were used to compare with
the AA simulation. For all CG methodologies the first two clusters describe more
than 70 % of the trajectory as can be seen in Figure 5.14 and consequently are
used for the subsequent analysis.
Figures 5.8 and 5.9 represent the distance matrices between ECD-ErbB2 and
Trastuzumab-Fab for cluster 1 of each CG simulation (Figure 5.8 for rlist = 1.2nm
and Figure 5.9 for rlist = 1.4nm). The corresponding maps for cluster 2 are
presented in Figures 5.15-5.16 in the Additional Information section. Each one is
compared with cluster 1 and 2 from the AA simulation (Figure 5.7). In general,
it can be observed that CG simulations enhance the contacts since CG tends to
aggregate the proteins. Overall, CG simulations reproduce satisfactory well the
AA pattern at the interfaces corresponding to the crystallographic contacts (VL-
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Figure 5.8: Distance matrices between ECD-ErbB2 and Trastuzumab-Fab for cluster 1
corresponding to each Martini method with rlist = 1.2nm. The averaged interfaces are
shown in dashed lines for VL-d4, VH -d4, VH -d2, VH -d3 and CH -d2 respectively.
d4 and VH -d4) except for those obtained with Shift and rlist = 1.2nm (compare
Figure 5.8 and 5.9). Looking at the new interface predicted by the AA simulation
[16] using OPLS corresponding to the interactions between subdomains VH -d2
and CH -d2, there is not such a good correlation with the CG simulations. In
Figures 5.8-5.9 it can be seen that P1.2, Pd1.2 and Sd1.4 described very well
the interface between subdomains CH -d2 and VH -d2, but additional contacts
appear on the map. It is also noticeable that cluster 1 of Pd1.4 shows a good
correlation with cluster 2 of the AA simulation at both interfaces (See Figure
5.9). Although P1.2 and Pd1.2 have a good similarity with the AA pattern in
the specific interface VH -d2, Pd1.4 is still better when a detailed comparison is
done.
The ErbB2-Trastuzumab contacts revealed by each AA cluster were merged
and selected for the comparison with the CG simulations. The number of matches
between the AA and CG contacts are expressed in % (where 100 % corresponds
to hit all contacts) and shown in Figure 5.10. The plot represents the results
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Figure 5.9: Distance matrices between ECD-ErbB2 and Trastuzumab-Fab for cluster 1
corresponding to each Martini method with rlist = 1.4nm. The averaged interfaces are
shown in dashed lines for VL-d4, VH -d4, VH -d2, VH -d3 and CH -d2 respectively.
for the crystallographic contacts (VL-d4 and VH -d4) (black and blue bars) on
one hand, and the additional contacts between CH -d2 and VH -d2 (red and cyan
bars) on the other. The contacts between subdomains VH -d3 (gray bar) involve
the interactions between two pair of residues (see Table 5.10) that can be found
in most CG methodologies, excepting the Sd1.2 and S1.2 simulations. Using the
same rlist and EN protocol the best results for the crystallographic contacts is
obtained when PME is applied. A better result can be reached using ElNeDyn
than domElNeDyn when the same rlist and Shift EI method are used, whereas
domElNeDyn achieves better results than ElNeDyn when the EI method is PME.
The percentage of matches increases when rlist is reduced for the Shift models
irrespective of the EN choice, whereas the same conclusion is not so clear for
PME. On other hand, there is not a very clear trend in the VH -d2 and CH -d2
interfaces. However, for the same EI method and EN protocol the percentage
of contacts increases with rlist. That tendency is more clear for Shift than for
PME. In addition to this, it should be noticed that the CG models labeled as
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Pd1.2 and Sd1.4 reach a good correlation with the AA results in the VH -d2 and
CH -d2 interfaces as shown in Figures 5.7-5.9. The Pd1.4 method shows a worse
result than P1.2, Pd1.2 and Sd1.4 in the matched percentage (see Figure 5.10) in
spite of having a very similar pattern regarding this interface (Figure 5.9). It is
probably due to the displacement of one residue in the pair list as can be deduced
from Figure 5.9.
5.4 Discussion
Based on the results reported in the previous section, a more detailed view of
the interesting protein-protein interactions in the ECD-ErbB2/Trastuzumab-Fab
complex is discussed in terms of the comparative performance of the CG methods
with the AA simulation. The interactions showed in the crystallographic struc-
ture are analyzed first. In a second term, the additional interactions captured by
the AA simulations are also discussed.
5.4.1 Crystallographic Interactions
The X-ray structure corresponds to an open complex which has a binding pocket
involving the three loop regions of subdomain IV in ErbB2 with residues 557-
561 (loop1), 570-573 (loop2) and 593-603 (loop3) and some loops in the variable
subdomains of Trastuzumab, VL and VH [loop1-(VH :57 and VL:92-94); loop2-
(VH :103-105 and VL:29-32,91-93); and loop3-(VL:29-32, 66-68, 50-52)]. The first
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Table 5.3: Percentage of native contacts in the crystallographic interface conserved in
the CG simulations.
Label Loop 1 Loop 2 Loop 3
Pd1.4 100.0 76.7 50.0
Pd1.2 90.9 50.0 40.0
P1.4 81.8 70.0 45.0
P1.2 63.6 46.7 60.0
Sd1.4 18.2 36.7 35.0
Sd1.2 0.0 30.0 25.0
S1.4 18.2 50.0 30.0
S1.2 81.8 50.0 35.0
and third loops have interactions primarily of electrostatic nature and the second
loop makes mostly hydrophobic contacts, as was described by Cho and et al [29].
These crystallographic interactions have been kept along the AA simulation and
by most of the CG simulations (See Figures 5.7-5.9). Nevertheless, in addition to
those crystallographic contacts, the molecular dynamics on this system increase
the interacting surface adding more residues at the interface between the VL,
VH and IV subdomains. These findings were previously discussed [16]. The
original binding interface reported in the X-ray structure is included in the native
contacts considered in Figure 5.10 and listed in Tables 5.8-5.12. The calculated
percentages of those native contacts involved in the binding interface that are
matched in the CG simulations are shown in Table 5.3. It can be observed that
Pd1.4 keeps the original binding interface better than the other CG methods.
This is consistent with the fact that a larger rlist value (1.4 nm instead 1.2 nm)
will take into account more interactions. In addition to this, the precision of
the PME method to calculate the electrostatic interactions is well established
[12, 13, 52, 53]. The worst result, which misses in fact most of the binding
interface, is for the traditional Shift with rlist of 1.2 nm and an EN by domains.
5.4.2 Additional Protein-Protein Interaction
Franco et al. reported an additional interaction to that described in the X-
ray structure between subdomain II and the subdomain CH from Trastuzumab
obtained by atomistic MD simulation. In reference [16] and in a recent work
considering the full receptor in membrane simulated at a CG scale, this interaction
was described [6]. The additional interface is mediated by subdomain II of the
ECD-ErbB2 receptor, primarily by the dimerization arm and the subdomain CH
of the Trastuzumab-Fab. This happens due to a hinge movement intrinsic to the
EGFR receptor in its ectodomain as has been reported previously [51]. As can
be seen in Tables 5.8-5.12 of the Additional Information section the additional
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1
Figure 5.11: The structures corresponding to cluster 1 that have been fitted to the
x-ray structure of the complex ECD-ErbB2/pertuzumab identified as PDB code 1S78.
Blue and red are ECD-ErbB2/Trastuzumab-Fab from cluster 1 while green and yellow
are ECD-ErbB2/Pertuzumab-Fab
interface of subdomain II and the constant domain involves residues 253-261 of
ErbB2 (where residues 259-261 correspond to a sheet) and the residues 121, 123-
125, 153-154, 206-213 of Trastuzumab (where residues 208-211 form an helix and
151-152, 206-207 form sheets). This description reveals an interface with a mixing
of hydrophobic and electrostatic contacts.
In view of these results, we can speculate about the potent anti-ErbB2 charac-
teristic of Trastuzumab [15, 54, 55] because the antibody constant domain is able
to interact with the dimerization arm. It has been reported that an antibody can
increase its therapeutic potential if it is able to also bind by the constant domain
[56] in addition to the ability of the variable Fab domain to recognize the surface of
the antigen (epitope) [57]. The additional interaction suggests new questions re-
garding the accessibility of the dimerization arm and their biological implications
for other antibodies. It has been reported that the usage of a combinatory ther-
apy with two antibodies, pertuzumab and trastuzumab results in a better clinical
outcome [58–63]. The Pertuzumab target is the ErbB2 dimerization domain. In
fact, a crystallographic structure of the complex ECD-ErbB2/Pertuzumab has
been reported and identified as 1S78 in the PDB [36]. Therefore, we were won-
dering whether the additional ErbB2-Trastuzumab interface observed in the AA
and CG simulations is compatible with the ErbB2-Pertuzumab interaction or
with the dimerization activity. Looking to our molecular dynamics structures,
the presence of both interacting antibodies with the ErbB2 ectodomain is well-
matched. The binding region corresponding to the pertuzumab epitope is placed
in the opposite side to the ErbB2-Trastuzumab VH -d2 and CH -d2 interface. Fig-
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ure 5.11 shows the atomistic cluster 1 structure fitted to the crystallographic
ECD-ErbB2-pertuzumab complex (PDB: 1S78). The RMSD of the fitting per-
formed onto the ECD-ErbB2 backbone atoms was only 0.25 nm, indicating an
acceptable match.
5.5 Conclusions From This Work
We have reported a comparative study between the Martini CG and the atomistic
OPLS-AA models applied to the MD simulation of the ECD-ErbB2/Trastuzumab-
Fab complex. In particular, the following CG settings have been evaluated: the
effect of the cutoff radius to find neighbors (rlist), the influence of the method to
calculate the electrostatic interactions (PME or Shift) and the usage the Elas-
tic Networks (an elastic network for ErbB2 protein and an elastic network by
each chain of Trastuzumab-Fab) either by domains or just for the w hole protein
(domElNeDyn or ElNeDyn).
In general the CG simulations are able to satisfactorily reproduce the crys-
tallographic determined interaction contacts between the ECD-ErbB2 and the
Trastuzumab-Fab proteins as well as the additional interface involving the ErbB2
subdomain II already described in the atomistic simulations. The PME treat-
ment of electrostatic interactions seems to behave as good as or even better than
the Shift methodology in view of the different results reported in this chapter.
The ElNeDyn protocol for the treatment of elastic networks shows more flexi-
bility when the networks are built by domains instead of considering the whole
protein. It allows exploring a wider region of the conformational space at the
expense of some mismatch with the atomistic models.
It also can be concluded that the larger neighbor lists cut-off radius of 1.4 nm
gives better results when compared with the atomistic system. The combination
of PME, rlist of 1.4 nm and an EN by domains gives an overall satisfactory corre-
lation with the atomistic simulation structures, in particular, the protein-protein
interface has been captured adequately by the CG model. This result can have
important consequences regarding the consideration of using GPU technologies.
Currently, the Gromacs package (and most of other packages) only implements
PME for electrostatic interaction calculations in the GPU versions. Keeping in
mind, that originally Martini CG models were developed using the Shift method
in the electrostatic calculations, it is important to check that PME is suitable for
CG simulations on GPUs.
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5.6 Additional Information
Secondary Structure Analysis
Figure 5.12: Analysis DSSP for AA simulation. Left , ecto-ErbB2 and Right ,
Trastuzumab-Fab
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RMSF for CG Trajectories
Figure 5.13: RMSF per
residue for the BB particles
of the Martini and Cα of the
atomistic simulations (green
line). Minimized atomistic
structure converted to CG was
used as the reference structure.
(A) Shift-ElNeDyn methods, (B)
Shift-domElNeDyn methods,
(C) PME-ElNeDyn methods,
and (D) PME-domElNeDyn
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Distance Matrices
Figure 5.15: Distance ma-
trices between ECD-ErbB2
and Trastuzumab-Fab for
cluster 2 corresponding to
each Martini method with
rlist = 1.2nm. The aver-
aged interfaces are shown in
dashed lines for VL-d4, VH -
d4, VH -d2, VH -d3 and CH -
d2 respectively.
Figure 5.16: Distance ma-
trices between ECD-ErbB2
and Trastuzumab-Fab for
cluster 2 corresponding to
each Martini method with
rlist = 1.4nm. The aver-
aged interfaces are shown in
dashed lines for VL-d4, VH -
d4, VH -d2, VH -d3 and CH -
d2 respectively.
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RMSD Mean
Table 5.4: Average RMSD on the last 200 ns at atomistic simulation time window
Label Replica Mean SD
AA n.a 0.90 0.05
P1.2
1 0.91 0.05
2 1.03 0.04
P1.4
1 0.83 0.04
2 0.98 0.03
Pd1.2
1 1.04 0.04
2 1.10 0.08
Pd1.4
1 0.86 0.02
2 1.09 0.05
S1.2
1 1.01 0.05
2 1.01 0.04
S1.4
1 0.85 0.06
2 1.05 0.05
Sd1.2
1 1.58 0.06
2 1.53 0.28
Sd1.4
1 1.17 0.04
2 1.22 0.06
Table 5.5: Average RMSD on the last 16 µs at µ-second timescale
Label Replica Mean SD
P1.2
1 0.96 0.07
2 1.11 0.04
P1.4
1 0.84 0.04
2 0.94 0.06
Pd1.2
1 1.16 0.05
2 1.29 0.03
Pd1.4
1 0.95 0.05
2 1.12 0.06
S1.2
1 0.92 0.04
2 1.23 0.07
S1.4
1 0.92 0.05
2 0.91 0.07
Sd1.2
1 2.09 0.04
2 2.55 0.06
Sd1.4
1 1.28 0.05
2 1.14 0.02
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RMSIP Analysis
Table 5.6: RMSIP for the different CG methods at atomistic simulation time window
Label Mean SD
P1.2 0.68 < 0.0
P1.4 0.70 < 0.0
Pd1.2 0.67 0.01
Pd1.4 0.69 0.01
S1.2 0.67 < 0.0
S1.4 0.70 < 0.0
Sd1.2 0.68 0.01
Sd1.4 0.69 0.01
Table 5.7: RMSIP for the different CG methods at µ-second timescale
Label Mean SD
P1.2 0.66 < 0.0
P1.4 0.68 0.02
Pd1.2 0.66 < 0.0
Pd1.4 0.66 0.02
S1.2 0.67 0.03
S1.4 0.67 0.01
Sd1.2 0.50 0.02
Sd1.4 0.68 0.01
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Pair Lists Involved in the Interaction Patterns
Table 5.8: Residues Involved in the Interface VL-d4.
Pair List
29 VAL 571 PRO 31 THR 600 ALA 50 SER 602 GLN 68 GLY 599 GLY 93 THR 571 PRO
29 VAL 600 ALA 31 THR 601 CYS 50 SER 603 PRO 68 GLY 600 ALA 93 THR 572 PRO
29 VAL 570 ASP 31 THR 570 ASP 50 SER 604 CYS 91 HIS 571 PRO 93 THR 573 PHE
29 VAL 572 PRO 31 THR 602 GLN 52 SER 587 SER 91 HIS 572 PRO 93 THR 559 ALA
29 VAL 601 CYS 31 THR 603 PRO 52 SER 588 TYR 91 HIS 570 ASP 93 THR 561 GLN
30 ASN 571 PRO 32 ALA 571 PRO 52 SER 603 PRO 91 HIS 573 PHE 93 THR 562 CYS
30 ASN 599 GLY 32 ALA 572 PRO 53 PHE 587 SER 92 TYR 560 ASP 93 THR 570 ASP
30 ASN 600 ALA 32 ALA 570 ASP 53 PHE 588 TYR 92 TYR 570 ASP 94 THR 560 ASP
30 ASN 601 CYS 32 ALA 601 CYS 53 PHE 589 MET 92 TYR 571 PRO 94 THR 561 GLN
30 ASN 570 ASP 50 SER 588 TYR 54 LEU 587 SER 92 TYR 572 PRO 94 THR 572 PRO
30 ASN 602 GLN 50 SER 589 MET 54 LEU 588 TYR 92 TYR 573 PHE 94 THR 558 GLU
30 ASN 603 PRO 50 SER 590 PRO 66 ARG 599 GLY 92 TYR 559 ALA 94 THR 559 ALA
31 THR 571 PRO 50 SER 592 TRP 67 SER 599 GLY 93 THR 560 ASP 94 THR 562 CYS
Table 5.9: Residues Involved in the Interface VH -d4.
Pair List
57 TYR 557 PRO 102 ASP 580 SER 103 GLY 573 PHE 103 GLY 590 PRO 104 PHE 591 ILE
57 TYR 558 GLU 102 ASP 590 PRO 103 GLY 577 ARG 103 GLY 591 ILE 105 TYR 571 PRO
101 GLY 591 ILE 102 ASP 591 ILE 103 GLY 578 ARG 103 GLY 592 TRP 105 TYR 572 PRO
102 ASP 577 ARG 103 GLY 570 ASP 103 GLY 579 PRO 103 GLY 593 LYS
102 ASP 578 ARG 103 GLY 571 PRO 103 GLY 580 SER 104 PHE 571 PRO
102 ASP 579 PRO 103 GLY 572 PRO 103 GLY 589 MET 104 PHE 590 PRO
Table 5.10: Residues Involved in the Interface VH -d3.
Pair List
75 SER 346 LYS
75 SER 347 LYS
Table 5.11: Residues Involved in the Interface VH -d2.
Pair List
7 SER 313 SER 13 GLN 262 ASN 67 ARG 303 GLU 76 LYS 314 LYS 83 MET 303 GLU
9 GLY 259 SER 15 GLY 303 GLU 69 THR 302 ALA 76 LYS 315 PRO 84 ASN 301 THR
10 GLY 259 SER 16 GLY 302 ALA 70 ILE 302 ALA 76 LYS 316 CYS 84 ASN 302 ALA
11 LEU 258 GLU 16 GLY 303 GLU 71 SER 301 THR 78 THR 313 SER 84 ASN 303 GLU
11 LEU 259 SER 17 SER 302 ALA 71 SER 302 ALA 78 THR 314 LYS 84 ASN 304 ASP
11 LEU 260 MET 17 SER 303 GLU 73 ASP 314 LYS 80 TYR 302 ALA 85 SER 303 GLU
11 LEU 261 PRO 18 LEU 301 THR 76 LYS 298 GLN 81 LEU 302 ALA 119 ARG 261 PRO
12 VAL 259 SER 18 LEU 302 ALA 76 LYS 299 GLU 82 GLN 301 THR 120 SER 261 PRO
12 VAL 260 MET 19 ARG 310 GLU 76 LYS 311 LYS 82 GLN 302 ALA 120 SER 262 ASN
12 VAL 261 PRO 19 ARG 311 LYS 76 LYS 312 CYS 83 MET 301 THR 120 SER 263 PRO
13 GLN 261 PRO 20 LEU 302 ALA 76 LYS 313 SER 83 MET 302 ALA
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Table 5.12: Residues Involved in the Interface CH -d2.
Pair List
121 ALA 261 PRO 153 PHE 255 ASP 208 LYS 258 GLU 210 SER 255 ASP 211 ASN 258 GLU
123 THR 253 ASN 153 PHE 256 THR 208 LYS 259 SER 210 SER 256 THR 211 ASN 259 SER
123 THR 254 THR 154 PRO 256 THR 209 PRO 253 ASN 210 SER 257 PHE 211 ASN 260 MET
123 THR 255 ASP 206 ASN 256 THR 209 PRO 254 THR 210 SER 258 GLU 212 THR 254 THR
123 THR 256 THR 207 HIS 255 ASP 209 PRO 255 ASP 210 SER 259 SER 212 THR 255 ASP
123 THR 258 GLU 207 HIS 256 THR 209 PRO 256 THR 210 SER 260 MET 212 THR 256 THR
123 THR 260 MET 207 HIS 257 PHE 209 PRO 257 PHE 210 SER 261 PRO 212 THR 257 PHE
123 THR 261 PRO 208 LYS 253 ASN 209 PRO 258 GLU 211 ASN 253 ASN 213 LYS 255 ASP
124 LYS 255 ASP 208 LYS 254 THR 209 PRO 259 SER 211 ASN 254 THR 213 LYS 256 THR
124 LYS 256 THR 208 LYS 255 ASP 209 PRO 260 MET 211 ASN 255 ASP
125 GLY 255 ASP 208 LYS 256 THR 210 SER 253 ASN 211 ASN 256 THR
125 GLY 256 THR 208 LYS 257 PHE 210 SER 254 THR 211 ASN 257 PHE
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Chapter 6
Full–Length ErbB2 Receptor
Description
This chapter is based on the published article “Exploring the dynamics and inter-
action of a full ErbB2 receptor and Trastuzumab-Fab antibody in a lipid bilayer
model using Martini coarse-grained force field” by JF Franco-Gonzalez, J Ramos,
VL Cruz and J Mart´ınez-Salazar, J. Comput. Aided Mol. Des., 28(11):1093-1107,
2014
Abstract
Coarse Grained modeling has been applied to study the influence
of the Trastuzumab monoclonal antibody on the structure and dy-
namics of the full ErbB2 receptor dimer, including the lipid bilayer.
We will show that the Martini model performs satisfactorily well, giv-
ing results well-matched with those obtained by atomistic models as
well as with the experimental information existing on homolog recep-
tors. The Trastuzumab Fab hinders the interaction of the receptors
with the lipid bilayer and generate the disruption of the antiparallel
arrangement of the juxtamembrane segments in the dimer case.
6. Full–Length ErbB2 Receptor Description
6.1 Introduction
Most of the structural studies, either computational or experimental, performed
on the EGFR family members have been carried out separately on ECD[1–6],
transmembrane[7–17] and TKD[18–29]. The inherent difficulties associated to
both the presence of the membrane and the size of the full systems are the main
reason of such fragmented structural analysis. Several authors have used Fluo-
rescence Resonance Energy Transfer (FRET) techniques to study the disposition
of the full receptors in the membrane[30–32]. Some donor labels are placed in
the protein structure and some acceptor labels in the lipid polar heads, allow-
ing the measurement of the distance between the labeled residues and the lipid
bilayer surface. Some set of FRET measurements using a labeled Trastuzumab
Fab along with homology modeling techniques allowed Bagossi et al. to propose a
structural model for the full ErbB2/Trastuzumab-Fab dimer inserted in the lipid
bilayer[33].
There are only two molecular simulations studies dealing with an EGFR re-
ceptor inserted in the membrane. Kastner et al. studied the solvated EGFR
tetramer in a lipid bilayer[30]. The study considers the extracellular and trans-
membrane domains of the receptors summing up to more than 8x105 atoms.
The multinanosecond simulations (∼75ns) were performed using 4096 processors
of the BlueGene supercomputer. Another related system studied by atomistic
molecular dynamics simulation is the near half million atom complex simulated
over tens of µs by Shaw’s group on the Anton supercomputer, a “hardware”
specifically designed to accommodate molecular dynamics algorithms. This sys-
tem consisted of a complete EGFR dimer including the lipid bilayer[34].
Both studies used massive supercomputer resources which are hardly accessi-
ble to the scientific community. The coarse grained (CG) models offer an alterna-
tive way to study both larger spatial and time scales of huge biomolecular systems,
beyond what is possible with all-atom models (AA), using moderate computa-
tional resources[35]. In particular, the Martini force field has been established as
a suitable model for the coarse grained description of biological systems[36, 37].
Four atoms per coarse grained particle are mapped in Martini, which offers pa-
rameters for several types of molecules including, essentially, lipids and proteins.
This model has been successfully used to investigate the structure and dynam-
ics of systems containing lipids and peptides such as transmembrane proteins or
antimicrobial peptides[38–40].
Here, we report on the molecular dynamics simulations of the structure and
dynamics of the ErbB2 receptor and its interaction with the Trastuzumab mon-
oclonal antibody Fab(mAb) from the experimental and computational points of
view [41–43]. The ErbB2 receptor is studied in monomer and dimer forms, for
which existence experimental evidence has been reported [44, 45]. The dimer is
associated to receptor overexpressed in cancer cells[45]. Thus, in this manuscript
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we analyze the capability of the Martini model to perform coarse grained sim-
ulation of interaction of a full ErbB2 receptor and Fab-Trastuzumab comparing
the results with those obtained by atomistic modeling and also with other ex-
perimental data available on similar systems. It should be also pointed out that
the simulation of these ErbB2 full receptor systems in its monomeric and dimeric
forms, including the lipid bilayer and an antibody Fab has not been performed
before.
6.2 Computational Methods
Protein – Bilayer Setup
An atomistic model of the full ErbB2 receptor and the Trastuzumab Fab were
taken from the homology structure published by Bagossi [33]. Tables 6.3 – 6.5
in the section 6.9 provides the amino acid sequences of the different receptor and
the antibody domains used in the present work. The Martini Force Field and its
extension to proteins (version 2.2) were used to build the CG topology[36, 37].
Elastic Networks (EN) for the CG model of the protein in solution was employed
using the ElNeDyn method[46].
The application of EN to the whole receptor might introduce undesirable
rigidity to the system. The subdomain selection for the EN model is based on
the receptor structural characteristics and our previous results on the atomistic
ECD. For example, the extracellular subdomains I and III consists of a series
of β-sheets which confer a relative rigidity to them. Subdomains II and IV
are cystein-rich regions which may be assumed to be also relatively stable in
water solution. These assumptions are confirmed by the different ErbBs struc-
tures experimentally elucidated either in the staggered or opened conformations
simulations[30, 34, 41, 42, 47]. Therefore, the major sources of flexibility may be
associated, in principle, with the interdomain connections. However, a validation
of the EN setting procedure was performed by comparison between coarse-grained
and atomistic simulations.
Elastic networks between backbone particles were applied separately at each
subdomain for the ErbB2 complex and for the Trastuzumab Fab. The parameters
controlling the elastic networks were a cutoff radius Rc = 0.8nm and a spring
constant Kspring = 500kJmol
−1nm−2. We followed the methodology suggested
by Periole et al.[46] regarding the selection of parameters for the EN. In the
Figure 6.16 of section 6.9, the root mean squared fluctuation (RMSF) values
corresponding to the ECD are represented for the different combinations of Rc
and Kspring values compared with the atomistic data. As can be observed the
best fit with the atomistic model is obtained with the combination Rc and Kspring
suggested above.
We have selected the Dipalmitoylphosphatidylcholine (DPPC) lipid as a model
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Table 6.1: Number of replicas and simulation time for each system
System # Replicas MD productiona(µs)
Monomer 3 4
Monomer+Tzb 2 4
Dimer
3 4
1 28
Dimer+Tzb
1 4
1 38
a Scaled time.
for the bilayer forming element. Other more complex membrane compositions
may exist in the ErbB2 system but these are not clearly defined. Systems con-
sisting of 1041 to 1052 DPPC molecules solvated in 79453 to 80642 Martini water
particles were prepared to build the different lipid bilayers. A triclinic box with
cartesian dimensions 17x17x35 nm was selected so that periodic image interac-
tion were avoided. The protein was positioned so that the TM helix was inside
of the lipid bilayer.
Several replicas were performed for each system. Table 6.1 collects that num-
ber and the simulation time for each one.
Simulation details
All CG molecular dynamics (MD) simulations were performed using the version
4.5.3 of the GROMACS simulation package[48]. An energy minimization using
the steepest descent algorithm over 1000 steps was carried out for the initial
structure. Then, a NPT equilibration with position restraints for all protein beads
was run for 40 ns, and finally, a NPT equilibration without position restrains was
run for 8 ns.
The Particle Mesh Ewald (PME) method[49] was used to calculate long-range
electrostatic interactions, using a maximum grid spacing of 2.5 A˚, fourth-order
(cubic) interpolation for the fast Fourier transforms and a relative dielectric con-
stant of 15. A dielectric constant of 15 is used for explicit screening to balance
the increased hydration strength of many of the CG particle types[36]. The tem-
perature was kept constant at 310 K by coupling the protein and the solvent
independently to an external bath using the Berendsen algorithm with a cou-
pling constant of 1 ps[50]. Isotropic scaling was used for the pressure (1 bar)
with a coupling constant of 2.0 ps and a compressibility of 3.5e−5 bar−1 follow-
ing the Berendsen algorithm[50]. The temperature range used in the original
Martini force field parameterization for lipids was 270–330 K. The calculated
transition temperature for DPPC is 295.5 K below the experimental value of
315K[36]. Therefore, the 310 K temperature selected for our simulations could
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be considered physiologically relevant.
The dynamics were integrated using the velocity Verlet integrator, with a time
step of 20 fs and bonds constrained using the LINCS algorithm[51]. Thus, pro-
duction dynamics were performed at constant pressure and temperature (NPT
ensemble) storing the trajectory every 0.5 ns to increase the statistical signif-
icance. Independent trajectories were generated for each studied model using
different seed numbers for the initial velocity assignment.
It has been proposed that the time unit used in coarse grained simulations
using the Martini force field should be multiplied by four to obtain an estimation
of the corresponding atomistic time unit[52]. This conversion factor is derived
from the diffusion dynamics of CG water compared to atomistic water. Therefore,
the dynamic properties analyzed through the results section are reported in the
scaled time units.
Distance maps between the backbone particles were calculated in order to an-
alyze the interdomain interactions. Normalized maps were constructed by count-
ing the number of frames where the inter residue backbone particle distance is
below a threshold of 0.7 nm and dividing by the total number of frames. Thus,
a value of one in the distance map would corresponds to a persistent distance
below 0.7 nm between the corresponding residue backbone particles along the
whole trajectory.
Principal component analysis (PCA)[53, 54] is a method that takes the trajec-
tory of long MD simulations and calculates the dominant modes in the molecular
motion. Thus, the configurational space is reduced, containing few relevant col-
lective degrees of freedom in which long range fluctuation can be studied. A PCA
diagonalizes the covariance matrix of the atom fluctuations from their average
trajectory. In this framework, the larger eigenvalues correspond to eigenvec-
tors which explain most of the variance associated to particle fluctuations. The
eigenvalue ordering allows to identify a small set of modes that capture most of
the fluctuations. We have performed a PCA analysis in order to identify the
lowest frequency motions occurring in the tyrosin-kinase dimer. The g covar and
g anaeig tools in the GROMACS package were used to perform the PCA analysis.
6.3 Findings for the Monomer and Homodimer Sys-
tems
CG simulations were performed on both the monomer and dimer forms of the
ErbB2 receptor in a bilayer model. The complexes with the Tzb-Fab bound to
its corresponding epitope at the ECD are modeled in order to study the antibody
effect on the structure and dynamics of the receptor. Figure 6.1 depicts both the
Trastuzumab Fab antibody bound to the ECD of the monomer and dimer forms
of the full ErbB2 receptor embedded in a lipidic bilayer membrane model.
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Figure 6.1: Schematic Representations. A Antibody-Free ErbB2 monomer
receptor. The subdomains I, II, III and IV of the ECD domain, TM domain, JX domain
and the TKD domain are shown in red. The C and N label stands for the C-lobe and
N-lobe domains of the TKD. The shadow area represents the lipid bilayer. B Antibody-
Bound ErbB2 Monomer receptor. The Tzb-fab is bound to the subdomain IV of the
ErbB2 receptor. The variable (VD) and constant (CD) domains are shown in green and
yellow colors, respectively. C Antibody-Free ErbB2 Homodimer. D Antibody-
Bound ErbB2 Homodimer, the two antibodies bound to their respective subdomains
IV are shown with the same color code.
In what follows, the structure and dynamics of the ECD, TM and TKD
domains will be separately discussed for both the monomeric and dimeric forms
without and with Trastuzumab bound to the ECD, respectively. A comparison
with other available atomistic simulation models as well as with experimental
data will be done, whichever is possible, in order to evaluate the performance of
the CG models. Finally, we make a discussion of all results.
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d
(a)
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Figure 6.2: Initial and final conformations of a selected replica of (a) the antibody
free ErbB2 monomer and (b) the antibody-bound ErbB2 monomer. ErbB2 receptor
and antibody are shown in blue and green, respectively. Space fill representation for
the CG particles. Lipid bilayer molecules are depicted as gray lines and water particles
are omitted. The distance d is defined to measure the approach of the receptor to the
lipid bilayer (see text for details). The initial conformations of the ErbB2 monomer were
prepared using the Bagossi’s structure
6.4 ECD domain
6.4.1 Monomeric form without and with Trastuzumab
Selected initial and final snapshots of the monomer simulations without (antibody-
free) and with (antibody-bound) Tzb are depicted in Figure 6.2. Firstly, in the
antibody-free monomer system the ECD presents a hinge movement at the inter-
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Figure 6.3: First PCA eigenvector for
the ECD-ErbB2 monomer corresponding
to the antibody-free (left) and antibody-
bound (right) systems. Only the back-
bone is represented (as connecting lines).
Several projections of the backbone are
plotted between the two extremes denoted
with red and blue colors.
Antibody-free
ErbB2
Antibody-bound
ErbB2
face of subdomains III and IV (residues 460–480) that approaches subdomain IV
to the dimerization arm (subdomain II). Figure 6.3 shows the first eigenvector
of the PCA analysis performed on simulations of both monomeric systems. A
remarkable similarity can be observed to the result obtained with the PCA anal-
ysis performed on atomistic simulations of ECD-ErbB2 (see, for example, Figure
4.5). This movement in the CG simulations agrees also with previous atomistic
simulations performed on the monomeric ErbB2 extracellular domain[41, 47].
Remarkably, a similar motion has been recently described by MD simulations
of the full EGFR receptors with and without ligand[34]. This structure has not
been yet reported by crystallographic techniques likely due to the rigid packing of
the produced crystals[41]. Thus, the CG model reproduces the intrinsic flexibility
of the ECD domain observed in atomistic simulations. Furthermore, the presence
of the membrane does not seem to hinder this intrinsic flexibility of the ECD.
A closer comparison with the atomistic simulations can be seen in Figure
6.4. This shows the RMSF analysis of the residues in the ECD domain for
both the CG and atomistic simulations of the monomer taking as a reference the
Bagossi’s structure [33]. The plot compares the fluctuation values for the Cα in
the atomistic models against the backbone particles of the CG particles (mapped
in the Cα atoms in Martini). In spite of the elastic networks treatment of the
CG model (see details in Computational Methods section), which is expected
to reduce fluctuation values, the profile is rather similar in both cases, showing
higher values in the loops and in the subdomains involved in the hinge motion
above mentioned.
The binding region between the ECD-ErbB2 epitope (subdomain IV) and
the Variable Domains of both the Heavy (VH) and the Light Chain (VL) of
the monoclonal antibody has been experimentally characterized by three ErbB2
loops. Loops formed by residues 557–561 and 593–603 are mainly electrostatic,
whereas the 570–573 loop makes principally hydrophobic contacts with the VH of
the antibody. Figure 6.5 shows the distance maps of the contact interface between
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Figure 6.4: RMSF plots for the ECD-
ErbB2 (top), Tzb-Fab heavy chain (HC,
middle) and light chain (LC, bottom).
The atomistic simulations were performed
on the antibody-bound ErbB2 ECD in wa-
ter. The CG 1 and CG 2 labels corre-
spond to two independent CG MD simula-
tions. The reference structure in all cases
was taken from the Bagossi’s structure
the subdomain IV and the antibody variable domain for the crystal, atomistic
and the CG structures, respectively. As it can be seen, the variable domain
of the monoclonal antibody structure maintain its interactions with the ECD-
ErbB2 epitope (subdomain IV) in all CG replicas as compared to the experimental
structure (PDB code: 1N8Z)[1]. The same observations have been obtained
in the second replica as can be seen in distance matrix showed in the Figure
6.17. Furthermore, a hinge movement is also observed in this case, which favors
the interaction of the antibody constant domain with the dimerization arm in
subdomain II. Thus, residues Thr256–Pro263 at the dimerization arm are found
at distances below 0.7 nm from Fab residues Ser120–Gly125 and Ser210–Asn211
in the Heavy Chain (HC), in line with the interactions reported for the atomistic
simulations[41].
Along the manuscript, the comparison with the atomistic model was de-
scribed using the ECD from the full-receptor structure (Figure 6.4 and 6.5).
A most appropriate comparison should be made with the CG model of the ECD-
ErbB2/Tzb-fab complex alone. The comparison of RMSF plots that was dis-
cussed in answering the EN question is a source of validation of the coarse-grained
model. Another source of validation regarding the protein–protein interactions
are the distance matrices evaluated between the ECD epitope and its interac-
tion with the Tzb-Fab. In Figure 6.18, the distance matrices calculated on the
atomistic and coarse-gained models for the ECD and Trastuzumab complex are
shown. It can be observed that most of the crystallographic contacts are well
preserved in the atomistic as well as in the Martini system.
A third validation test contemplates the dynamic properties of the system.
A comparative PCA analysis of the atomistic and CG simulations following the
113
6. Full–Length ErbB2 Receptor Description
Figure 6.5: Distance matrix between residue pairs of the ErbB2 subdomain IV and the
variable domain (VD) of the antibody monomer. The distance corresponds to the small-
est distance between the CG-beads of two residues in the receptor and in the antibody,
respectively. A cut-off distance of 0.7 nm was used. The experimental structure (PDB
code: 1N8Z) was mapped on the MARTINI CG model
method proposed by Siuda and Thogersen[55] was carried out. The eigenvectors
found when diagonalizing the covariance matrix were then used in the root mean-
square inner-product (RMSIP) analysis (see equation 1 of [55]), that quantifies the
overlap between the essential subspaces (described by the 10 first eigenvectors)
obtained from the AA and CG simulations. The RMSIP obtained was 0.51,
which may be considered satisfactory taking into account that a value of 1 means
a perfect overlap and 0 refers to an orthogonal space.
In Figure 6.6, it is shown two snapshots corresponding to a fitting between
the backbone CG particles and the Cα atoms of the atomistic model for the
ECD-ErbB2/Tzb-Fab complex. A RMSD value of 0.8 nm was obtained for the
full complex, whereas the RMSD values calculated separately for each constituent
were 0.4 nm for the ECD chain and 0.3 for the Tzb-Fab. In this figure, it can
be also observed the additional interaction between the antibody constant do-
main and the ErbB2 dimerization arm that has been captured similarly by both
atomistic and CG simulations.
As it can be seen in Figure 6.2, the final configurations of the protein with
respect to the lipid bilayer are rather different in the free and bound-antibody
monomer forms. In all replicas of the free-antibody monomer, an approach of the
protein to the lipid bilayer surface is observed. On the contrary, this approach has
not been detected in the case of bound-antibody complexes. In our simulations,
the vertical distance between the lipid polar head particles and the backbone
center of mass (COM) corresponding to subdomains I, II and III was evaluated
to quantify the approach of the ectodomain to the bilayer surface (d in Figure
6.2). Indeed, in the monomer systems, the calculated distance d drops from the
initial 10.5 nm to final values around 4.0 ± 0.3 nm and 7.9 ± 0.3 nm for the free
and the bound-antibody monomer forms, respectively.
The approach of the free-bound antibody monomer is in agreement with some
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Figure 6.6: ECD-ErbB2/Tzb-Fab complex showing the interaction between the dimer-
ization arm and the antibody constant domain. Left: atomistic model. Right: CG model.
The two Fab chains are depicted in green and brown colors. Roman numbers indicate
the location of the subdomains in the ErbB2 receptor. The ECD-ErbB2/Tzb-Fab (CG)
was extracted from the full receptor simulation
FRET experiments for the homolog EGF-ErbB1 homodimer where no antibody
is present[31, 32, 56]. In those experiments, it has been shown that the ErbB1
ectodomain lies parallel to the cell membrane at distances around 4.0 nm. The
geometric parameter used in the FRET experiments for the homolog ErbB1
(EGFR) receptor is the distance between a labeled Epidermal Growth Factor
(EGF) ligand bound to the ErbB1 receptor and the bilayer surface, which is
comparable to the d distance for our system defined above. These authors have
proposed that this approach of the receptor to the membrane is caused by the
high flexibility of the subdomain IV in the ECD. Anyhow, the antibody bound
to the subdomain IV is also anchored to the bilayer membranes (see final state
in Figure 6.2b), which in our models does not allow the approach of the receptor
to the membrane in the case of the bound-antibody monomer.
The final structures corresponding to the antibody-free monomer present per-
sistent interactions between residues 359–364 and 393–397 of the subdomain III,
residues 481–484 and 611–620 of subdomain IV and the bilayer surface. These
fragments contain several negatively charged ASP and GLU amino acids able
to interact with the positively charged lipid choline heads of the bilayer. In the
antibody-bound monomer case, the Tzb is able to develop permanent interactions
with the bilayer surface, as above mentioned, hindering the approach process of
the receptor to the lipid bilayer. The closest residues of the antibody to the bi-
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Figure 6.7: Normalized contact maps for subdomain II – subdomain II interaction
between both monomers in the antibody-free. (A) and the antibody-bound (B) ErbB2
dimers. This map is constructed by counting the number of frames where the inter
residue backbone particles distance is below a threshold of 0.9 nm and dividing by the
total number of frames. Lowercase letters stand for the different regions of contact
between dimerization arms. The color scale is in the range of 0 (no interaction along the
trajectory) to 1 (full interaction along the trajectory)
layer surface are Gly16, Asp17, Arg18 and Ser76 located at the heavy chain of
the Fab.
Several replicas of the simulated systems were performed as stated in Table
6.1. As it might be expected all replicas do not behave identically. A brief
discussion about variance across replicas has been added as MD monomer replicas
discussion in section 6.9 (Monomer MD Simulations: Replicas).
6.4.2 Dimeric form without and with Trastuzumab
The antibody-free ECD dimer structure (Figure 6.1C) is mainly driven by the
interaction between the dimerization arms at the subdomain II of each monomer.
The overall interaction through the dimerization arms originally found in the crys-
tallographic structures of the ECD-ErbB1[57] and subsequently used by Bagossi
for his ErbB2 model[33] is preserved along the CG simulations. However, some
weakening of the dimer interaction appears in the antibody-bound dimer model
(Figure 6.1D). Figure 6.7 presents the normalized residue contact maps for sub-
domain II – subdomain II complex interface for the antibody-free and antibody-
bound models, respectively. It can be observed that the residue contacts in
regions A and B are weakened in the antibody-bound dimer model. Further-
more, the interaction in the subdomain II C-terminal region (residues 306–309 in
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Monomer 1
Monomer 2
Fab 1
Fab 2
Figure 6.8: Full antibody-free (left) and antibody-bound (right) ErbB2 homodimer
structures at the end of the simulation. Space fill representation of the dimeric structures
of ErbB2 are shown in red (monomer 1) and blue (monomer 2) for each monomer. On the
other hand, the antibody (Trastuzumab) is represented in green. Lipid bilayer molecules
are depicted as gray lines. Water particles are omitted for clarity
region c) has disappeared in the antibody-bound case. Thus, the proximity of the
constant domain of the antibody disturbs the loops at subdomain II connecting
the dimeric interface. The variable domain of the antibody structure maintains
its interaction with the ErbB2 extracellular epitope (subdomain IV). The Tzb –
subdomain IV interaction observed in the monomer is rather similar to that found
in chain 1 of the ErbB2 dimer(see Figure 6.8). The other ErbB2 chain presents
a somewhat different interaction pattern with Trastuzumab. Figure 6.19 in sec-
tion 6.9 shows the distance matrices for the two monomers corresponding to the
longest replica of the Trastuzumab-bound homodimer system. The matrix la-
beled “Monomer 1” correspond to the monomer lying on the bilayer surface (see
Figure 6.8). This matrix is essentially similar to that described for the monomer
case (see Figure 6.5) and comparable to the crystallographic structure. The ma-
trix labeled “Monomer 2” corresponds to the monomer standing upright. The
residues involved in the ECD epitope – Tzb-Fab interaction are maintained. How-
ever a different distance matrix pattern is obtained concerning residues 560–565
and 586–593 of the ErbB2 chain. These interactions may correlate with the loose
interface in the subdomain II dimerization region for the Trastuzumab-bound
homodimer system.
The C-terminal fragment of subdomain IV is another structural characteristic
of the ECD dimer structure. Atomistic scale simulations performed on ErbB2-
ErbB3 ECD dimers in solution show a clear interaction between the C-terminal
segments of the subdomains IV [42]. This is also the situation exhibited by some
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crystallographic structures of homolog receptors, e.g., the ECD-ErbB1 dimer[57].
The CG simulations of the antibody-free dimer system show the expected subdo-
main IV C-terminal interaction between the two ErbB2 monomers. The contact
map associated to subdomains IV for both monomers presents a remarkable in-
teraction between the C-terminal fragments in the antibody-free system. These
contacts disappear in the antibody-bound dimer complex (see Figure 6.20). Thus,
the antibody bound in the vicinity of subdomain IV exerts a hindering effect on
the association of these subdomains at their respective C-terminal fragments lo-
cated above the membrane surface.
In Figure 6.8, the final conformation of the antibody-free (on the left) and
antibody-bound (on the right) homodimer systems are shown. It can be observed
that for the antibody-free homodimer, one of the ECD-ErbB2 monomer lies on
the bilayer surface (monomer 1) whereas the other monomer remains in a more
upright position (monomer 2). The measured distances from the ECD COM to
the bilayer surface, as defined in the previous section, reach a plateau with values
of 7.8 ± 0.3 and 4.0 ± 0.3 nm for monomer 2 and 1, respectively. These values
agree with the FRET measurements reported on the ErbB1 receptor [31, 32, 56]
and shown in the previous section. In the system containing Trastuzumab, the
presence of the antibody hinders in some way the approach of any of the ECD-
ErbB2 segments to the membrane (see Figure 6.8 left). In analogy to what is
observed in the antibody free case, one monomer approaches the bilayer surface
more than the other, keeping distances from both ECD to the lipid layer of 5.5
and 8.5 nm for the labeled monomer 1 and 2 in Figure 6.8 left, respectively. These
distances are larger than the corresponding to the antibody-free system due to
the interposition of the antibody between the bilayer and the ErbB2 receptors.
A comparative analysis of these results with atomistic models reported for
the ErbB1 dimer can be done. The ECD-ErbB1 dimer model described in
references[30, 34] for the active forms is very similar to our CG model. The
interaction between the C-terminal fragments of both subdomains IV is a weakly
crossing interface so that the N-terminal portions of the transmembrane domains
can be close. The inactive form described in reference [34] shows both C-terminal
fragments far enough to avoid the N-terminal transmembrane interaction. The
Trastuzumab effect is to weaken the subdomain IV interaction, giving rise to a
distortion of the transmembrane domain association. The relative orientation
of the ECD domains to the bilayer surface may be driven by the electrostatic
properties of the lipid polar heads. In reference [30] the lipid molecules are zwit-
terionic and the active ECD-ErbB1 domains lay down the lipid bilayer. The same
ECD domains remain in an upright position when a mixture of zwitterionic and
charged lipids is considered (reference [34]). Our CG models, which takes into
account zwitterionic lipids, shows a similar behavior to the active ErbB1 system
described in reference [30]. We also found one monomer being closer to the bilayer
surface than the other. A more detailed discussion about the relative disposition
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Figure 6.9: Normalized contact maps of the transmembrane (TM) interaction for the
antibody-free (a) and antibody-bound (b) ErbB2 homodimer. The scale represents the
occupancy of the interaction along the analyzed trajectory. See computational section
for details of how the contact map is calculated. The tandem makes reference to the
GxxxG-like motifs along the chain
of the ECD domains respect to the lipid bilayer has been provided above.
6.5 Transmembrane domain
The dimeric association of transmembrane domains has been related to have a
key role in the activation of the entire receptor [9, 58]. In this section we describe
the results obtained on the transmembrane association of the homodimer systems
from CG simulations.
The starting structures for the simulations, which come from the Bagossi’s
model, present the transmembrane fragments interacting mainly through the N-
terminal and central sections of each chain, namely, residues Arg625–Leu640.
This arrangement of the TM dimer is maintained along the simulations. Figure
6.9 shows contact maps for the residues belonging to the transmembrane domains
collected during the last µs of the antibody-free (Figure 6.9a) and antibody-bound
(Figure 6.9b) homodimers. Firstly, the contact maps of the antibody-free homod-
imer are in agreement with the TM helix packing interface reported for the ErbB2
dimer by Bocharov based on NMR experiments (PBD code: 2JWA)[9]. These au-
thors hypothesized that the arrangement experimentally elucidated would corre-
spond to an active form of the TM dimer. The dimer is favored by the interaction
between a tandem variant of GxxxG-like motifs located at the N-terminal section
(see Figure 2F of reference [9]). Our CG simulations arrive to a homolog in-
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Antibody-free Antibody-bound
Tandem———– ———–
Figure 6.10: Cartoon representation of the transmembrane (long α-helix) and jux-
tamembrane (short α-helix) fragments extracted from the final snapshot of the antibody-
free and antibody-bound ErbB2 dimer simulations. The lateral chains of the juxtamem-
brane domain are shown as blue and yellow CPK balls for the charged and hydrophobic
residues, respectively. Lipid polar head particles are represented as green CPK balls.
Water and the most lipid atoms are omitted to gain clarity in the figure.
teraction tandem corresponding to residues Ser627-xxx-Phe631-xxx-Thr635-xxx-
Val639 (see Figure 6.9). In addition, The contact maps are also very similar to
those reported by Arkhipov et al. for the homolog EGFR dimer in the disposition
associated to an active form of the complex (see Figure 4 of reference [34]).
On the other hand, the system containing the antibody develops additional
interactions between amino acids located close to the C-term region of the TM,
which are not seen for the antibody-free case (please compare Figure 6.9a and
Figure 6.9b). It can also be observed that in the antibody containing system, a
transmembrane helix is displaced asymmetrically with respect to the other one
(see Figure 6.10). This unsymmetrical arrangement is depicted in the contact
map by the off-diagonal marks near the N-terminal section (residues Pro620 and
Ala626, see Figure 6.9b). It can also be observed a four residue displacement of
the interaction tandem towards the TM C-terminal part (Thr630-X3-Ala634-X3-
Gly638-X3-Phe642 in Figure 6.9).
6.6 Juxtamembrane domain
The juxtamembrane domain (JX) (residues Lys659–Leu669), which is located
between the transmembrane and kinase domains, is related to important regula-
tory functions such as regulation of the receptor trafficking and inactivation[59].
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Table 6.2: Geometrical parameters of the juxtamembrane arrangement. The label n.a
means not applicable
System Torsion ϕ(o)
Angle θ(o)
Monomer 1 Monomer 2
Antibody-free monomer n.a 19 ± 2 n.a
Antibody-bound monomer n.a 21 ± 2 n.a
Antibody-free dimer 7 ± 5 7 ± 3 3 ± 2
Antibody-bound dimer 57 ± 9 27 ± 4 60 ±3
Thus, the arrangement of this JX domain with respect to the bilayer and to the
TKD has been studied and related to regulatory functions of the EGFR family.
In this section, we define the torsion angle (ϕ) between the JX α-helix axes
as well as the θ angles between these axes and the bilayer surface, i.e., θ gives an
idea of the position of the JX domain respect to the lipid bilayer whereas the ϕ
shows the relative orientation of the JX domains in the case of the homodimer
complex. These definitions are shown in Figure 6.11. They help to quantify the
JX spatial arrangement.
6.6.1 Monomeric form without and with Trastuzumab
In the monomer case, it can be observed that the juxtamembrane segment adopts
a parallel configuration with respect to the bilayer surface so that the polar
residues are oriented to the water phase whereas their hydrophobic amino acids
face the lipid interior. This observation agrees with the NMR experimental results
obtained on the EGFR juxtamembrane fragment[60]. The angle (θ) formed by
the juxtamembrane helix axis and the lipid bilayer surface is similar for both
cases (19 ± 2 for the Antibody-Free ErbB2 and 21 ± 2 for the Antibody-bound
complex).
6.6.2 Dimeric form with and without Trastuzumab
The Antibody-free homodimer reach an antiparallel arrangement of both jux-
tamembrane α-helices (ϕ ∼ 7o, see Table 6.2) as well as a parallel disposition
with respect to the bilayer surface (θ ∼ 3o and 7o, see Table 6.2). It can be noted
that the antiparallel disposition has been identified to be essential for an active
dimer conformation[34, 58].
On the other hand, it can be observed a severe distortion of the juxtamem-
brane antiparallel arrangement in the antibody-bound homodimer system (ϕ ∼
57o, see Table 6.2). In the same way, the parallel alignment respect to the bilayer
surface is lost (θ ∼ 27o and 60o, see Table 6.2).
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Figure 6.11: Schematic representa-
tion of the mutual disposition of the
JX fragments (cylinders) and the lipid
bilayer (prism).
Lipid Bilayer
θϕ
N
C
N
C
Besides the parallelism with the bilayer exhibited by the juxtamembrane seg-
ments in the antibody-free simulations, these fragments remain anchored on the
surface of the membrane, as can be observed in Figure 6.10. The hydrophobic
residues Ile660, Tyr663, Met665, Leu668 and Leu669 (yellow CPK balls in Figure
6.10) face the lipid acyl tails whereas the Lys and Arg charged amino acids (blue
CPK balls in Figure 6.10) interact with the lipid polar heads. This picture of
the interaction between the juxtamembrane fragment and the lipid bilayer are
in agreement with the NMR results [59] and with the description recently pro-
vided for the EGFR dimer[34, 58] in its active conformation. In the case of the
antibody-bound homodimer almost all these interactions are weakened, losing
the antiparallel arrangement of both juxtamembrane α-helices.
6.7 TKD intracellular domain
Regarding the TKD, the general observation in all the systems is that the TKD
approaches the lipid bilayer surface on the intracellular side.
In the monomer cases, the distance from the tyrosin-kinase COM to the bi-
layer surface is 2.6 ± 0.2 nm for both systems. The tyrosin-kinase residues at
distances to the membrane surface smaller than 0.8 nm correspond to the residues
Ile850–Gly859, Leu873–Arg875 and Asp940–Cys943.
The representation for the dimer structures in Figure 6.8 apparently shows
a closer approach of the TKD dimer to the bilayer surface in the case of the
antibody-bound ErbB2 homodimer. Looking at the distances between the TKD-
COM and the bilayer surface, averaged over the last µs of all the correspond-
ing replicas, the cytoplasmic domains of the antibody containing system present
a slightly closer approach to the membrane surface (2.8 ± 0.2nm) than the
antibody-free dimer case (3.0 ± 0.2nm). In Figure 6.21 the distance between
the TKD-COM and the bilayer surface along the simulation time for several
replicas of the Trastuzumab-free homodimer system is shown. The approach to
the bilayer surface occurs in the first microsecond reaching a distance between
both TKDs COM to the bilayer surface that fluctuates between 2.5 and 3 nm, as
illustrated in that Figure.
Figure 6.12 depicts the disposition of the TKD dimer relative to the bilayer
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Figure 6.12: Cartoon representation of the tyrosin-kinase domains extracted from the
final snapshot of the antibody-free and antibody-bound ErbB2 dimer simulations. Upper:
Relative position of the TKD dimer respect to the bilayer. Lipid polar head particles
are represented as green balls. Lower: TKD dimer image taken from the normal to
the bilayer viewpoint. Lipid particles are omitted. The N and C lobes are shown for
one of the chains to illustrate the back-to-back arrangement. Magenta shadow surfaces
correspond to residues involved in the active site
surface. There are three groups of residues that permanently approach the bilayer
surface at distances below 0.8 nm, namely, Gly850–Lys859, Leu873–Arg875 and
Trp937–Cys943 located in the C-lobe of the kinase domain. The first and third
fragments contain charged residues able to interact with the lipid polar head
particles. This result is in line with the X-ray elucidated structure of the TKD
ErbB1 dimer complexed with a lipid-like molecule[59]. It can also be observed in
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Figure 6.13: First PCA eigenvector
for the tyrosin-kinase dimer. Only the
backbone is represented (as connecting
lines). Several projections of the back-
bone are plotted between the two ex-
tremes denoted with red and blue col-
ors
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each case that the TKD dimer approaches the bilayer asymmetrically, being one
monomer closer to the bilayer surface. This result is in close agreement with the
full atomistic models of the EGFR dimer in a lipid bilayer[34].
The interaction between both tyrosin-kinase domains corresponds to the back-
to-back configuration as was proposed in the original Bagossi representation. The
N-lobe of one chain interacts with the C-lobe of the other, leaving the active site
in the opposite sides of the contact surface formed by the N → C → C → N
interaction of both TKDs (see Figure 6.12). As the dynamics evolves, the back
to back interaction is continuously lost due to a progressive disruption of one
of the two N-lobe C-lobe interactions. In order to examine the opening move-
ment of the tyrosin-kinase dimer, we performed a Principal Components Analysis
(PCA) on the last µs of the trajectory focusing on the backbone particles of the
tyrosin-kinase domain. The first eigenvector extracted from the fluctuation anal-
ysis shows the increased displacement of one tyrosin-kinase C-lobe with respect
to the N-lobe belonging to the other ErbB2 tyrosin-kinase chain. Figure 6.13
depicts a schematic representation of the main PCA component corresponding to
the Trastuzumab-free system. Several projections of the backbone are shown in
different colors between the two extreme points (blue and red colors) to illustrate
the displacement of one C-lobe out of its N-lobe partner.
The influence of the Trastuzumab Fab in the TKD dimer interface seems to
be rather subtle as can be deduced from the simulations reported in this work.
Figure 6.14 presents the time evolution of the COM distance between the N and
C lobes of the two monomers (part A) and from these to the bilayer surface (part
B). On one hand, one of the two interacting N-lobe C-lobe pairs in the TKD
dimer is weakened along the dynamics. As can be observed in Figure 6.14, part
A, the inter-COM distance between the monomer 1 C-lobe and monomer 2 N-
lobe is elongated to values above 3.5 nm whereas the equivalent distance between
monomer 1 N-lobe and monomer 2 C-lobe remains around 3 nm. The evolution
is similar in the Trastuzumab-free and bound cases as well. This is in agreement
with the PCA analysis discussed above where an analogous opening was reported.
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On the other hand, the relative position of the TKD dimer respect to the bilayer
surface shows some features already discussed in the monomer case. Each TKD
chain shows one lobe closer to the bilayer than the other. Either the N or C
lobe can alternate the approaching to the bilayer surface (see for example the red
and green lines in part B graphs of the Figure 6.14). The inter-chain N lobe C
lobe interaction is revealed by the superposition of red (N lobe monomer 1) and
cyan (C lobe monomer 2) curves on one side and blue(N lobe monomer 2) and
green (C lobe monomer 1) lines on the other. The interaction pair formed by the
N lobe in monomer 2 and the C lobe in monomer 1 seems to be systematically
farther from the membrane surface than the other N-lobe – C-lobe interaction.
This observation correlates with the distance elongation shown by monomer 1 C-
lobe and monomer 2 N-lobe interaction. Finally, a subtle observation regarding
the effect of the antibody can be the slightly lower overall distance between the
TKD dimer to the bilayer surface as can be deduced from the plots in part B
(points in the antibody-bound case plot reach distance values lower than 2 nm
more frequently than in the antibody-free case)
The TKD is marginally modified respect to the initial model proposed by
Bagossi. Due to the Elastic Networks treatment, no conformational changes in
the active site are contemplated and a comparison with simulations of the TKD
cannot be performed at the moment. The TKD dimerization is stable in its
initial conformation although some trend to an asymmetric disposition of the C–N
lobes can be depicted from the PCA analysis performed on the particle dynamics
fluctuations. An extrapolation of this movement will presumably drive to an
asymmetric configuration of the tyrosin-kinase dimer with only an N-lobe/C-lobe
interaction between the two monomers.
Once the CG model is validated against available experimental data and atom-
istic simulations, we discuss the effect of the monoclonal antibody Trastuzumab
on the receptor dimerization at a molecular level. The simulation of the full re-
ceptor allows us to suggest an action mechanism for the Trastuzumab Fab while
interacting with the ErbB2 dimer as follows. The binding of the Trastuzumab
Fab to its native epitope at subdomain IV hinders the interaction of both ECDs
through the subdomain IV C-terminal fragment. This defective interaction causes
in turn a small disruption of the transmembrane dimerization which is slightly
displaced towards the C-terminal fragment. The juxtamembrane segments in
the intracellular domain should be affected by this displacement so that an an-
tiparallel arrangement cannot be observed in our simulations. This lack of an
antiparallel disposition might be associated to an inactive conformation of the
TKD domain. The proposed mechanism is in line with the recent biological
observations regarding the effective antibody deactivation on the proliferation
signaling cascade initiated by the ErbB2 dimer[45].
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Figure 6.14: A) Distances between the COM of N and C lobes in the TKD dimer
interface. B) Distances from the TKD dimer N and C lobes to the bilayer surface.
6.8 Conclusions From This Work
We report, for the first time, molecular dynamics simulations of full models of
ErbB2 monomer and dimer systems embedded in a lipid bilayer and complexed
with the Trastuzumab-Fab monoclonal antibody. The system has been simu-
lated within the Coarse Grained approach using the Martini force field. This
force field is a well established model for molecular dynamics simulations of sys-
tems containing proteins and lipids. The results presented in this paper support
this assertion in view of the satisfactory comparison with experimental data and
atomistic simulations.
Starting from the models proposed by Bagossi, we have carried out several
µs coarse grained molecular dynamics simulations on systems containing either
the full ErbB2 monomer or dimer with or without the monoclonal antibody Fab
and embedded in a lipid bilayer. The model proposed in this work seems to
fulfill a number of experimental and computational observations about the full
ErbB2 structure and its interaction with the lipid bilayer. Some details observed
in atomistic simulations of the different ErbB domains are reproduced in the
coarse grained models. The most relevant observations are summarized below.
In the monomer case an interaction between the antibody constant domain and
the dimerization arm can be observed in addition to the native interaction with
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the epitope in subdomain IV. This was also observed in atomistic simulations of
the ECD alone. The ECD-ErbB2 domain tends to lay down on the lipid bilayer
surface in agreement with recent FRET analysis and detailed atomistic simula-
tions of homolog systems. The intracellular domain also presents a noticeable
interaction with the bilayer surface. In particular, the juxtamembrane fragment
has been found to partially penetrate the membrane bilayer, in agreement with
NMR measurements made with this fragment in a micelle environment.
The inclusion of the Trastuzumab Fab monoclonal antibody has a pronounced
effect on the structural disposition of the ectodomain, due to the hindrance ex-
erted on those amino acids mainly responsible for the interaction at subdomain
IV C-terminal. The antibody containing system shows a displacement towards
the C-terminal segment of the transmembrane domain contacts in the dimer and
a complete lost of the juxtamembrane antiparallel arrangement characteristic of
the active state that is also observed in the pure homodimer case. This action
mechanism may explain the lost of signaling ability impaired by Trastuzumab
to ErbB2 homodimers experimentally found. Despite the disarrangement of the
juxtamembrane segments observed in the antibody case, the TKD dimer archi-
tecture is similar in both systems probably due to the tighter interaction in the
initial Bagossi’s model. The PCA analysis of the different trajectories reveals
a rupture of the symmetric structure driving to a more asymmetric ensemble
compatible with an active version of the TKD dimer.
6.9 Additional Information
Protein Sequences
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6. Full–Length ErbB2 Receptor Description
Monomer MD Simulations: Replicas
Regarding the monomer system, the three replicas corresponding to the trastuzumab-
free case arrive to a collapsed structure of the receptor on the lipid bilayer. How-
ever, the ECD approach to the lipid surface takes different times on each replica
as can be observed in Figure 6.15. In the same Figure, it can be observed that
the trastuzumab-bound replicas converge to a value around 6 nm well above the
average 4 nm distance in the trastuzumab-free systems. Regarding the TKD the
approach is indistinguishable, reaching a plateau value of around 2.5 nm in the
first 400 ns, as can be observed in the same Figure. The RMSD values corre-
sponding to the backbone particles for all replicas were also calculated for the
first 4 µs. All the replicas show that the studied systems are well stabilized ar-
riving to similar RMSD values after the first µs. However, the antibody-bound
dimer gives different RMSD values for the two replicas, both around 3 nm, lower
than the other systems.
On the other hand, we include the Figure 6.17 containing the equivalent
information to that provided in Figure 6.5 but for the second replica. The two
Martini graphs corresponding to the different replicas show essentially the same
features. The trastuzumab residues involved in the interaction are the same while
the ECD interface shows minor discrepancies in residues 575–580 and 583–584.
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Figure 6.15: Distance from ECD-ErbB2 COM domains to the lipid bilayer surface for
the different replicas described in Table 6.1 of the Chapter 6. A) Extracellular domain.
B) Tyrosin kinase domain. C) Inset of the TKD.
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6.9. Additional Information
Rc and Kspring Comparison
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Figure 6.16: RMSF at different values of Rc and Kspring on ErbB2 receptor.
Distance Matrices
Figure 6.17: Distance matrices for the second MD replica of the trastuzumab-bound
ErbB2 monomer compared with atomistic and X-ray data. The interaction between
subdomain IV and the antibody Fab is plotted
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6. Full–Length ErbB2 Receptor Description
Figure 6.18: Distance matrices calculated on the atomistic and coarse-gained models
for the ECD-ErbB2 and Tzb-Fab
Figure 6.19: Distance matrices for the subdomain IV – Tzb-Fab interaction in the
antibody-bound dimer system
Figure 6.20: Normalized contact maps for the inter subdomain IV interaction in both
dimer systems, namely, with and without Trastuzumab
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TKDCOM – Bilayer Surface Distances
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Figure 6.21: Distance from the TKD to the bilayer surface for the four replicas of the
trastuzumab-free homodimer system
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Concluding Remarks
The present thesis yields a useful collection of homology models for the ECD
ErbB receptors updated with the information provided by the latest crystallo-
graphic structures of suitable templates deposited in the Protein Data Bank. In
particular, the model for ErbB3 and ErbB4 receptors includes the structure of
subdomain IV which was absent previously. These models were subsequently
refined by MD simulation. A set of common features was found for all the re-
ceptors, namely a periscope movement of the dimerization arm in subdomain II.
What is more important is the remarkable flexibility found for subdomain IV. A
hinge movement of this domain towards subdomains II and III was observed in
all cases. A model for the interaction of ErbB2 and ErbB3 was also proposed.
This complex forms one of the most biologically relevant dimers associated with
aggressive carcinomas. To the best of our knowledge, the model proposed is the
first atomistic scale model for ECD interaction in this heterodimer. The hinge
movement observed in the separated receptors is also noticeable in the complex
in an asymmetric way, being less mobile in ErbB2 than in ErbB3. The biological
consequences of this information are not so evident, and further studies need to
be carried out. However, the generation of the ECD ErbBs models presented
in this thesis will serve as an starting point for a systematic study of these im-
portant receptors in order to provide clues for the development of more effective
therapeutic strategies.
MD and PCA studies of the flexibility of the complex between the extracellular
domain of the ErbB2 receptor and the Trastuzumab antibody has been presented.
Both secondary structure for the complex and putative interactions between sub-
domain IV of ErbB2 and variable domains (VH and VL) of Trastuzumab are
well conserved along the MD trajectory. Besides that, a hinge move approaching
the subdomain II to the Trastuzumab component is revealed by combining the
MD trajectory and PCA analysis of the most relevant eigenvectors. This col-
lective motion allows the interaction between the dimerization arm of the ECD-
ErbB2 subdomain II and subdomain CH of the antibody. In addition, it has
been observed some differences attributed to the crystal packing between the
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MD simulation and the X-ray structure. Thus, the monomer packing in the crys-
talline cell hinders the hinge move discussed above due to the presence of two
other nearby ECD-ErbB2/Trastuzumab-Fab complexes, in this manner prevent-
ing the interaction between the dimerization arm and the CH subdomain of its
own Trastuzumab protein. The observed interaction of the antibody with the
dimerization arm could provide new clues to design possible modifications of the
antibody that may then enhance its therapeutic power. An effective blockade
of the dimerization arm would disrupt the ErbB dimerization and consequently
would lead to the interruption of the signaling cascade. The simultaneous effect
on both ErbB2 subdomains II and IV exerted by a modified Trastuzumab would
be of great interest in the treatment of ErbB2 over-expressed tumors.
A comparative study between the Martini CG and the atomistic OPLS-AA
models applied to the MD simulation of the ECD-ErbB2/Trastuzumab-Fab have
been performed. In particular, the following CG settings have been evaluated:
the effect of the cutoff radius to find neighbors (rlist), the influence of the method
to calculate the electrostatic interactions (PME or Shift) and the usage the Elas-
tic Networks either by domains or just for the whole protein (domElNeDyn or
ElNeDyn). In general the CG simulations are able to satisfactorily reproduce
the crystallographic determined interaction contacts between the ECD-ErbB2
and Trastuzumab-Fab proteins as well as the additional interface involving the
ErbB2 subdomain II already described in the atomistic simulations. The PME
treatment of electrostatic interactions seems to behave as good as or even better
than the Shift methodology in view of the different results reported in this thesis.
The ElNeDyn protocol for the treatment of elastic networks shows more flexi-
bility when the networks are built by domains instead of considering the whole
protein. It allows exploring a wider region of the conformational space at the
expense of some mismatch with the atomistic models. It also can be concluded
that the larger neighbor lists cut-off radius of 1.4 nm gives better results when
compared with the atomistic system. The combination of PME, rlist of the 1.4
nm and an EN by domains gives an overall satisfactory correlation with the atom-
istic simulation structures, in particular, the protein-protein interface has been
captured adequately by the CG model. This result can have important conse-
quences regarding the consideration of using GPU technologies. At present, the
GPU version of the Gromacs package used for MD simulations contemplates only
the usage of PME for electrostatic interaction calculation. The GPU technology
yields supercomputer performance on common server machines, so it is receiving
considerable attention by software developers.
Taking into account the results mentioned above, for the first time, MD sim-
ulations of full-length models of ErbB2 monomer and dimer systems embedded
in a lipid bilayer and complexed with the Trastuzumab-Fab monoclonal antibody
have been reported. The system has been simulated within the CG approach
using the Martini force field, based on the parameters prevously established. The
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results presented in this thesis show a satisfactory comparison with experimental
data and atomistic simulations. It has been carried out several microsecond CG
MD simulations on systems containing either the full-length Erbb2 monomer or
dimer with or without the monoclonal antibody Fab and embedded in a lipid bi-
layer. The model proposed in this thesis seems to fulfill a number of experimental
and computational observations about the full-length ErbB2 structure and its in-
teraction with the lipid bilayer. Some details observed in atomistic simulations
of the different ErbB domains are reproduced in the CG models, as for example:
(i) in the monomer case an interaction between the antibody constant domain
and the dimerization arm can be observed in addition to the native interaction
with the epitope in subdomain IV; (ii) the ErbB2 receptor extracellular domain
tends to lay down on the lipid bilayer surface in agreement with recent FRET
analysis and detailed atomistic simulations of homolog systems; (iii) the intra-
cellular domain also presents a noticeable interaction with the bilayer surface;
and, (iv) the JM fragment has been found to partially penetrate the membrane
bilayer, in agreement with NMR measurements made with this fragment in a
micelle environment. On the other hand, the inclusion of the Trastuzumab Fab
monoclonal antibody has a pronounced effect on the structural disposition of the
ectodomain, due to the hindrance exerted on those amino acids mainly respon-
sible for the interaction at subdomain IV C-terminal. The antibody containing
system shows a displacement towards the C-terminal segment of the transmem-
brane domain contacts in the dimer and a complete lost of the JM antiparallel
arrangement characteristic of the active state that is also observed in the pure
homodimer case. This action mechanism may explain the lost of signaling ability
impaired by Trastuzumab to ErbB2 homodimers experimentally found.
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Conclusiones Finales
La presente tesis aporta una coleccio´n muy u´til de modelos de homolog´ıa de los
dominios ECD de los receptores ErbB, actualizada con la informacio´n proveista
por las u´ltimas estructuras cristalogra´ficas de patrones apropiados depositados
en la base de datos Protein Data Bank (PDB). En particular, el modelo para
los receptores ErbB3 y ErbB4 incluyen las estructuras del subdominio IV el cual
estaba ausente previamente. Estos modelos fueron subsecuentemente refinados
por simulaciones de MD. Se ha encontrado un conjunto de caracter´ısticas comunes
para todos los receptores, concretamente un movimiento de periscopio del brazo
de dimerizacio´n en el el subdominio II. Lo que es au´n ma´s importante es la
notable flexibilidad encontrada para el subdominio IV. En todos los casos se ha
observado un movimiento de bisagra de este dominio hacia subdominios II y III.
Tambie´n ha sido pro-puesto un modelo para la interaccio´n de la ErbB2 y ErbB3.
Este complejo forma uno de los d´ımeros ma´s relevantes asociados con carcinomas
agresivos. Hasta donde tenemos conocimiento, el modelo propuesto es el primer
mo-delo a escala atomı´stica para la interaccio´n ECD en este heterod´ımero. El
movimiento de bisagra observado en los receptores de manera separada es tambie´n
notable en el complejo en una forma asime´trica, siendo menos mo´vil la ErbB2 que
la ErbB3. Las consecuencias biolo´gicas de esta informacio´n no son muy evidentes,
por lo tanto es necesario llevar a cabo futuros estudios. Sin embargo, la generacio´n
de modelos para los ECD de ErbBs presentados en esta tesis servira´n como un
punto de partida para un estudio sistema´tico de estos importantes receptores con
el fin de proveer pistas para el desarrollo de estrategias terape´ticas ma´s efectivas.
Por otro lado, se han presentado estudios de MD y PCA de la flexibilidad
del complejo entre el dominio extracelular del receptor ErbB2 y el anticuerpo
Trastuzumab. Tanto la estructura secundaria para el compejo como las presun-
tas interacciones entre el subdominio IV de la ErbB2 y el dominio variable (VH
y VL) del Trastuzumab son bien conservadas a lo largo de la trayectoria de MD.
Adema´s, combinando MD y los autovectores ma´s relevantes del ana´lisis de PCA se
revela un movimiento de bisagra que aproxima el subdominio II al Trastuzumab.
Estos movimientos colectivos permiten la interaccio´n entre el brazo de dimer-
izacio´n del ECD-ErbB2 en el subdominio II y el subdominio CH del anticuerpo.
Conclusiones Finales
Adicionalmente, se han observado algunas diferencias atribuidas al empaque-
tamiento cristalino entre la simulacio´n MD y la estructura de Rayos-X. As´ı, el
empaquetamiento del mono´mero en la celda cristalina dificulta el movimiento bis-
agra discutido anteriormente debido a la presencia de otros dos complejos vecinos
de ECD-ErbB2/Trastuzumab-Fab, de esta manera se impide la interaccio´n entre
el brazo dimerizacio´n y el subdominio CH de su propio anticuerpo Trastuzumab.
La interaccio´n observada del anticuerpo con el brazo de dimerizacio´n podr´ıa ofre-
cer nuevas pistas para disen˜ar posibles modificaciones del anticuerpo que puedan
mejorar su poder terape´utico. Un bloqueo efectivo del brazo de dimerizacio´n
podr´ıa afectar la dimerazacio´n de ErbBs y consecuentemente permitir´ıa la inter-
rupcio´n de la cascada de sen˜alizacio´n. Los efectos simulta´neos en sendos subdo-
minios de la ErbB2, II y IV ejercidos por un Trastuzumab modificado podr´ıa ser
de gran intere´s en el tratamiento de tumores por sobre-expresio´n de ErbB2.
Complementariamente, se ha realizado un estudio comparativo entre los mod-
elos de CG Martini y AA OPLS aplicados a la simulacio´n MD del complejo
ECD-ErbB2 / Trastuzumab-Fab. En particular, se han evaluado los siguientes
para´metros en los algoritmos de MD para simulaciones CG: el efecto del radio
cut-off para encontrar vecinos (rlist), la influencia del me´todo para calcular las
interacciones electrosta´ticas (PME o Shift) y el uso de las redes ela´sticas, ya sea
por dominios o so´lo para toda la prote´ına (domElNeDyn o ElNeDyn). En general,
las simulaciones CG son capaces de reproducir satisfactoriamente los contactos
de interaccio´n determinados cristalogra´ficamente entre las prote´ınas ECD-ErbB2
y el Trastuzumab-Fab, as´ı como la interface de interaccio´n adicional que involu-
cra el subdominio II de ErbB2 ya descrita en las simulaciones atomı´sticas. El
tratamiento PME para las interacciones electrosta´ticas parece comportarse tan
bien o incluso mejor que el me´todo Shift a la luz de los diferentes resultados
presentados en esta tesis. El protocolo ElNeDyn para el tratamiento de redes
ela´sticas muestra ma´s flexibilidad cuando las redes se construyen por los domin-
ios en lugar de considerar la prote´ına entera. Esto permite la exploracio´n de
una regio´n ma´s amplia del espacio conformacional a expensas de alguna falta de
coincidencia con los modelos ato´micos. Tambie´n se puede concluir que a radios
cut-off de las listas de vecinos ma´s grandes de 1.4 nm dan mejores resultados que
radios menores cuando es comparado con el sistema atomı´stico. La combinacio´n
de PME, rlist de 1.4 nm y una EN por dominios proporciona una correlacio´n
satisfactoria general con las estructuras de simulacio´n atomı´stica, en particular,
la interface prote´ına–prote´ına ha sido capturada adecuadamente por el modelo
CG. Este resultado puede tener consecuencias importantes en cuanto a la consid-
eracio´n de utilizar las tecnolog´ıas basadas en GPU. En la actualidad, la versio´n
GPU del paquete Gromacs utilizado para simulaciones MD contempla so´lo el
uso de PME para el ca´lculo de la interaccio´n electrosta´tica. La tecnolog´ıa GPU
produce rendimientos de superordenador en servidores comunes, por lo que esta´
recibiendo una considerable atencio´n por parte de los desarrolladores de software.
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Teniendo en cuenta los resultados mencionados anteriormente, se ha reportado
por primera vez, simulaciones de MD de modelos enteros de sistemas monome´ricos
y dime´ricos de ErbB2 embebidos en bicapa lip´ıdica y complejados con el antic-
uerpo monoclonal Trastuzumab-Fab. El sistema ha sido simulado dentro de la
aproximacio´n CG usando el campo de fuerzas Martini, basado en los para´metros
previamente establecidos. Los resultados presentados en esta tesis muestran una
comparacio´n satisfactoria con datos experimentales y simulaciones atomı´sticas.
Se han llevado a cabo varias simulaciones de CG MD con una extencio´n de mi-
crosegundos sobre sistemas conteniendo tanto el mono´mero de ErbB2 entero o
el d´ımero con o sin el anticuerpo monoclonal Trastuzumab-Fab y embebidos en
la bicapa lip´ıdica. Los modelos propuestos en esta tesis satisfacen un nu´mero
de observaciones experimentales y computacionales acerca de la estructura de
ErbB2 entera y su interaccio´n con la membrana lip´ıdica. Algunos detalles ob-
servados en simulaciones atomı´sticas de los diferentes dominios ErbB son repro-
ducidos en los modelos CG, como por ejemplo: (i) en el caso del mono´mero se
observa una interaccio´n entre el dominio constante del anticuerpo y el brazo de
dime-rizacio´n adema´s de la interaccio´n nativa con el ep´ıtopo en el subdominio
IV; (ii) el dominio extracelular del receptor ErbB2 tiende a tumbarse en la su-
perficie de la bicapa lip´ıdica en concordancia con los u´ltimos ana´lisis de FRET
y simulaciones atomı´sticas de sistemas homologos; (iii) el dominio intracelular
tambie´n presenta una notable interaccio´n con la superficie de la bicapa lip´ıdica;
(iv) se ha encontrado que el fragmento JM penetra parcialmente la bicapa, en
acuerdo con medidas de NMR hechas con este fragmento en un ambiente micel-
lar. Por otro lado, la inclusio´n del anticuerpo monoclonal Trastuzumab-Fab tiene
un efecto pronunciado sobre la disposicio´n estructural del ectodominio, debido
al impedimento ejercido de aquellos aminoacidos principalmente responsables en
la interaccio´n en el subdominio IV en el C-terminal. El sistema que incluye
el anticuerpo muestra un desplazamiento hacia el segmento C-terminal de los
contactos del dominio transmembrana en el d´ımero y una completa pe´rdida de
la disposicio´n anti-paralela de la JM, la cual es caracter´ıstica del estado activo
que tambie´n es observado en el caso de homod´ımero puro. Este mecanismo de
accio´n puede explicar la pe´rdida de capacidad de sen˜alizacio´n deteriorada por el
Trastuzumab en homod´ımeros ErbB2.
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Based on the knowledge learned in this thesis, a wide skyline has been uncov-
ered that allows one to continue the research on EGFR receptors with molecular
dynamics. The research on EGFR has some issues which can be described as fol-
lows: (i) the determination of the features that distinguish the population of cell
surface EGFR that binds ligand with high affinity is a key point for a complete
understanding of normal receptor activation; (ii) the role of ligand-independent
ErbB dimerization/clustering needs to be clarified; (iii) full characterization of
the effects of cancer mutations on ErbB activity is needed; and finally, (iv) greater
appreciation of similarities and differences in the mechanisms of activation is also
needed.
The following topics will try to describe some perspectives regarding the new
ideas for a future work:
– CG models play an essential role in capturing events at larger time and
spatial scales. Therefore, a study regarding the full-length ErbB receptors
using coarse graining is higly recommended.
– Martini force field has been widely used on lipids in a succesfully way.
Hence, taking into account the rich diversity of the membrane composition,
a study of its effect on the structure-function of ErbB receptors would be
prominent.
– The CG MD can be used like an enhanced sampling method. Then, a
backmapping or reverse transformation work should be proposed to study
the atomistic protein-protein interactions as a detailed chemical character-
ization.
– Mutations on ErbB receptors in the key regions could be performed to study
through MD simulations.
– Protein–protein interactions are still the weakness of the power of Martini
Force Field. Improvements on the potential parameters is a topic to be
studied.
Perspectives
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